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The glucose transporter isoform, GLUT2, has been investigated using the bis-D- 
mannose photolabel ATB-BMPA {2-N-[4-(l-azi-2,2,2-trifluoroethyl)benzoyl]-l,3-bis-(D- 
mannos-4-yloxy)propyl-2-amine}. Labelled protein with an apparent molecular mass of 
45-66 kDa was precipitated from both liver plasma membranes and islet tissue using anti- 
GLUT2 peptide antibodies. ATB-BMPA photolabelling of GLUT2 could be displaced by
4,6-0-ethylidene-D-glucose and D-glucose, which inhibited labelling by 92 and 57% 
respectively. Since GLUT2 was shown to have a similar affinity to GLUT1 and GLUT4 
for the external ligand ATB-BMPA, it is suggested that the varying affinities for substrates 
shown by the different transporter isoforms, may arise from differences in their ability to 
bind hexoses at the internal binding site.
The identity of the glucose transporter isoforms expressed by cultured 3-cell lines 
has been investigated by Western blotting and ATB-BMPA photolabelling. Protein 
labelled in a hexose-displaceable manner in HITm2.2, RINm5F and MIN 6 cells was 
precipitated by anti-GLUTl but not GLUT2 C-terminal peptide antibodies. 6-cell lines 
have been characterised in terms of their morphology, insulin secretion and 2-deoxyglucose 
uptake and their suitability as models of native 6-cells has been discussed.
An ELISA has been developed which detects slightly higher levels of antibodies 
that bind to 6-cell line plasma membranes in serum samples from children with recently 
diagnosed insulin-dependent diabetes mellitus (IDDM) compared with controls. 6-cell 
surface autoantigens have also been investigated by Western blotting.
It has been attempted to use ATB-BMPA photolabelling and immunoprecipitation 
to identify putative anti-GLUT2 autoantibodies in IDDM serum (Johnson et al., 1990a N. 
Engl. J. Med. 322, 653-659). The antibodies that were detected were present in both
normal and diabetic serum and precipitated liver plasma membrane proteins labelled in a
4,6-0-ethylidene-D-glucose displaceable manner. It has been proposed that these 
antibodies recognise cytoplasmic epitopes of detergent-solubilised GLUT2. The putative 
diabetes-specific anti-GLUT2 autoantibodies could not be detected using this technique.
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11.0 INTRODUCTION
1.1 GENERAL OUTLINE AND AIMS
Normal glucose homoeostasis in mammals is achieved by the secretion of insulin 
from pancreatic 8-cells, this is dependent on the ability of these cells to respond to 
fluctuations in blood glucose concentrations. This thesis examines the possibility that 
glucose sensing by 8-cells is partly accomplished by the expression of GLUT2, a high 
capacity glucose transporter. GLUT2 is also expressed in the liver, another organ 
involved in glucose homoeostasis (Thorens et al., 1988), and is just one member of a 
family of structurally similar glucose transport proteins that have different transport and 
regulatory characteristics and are expressed in a tissue-specific manner (Gould & Bell,
1990). There is some experimental evidence which implies that a defect in the glucose 
transport capacity of pancreatic 8-cells may render them unresponsive to hyperglycaemia 
and hence may be responsible for the development of the disease diabetes mellitus (Unger,
1991).
In non-insulin dependent diabetes mellitus (NIDDM) there is a decrease in GLUT2 
expression and glucose transport in 8-cells, the cause of which is currently unknown 
(Johnson et al., 1990b; Orci et al., 1990b; Thorens et al., 1990e). A similar reduction in 
GLUT2 expression and glucose transport in the residual 8-cells occurs at the onset of 
insulin-dependent diabetes mellitus (IDDM) (Tominaga et al., 1986; Orci et al., 1990a). 
In this type of diabetes the pathogenesis is almost certainly of an autoimmune nature. 
Circulating anti-islet cell surface antibodies (ICSA) have been detected which inhibit 
glucose-induced insulin secretion and glucose transport (Kanatsuna et al., 1983; Alden et 
al.., 1984; Johnson et al., 1990a; Kitagawa et al., 1990). It has been proposed that the 
antibodies that inhibit hexose transport may be directed against the 8-cell GLUT2 protein 
(Johnson etal., 1990a).
2Positive identification of B-cell autoantigens may be useful in the development of a 
screen and eventually a cure for IDDM, which at present is a chronic, incurable illness that 
impairs the health and shortens the life-span of sufferers to the extent that about one half of 
those diagnosed by the age of twenty-five will be dead before the age of forty (Keen,
1982).
The results of work undertaken for this thesis have been divided into three 
sections. Initially, an investigation of GLUT2 was carried out in liver tissue using specific 
anti-GLUT2 peptide antibodies to immunoprecipitate the GLUT2 protein after it had been 
radiolabelled using the photoaffinity probe ATB-BMPA {2-N-[4-(l-azi-2,2,2- 
trifluoroethyl)benzoyl]-l,3-bis-(D-mannos-4-yloxy)propyl-2-amine}. This photoprobe has 
previously been used to label other members of the glucose transporter family (Clark & 
Holman, 1990; Holman et al., 1990). The aim was to compare the characteristics of 
GLUT2 with those of the other transporter isoforms, and to develop techniques which 
could then be used to label GLUT2 in other tissues and potentially to detect anti-GLUT2 
autoantibodies in the serum of diabetic patients.
Part two of the results section describes the use of photolabelling and Western 
blotting to establish which transporter isoforms are expressed by three /3-cell lines (HIT, 
R1N and MIN) and to assess the suitability of these cells for use in assays designed to 
screen for anti-islet cell surface or anti-GLUT2 antibodies.
Finally, as described in part three, it was attempted to develop a simple ELISA 
which could be used to detect ICSA. Western blotting was used to identify the target B-cell 
autoantigens and attempts were made to confirm the presence of anti-GLUT2 
autoantibodies in IDDM patients by immunoprecipitation of proteins radiolabelled by the 
glucose transporter specific photoprobe, ATB-BMPA.
31.2 FACILITATFVE GLUCOSE TRANSPORT
Glucose transport in, and out of cells is required for the maintenance of glucose 
homoeostasis. The realization that defects in glucose transport may be associated with 
diseases such as diabetes mellitus has recently led to an increased interest in the 
mechanisms involved in the uptake of this hexose. D-glucose is the major source of energy 
for most mammalian cells and since the plasma membrane is impermeable to polar 
molecules, the uptake of this sugar occurs via specific carrier proteins.
The facilitative glucose transporter family of proteins is responsible for the carrier- 
mediated passive diffusion of glucose across the cell membranes of the majority of cell 
types. Transport is bidirectional, but net transport occurs from a high to a low sugar 
concentration. The carrier is a an integral membrane protein with a strong specificity for 
the D-stereoisomers of pentose and hexose monosaccharides adopting the chair formation 
of the pyranose ring (Carruthers, 1990).
Facilitative glucose transport has been most widely studied in human red blood 
cells. The protein responsible for transport activity has been purified and antibodies raised 
against it (Kasahara & Hinkle, 1977; Allard & Lienhard, 1985). This ultimately enabled a 
cDNA clone of the transporter to be isolated from a cell line, Hep G2 (Mueckler et al.,
1985). Further investigation revealed that this protein was not responsible for facilitative 
glucose transport in all tissues, but was just one member of a family of structurally related 
proteins which are the products of distinct genes found on different chromosomes (Bell et 
al., 1990). Expression of the transporter isoforms is tissue-specific, although any one 
tissue may contain more than one isoform, such that the expression reflects the precise 
transport requirements of the tissue concerned.
To date, seven genes for members of the facilitative glucose transporter family 
have been identified, they are named GLUT1-GLUT7. The numbers reflect the order in
4which the proteins were identified. GLUT6 is a facilitative transporter-like sequence 
which cannot encode a functional protein (Kayano et al., 1990). cDNA clones and 
sequences have been obtained for all the other transporters and the proteins have been 
functionally expressed and demonstrated to transport D-glucose (Kayano et al., 1990; 
Gould etal., 1991; Waddell etal., 1992).
1.2.1 Models of glucose transporter structure
From a hydropathic profile of the predicted GLUT1 protein sequence, Mueckler et 
al. (1985) proposed a structure for the membrane topology of the protein made up of 12 
membrane spanning hydrophobic regions (M l-M l2) linked by short cytoplasmic loops of 
hydrophilic amino acids and long intracellular C- and N-terminal regions. Infrared 
spectroscopic analysis indicates that the native glucose transporter is predominantly a- 
helical in structure, although some B-structure and random coil conformations are also 
present (Lienhard et al., 1992). The membrane spanning regions are probably composed 
of a-helices and, with the exception of the extracellular hydrophilic region between Ml 
and M2, which has a 6-sheet structure, the remaining extramembraneous domains are also 
believed to be a-helical as shown by tryptic digestion (Carruthers, 1990) and molecular 
modelling techniques (P. A. Hodgson - personal communication).
The basic model of GLUT1 shown in Figure 1 is also applicable to the other 
isoforms which have superimposable hydropathic plots and exhibit between 39% and 65% 
amino acid identity and 50-76% similarity (Gould et al., 1991). The similarity between 
the same transporter isoform in different mammalian species is also high.
5O U T S I D E
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Figure 1 A model for the arrangement of GLUT1 in the membrane. Numbered 
rectangles indicate putative membrane-spanning a-helices. (From Baldwin & Henderson, 
1989)___________________________________________________________________________
A study of the conserved regions of the glucose transporters is of interest, since 
these are likely to be the amino acids involved in the actual mechanism of transport. 
Regions that are significantly different are presumed to be responsible for the distinctive 
catalytic properties of each isoform and the differential susceptibility to physiological 
regulation by endocrine and metabolic factors.
Homology analyses have indicated that hydrophobic regions M5, M10 and M il 
are >90% conserved between transporter isoforms, and M l, M2, M4, M7, M8 and M12 
share > 80% sequence homology. Less homology is seen in the hydrophobic regions M6 
and M9 (>70% ) and M3 (>60% ) (Carruthers, 1990). Multiple sequence alignment data 
indicates that 4 of the 12 membrane spanning regions, M7, M8, M10 and M il show a high 
degree of conservation of key hydrophilic and aromatic side chains. Membrane-spanning
6regions M9 and M12 are less conserved and have fewer hydrophilic amino acids (P. A. 
Hodgson, D.J. Osguthorpe and G.D. Holman - unpublished work). This agrees with 
photoaffinity labelling data that it is the C-terminal half of the protein that is important in 
ligand binding.
A 3-dimensional atomic model for GLUT1 produced by Hodgson, Osguthorpe and 
Holman (unpublished work) proposes that the transporter consists of 2 rings of 6 
membrane spanning helices, M1-M6 and M7-M12 respectively. Membrane spanning 
regions M7-M12 are proposed to form a hydrophilic channel or pore through which 
glucose can move. The model proposes that the channel is lined with helices M7, M8, 
M10 and Mi l ,  which due to the large number of serine and glutamine residues, are able to 
interact with glucose. The more hydrophobic regions M9 and M12 may be positioned so 
they are not involved in the formation of the channel, but maintain the ring shape of the 
domain structure. There is a region in M10 which is rich in glycine and proline residues 
and might be expected to impart flexibility to this region, which could be important in the 
putative conformational change which accompanies the transport of glucose (Gould & Bell, 
1990). It has been proposed that the upward movement of helices M7 and M8 exposes the 
outer binding site, and when M10 and M il move down in the membrane plane, an inner 
binding site is exposed (A.F. Davies, A. Davies, R.A.J. Preston, A.E. Clark, G.D. 
Holman and S. A. Baldwin - unpublished work).
Another model of the glucose transporter called the "pentagonal pore" has also 
been proposed (Lienhard et al., 1992). The pore consists of the 5 transmembrane 
segments M3, M5, M7, M8 and Mi l ,  these are believed to take up an a-helical formation 
such that all of the hydrophilic groups are located on one side of the helix and the 
hydrophobic groups are on the other side. If these helices bound together with their 
hydrophobic sides facing towards the remaining transmembrane segments and the lipid 
environment of the membrane, their hydrophilic surface could form a pore which could 
bind glucose.
7These models are however speculative; in order to determine the real structure of 
the transporter proteins X-ray crystallographic studies are required which are dependent on 
the ability to form crystals from the glucose transporter proteins.
Several other regions of the transporter isoforms, in addition to the membrane- 
spanning domains, also have substantial sequence identity. For example, there is a 
conservation of charged amino acids in the short endofacial loops linking the 
transmembrane segments. It has been speculated that these regions may be responsible for 
ionic interactions with cytoplasmic proteins such as glucokinase in liver and ft-cells 
(Newgard et al., 1990).
Non-conserved regions of glucose transporter proteins include the large 
extracellular loop between Ml and M2, which varies greatly in length in different 
transporter isoforms and also contains a potential N-linked glycosylation site. The C- and 
N-termini are also very different in each of the isoforms. Other non-conserved regions of 
the transporters that may be responsible for the isoform-specific properties have not yet 
been identified.
1.2.2 Interaction of substrates and analogues
i) Investigation using sugar analogues
Since facilitative glucose transport is bidirectional, there must be binding sites for 
the hexose on both the endo-and exo-facial sides of the transporter protein. Hexoses have 
been shown to interact with the active site of the transporter by hydrogen-bonding, in 
which the hydroxyl (OH) groups on the sugar act as hydrogen (H) bond acceptors (Barnett 
etal., 1973a).
Studies involving the binding of sugar analogues to the erythrocyte sugar 
transporter have indicated that there are significant differences between the sugar influx
and efflux binding sites, and have allowed a model to be proposed for the mechanism of 
transport. The spatial arrangement of the internal and external binding sites has been 
investigated by substituting bulky groups into specific positions in the sugar molecule. 
Hexose derivatives with a large substituent group at C 1 cannot bind to the outer face of the 
transporter (Barnett et al., 1975). Conversely, since 4,6-O-ethylidene D-glucose and 4-O- 
propyl glucose can inhibit glucose transport at the exofacial site, bulky groups at the C4 
and C6 positions do not interfere with binding at the outside of the transporter. Therefore, 
binding at the exofacial site involves an interaction between OH groups at the Cl and C3 
positions of the sugar (Barnett et al., 1973a). The reverse occurs at the internal sugar 
binding site where Cl-alkyl-substituted compounds bind well, but C4 and C6 substituted 
compounds do not (Barnett et al., 1973b; Barnett et al. , 1975). A similar situation occurs 
in rat adipocytes (Holman et al., 1981; Holman & Rees, 1982).
The conclusion from such studies is that the sugar enters the transporter from the 
outside with Cl first and C4/C6 trailing. The orientation of the sugar is maintained but a 
conformational change of the transporter occurs and thus the C4/C6 end is recognised first 
by the endofacial site. This is illustrated in Figure 2 .
C onform ation A 
m em brane p rote in
C onform ation  B 
m em brane p rote in
InsideO u t s i d e 'Inside O utside)
Fig. 2 Possible model of sugar transport in the human erythrocyte (Barnett et al., 
1975)
9ii) Investigation using photoaffinity labels.
Since the deduced amino acid sequences of the glucose transporter proteins have 
been published, attempts have been made to establish which regions of the transporters are 
involved in interactions with sugar molecules. Photoaffinity labelling of the transporters 
has been used in such studies.
The fungal metabolite, cytochalasin B (cyt B), is a potent inhibitor of facilitative 
glucose transport (Jung & Rampal, 1977; Devds & Krupka, 1978; Axelrod & Pilch,
1983). When irradiated with high intensity ultra violet light, [^H] cyt B forms a covalent 
bond with a site on the cytoplasmic face of the erythrocyte transporter. Proteolytic 
cleavage of the erythrocyte transporter subsequent to covalent labelling with [^H] cyt B 
suggests that it specifically binds the endofacial surface of the transporter between Phe3 g9  
and Trp4i2, that is, between membrane spanning regions M10 and M il (Cairns et al., 
1984; Holman & Rees, 1987). This is not necessarily the endofacial glucose binding site, 
since although glucose can inhibit cyt B labelling, the substrate and inhibitor need not 
combine at the same site, as glucose could induce a long-range conformational change that 
reduces cyt B binding in a separate region of the protein (Devds & Krupka, 1978).
A series of photolabels, specific for the exofacial binding site, has also been 
developed (Midgley et al.t 1985; Holman, 1989). They are bis-D-mannose compounds in 
which the two sugars are cross-linked through the C4-hydroxyl group by a propyl-2-amine 
bridge. This gives an impermeant, non-transported molecule, l,3-bis-(D-mannos-4-yloxy)- 
propyl-2-amine or BMPA, which can then be radiolabelled (Holman, 1989). The bulky 
photoactive moiety is introduced into the bridge, and since it is in the C4 position of the 
hexose it does not interfere with the hexose groups required for binding (Clark & Holman, 
1990).
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Since the bis-D-mannose compounds have a low affinity for the transporter, the 
photolabel substituent must be selective (Clark & Holman, 1990). The aryl azide, 2-N-(4- 
azidosalicoyl)-l,3-bis-(D-mannos-4'-yloxy)-propyl-2-amine (ASA-BMPA), has been used 
to label the erythrocyte glucose transporter (Holman et al., 1986), but it was found to be 
unsuitable for labelling adipocytes, in which the transporter was present in low abundance. 
In this situation ligands containing precursor groups such as benzophones or 
(azitrifluorethyl)-benzoyl groups, which produce carbenes on irradiation, were found to be 
more effective (Holman et al., 1988). The benzophone derivative 2-N-(4-benzoyl)- 
benzoyl-BMPA (BB-BMPA) and 2-N-[4-(l-azi-2,2,2-trifluoroethyl)-benzoyl-BMPA (ATB- 
BMPA), the structure of which is shown in Figure 3, both label the erythrocyte and 
adipocyte transporters (Holman et al., 1988; Clark & Holman, 1990; Holman et al., 
1990). ATB-BMPA has the advantage that it is soluble in physiological buffers, requires 
short irradiation times and because of its improved selectivity can be used to label 
transporters in isolated membranes in addition to whole cells (Clark & Holman, 1990; 
Jordan & Holman, 1992). ASA-BMPA binds the exofacial surface of the transporter, 
probably between membrane-spanning regions M9 and M10 (Holman & Rees, 1987). 
ATB-BMPA has recently been shown to bind GLUT1 on the exofacial surface of 
transmembrane region M8  between AU3 0 1  and Arg3 3 Q (A.F. Davies, A. Davies, R.A.J. 








Figure 3 Structure of ATB-BMPA. From Clark & Holman, 1990
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Overall, the results obtained from photolabelling studies suggest that 
transmembrane segments M7-M10 are involved in ligand binding. That is, that the 
transport function is linked solely with the C-terminal half of the protein. Labelling has 
also provided information about the mechanism of transport, since it has shown that the 
internal and external binding sites cannot be occupied simultaneously (Holman et al.,
1986). This supports the alternating conformation model of glucose transport. Oka et al. 
(1990a) have also shown that the C-terminal 37 amino acids are essential for the catalytic 
function of GLUT1. Their role is to allow the formation of the outward facing 
conformation as indicated by the inability of a C-terminal mutant to be labelled by ATB- 
BMPA.
1.2.3 Proposed mechanism of transport.
Glucose is transported down its concentration gradient via a carrier protein which 
displays Michaelis-Menten saturation kinetics, is stereospecific and can be regulated and 
inhibited. As such, the interaction of hexoses with the transporter is similar to that of an 
enzyme with its substrate. Models developed to describe the proposed mechanism of 
glucose transport have been deduced from kinetic data, much of which has been obtained 
from measuring transport in the human erythrocyte.
The carrier model was proposed in 1952 by Widdas. Since hexose transport is 
bidirectional, there must be binding sites for D-glucose at both the endo-and exo-facial 
surfaces of the transporter. These sites are proposed to be mutually exclusive, that is, at 
any point in time a carrier is available for influx or efflux but not for both simultaneously 
(Carruthers, 1990).
Experimental evidence suggests that the transporter can exist in two forms, an 
inward facing conformation (Tj) and an outward facing conformation (T0). In the absence 
of glucose, the transporter is believed to oscillate rapidly between the Tj and T0 isomers.
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In the erythrocyte, isomerisation (Iq) between the two states occurs 100 times/sec at 20°C 
(Lienhard et a i ,  1992). The structures of the two conformations are not known but it 
seems probable that there is a channel open at one end and constricted at the other. 
Glucose would bind at the open end and be held by weak hydrogen bonds. It could be 
transported by a conformational change which would close the protein behind it and open 
the constricted end in front of it, releasing the hexose molecule on the opposite side of the 
membrane (Lienhard et a i ,  1992).
T . - T0S
O u ts id e
Inside
Tj Ary - ■ -TjS
Figure 4 Transport scheme for conventional carrier model
As illustrated in Figure 4, hexose transport is believed to involve 4 steps. When 
there is a high concentration of sugar outside the cell it binds to a transporter in the 
exofacial (T0) conformation. The transporter/substrate complex (T0S) changes 
conformation (TjS) so that glucose now occupies the endofacial binding site. The substrate 
is then released into the cytoplasm. When net sugar transport from a high to a low 
concentration occurs, the transporter isomerises from Tj to T0 so that it is again available 
for sugar binding at the cell surface. During equilibration exchange, the step involving 
isomerisation in the absence of substrate is unnecessary and the Tj form binds a substrate 
molecule and transports it out of the cell. The isomerisation (k2 ) of the transporter/glucose 
complex occurs 900 times/sec. This is much more rapid than the isomerisation of the 
unloaded transporter, since the presence of the substrate lowers the energy barrier between 
the two conformations (Lienhard et al. , 1992; Walmsley, 1988). This can explain the
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phenomenon of exchange acceleration observed in human erythrocytes, in which 
equilibrium exchange occurs faster than the uni-directional flux, since the conformational 
change of the empty transporter is rate limiting for net transport, this is known as the trans­
effect (Wheeler & Hinkle, 1985; Carruthers, 1990). The alternating conformation model 
also explains the asymmetry of glucose transport in the human erythrocyte where the Km 
and Vmax for sugar exit are higher than for sugar entry. This can arise if inward and 
outward facing conformations have different affinities for D-glucose or if the unloaded 
carrier is asymmetrically distributed.
Experimental evidence has been obtained supporting the alternating conformation 
model, since it is consistent with the existence of two forms of the transporter, the presence 
of one conformation reducing the availability of the other. For example, when 
erythrocytes are incubated with maltose, which binds to the exofacial site but cannot be 
transported, a high proportion of the transporters are trapped in the outward-facing 
conformation. If the cells are then mixed with glucose a rapid initial surge in glucose 
uptake occurs due to the availability of outward facing transporters. This is followed by a 
slower steady state uptake of D-glucose which is limited by the slow isomerisation of the 
unloaded transporter (Lowe & Walmsley, 1987; Walmsley, 1988).
In summary, the alternating conformation model is widely accepted as being the 
best model currently available since it accounts for most of the observed kinetic properties.
1.2.4 Characteristics of the transporter isoforms.
Details of the tissue-specific glucose transporter isoforms are given in Table 1.
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Mueckler a/. (1985) 
Gould & Lienhard 
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Gould et al. (1991) 
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Fukumoto et al. (1988) 
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James et al. (1989) 
Birmbaum (1989) 
Fukumoto et al. (1989) 
Charron et al. (1989) 
Kaestner et al. (1989) 





Minor expression in: Kidney, 








53 Liver microsomes Not determined
?
Waddell et al. (1992)
Table 1 The facilitative glucose transporter family
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1.2.4.1 GLUT1 - The erythrocyte-type glucose transporter
GLUT1 was the first member of the glucose transporter family of proteins to be 
identified. A cDNA clone coding for 492 amino acids was obtained from a human cell line 
Hep G2 (Mueckler et al., 1985). GLUT1 has since been cloned from a number of other 
tissues and species. There is a high degree of conservation between species, with a 98% 
identity between human and rat GLUT1 (Gould & Bell, 1990). The transporter is 
heterogeneously glycosylated giving it an apparent molecular mass which varies from 45- 
55 kDa.
GLUT1 is ubiquitous in its distribution and is often co-expressed with other tissue- 
specific glucose transporters. High amounts are expressed in erythrocytes and in the brain 
where it seems to be mostly associated with blood microvessels. It is also found in foetal 
tissues, including the placenta, and in most immortal cell lines. At low levels GLUT1 is 
expressed in adipose, muscle, kidney, colon and liver tissue (Gould & Bell, 1990; Holman 
& Gould, 1992). The expression of low levels of GLUT1 in most tissues suggests that it 
plays a role in supplying the basal glucose requirements of cells (Mueckler, 1990). Since 
GLUT1 has a high affinity for D-glucose the high expression of this isoform in 
erythrocytes and the brain allows these glucose-dependent tissues to take up glucose 
efficiently even when blood glucose concentrations are low.
The kinetics of isolated GLUT1 have been investigated by functional expression of 
the protein in Xenopus oocytes. Under equilibrium exchange conditions a Km for 3-0- 
methyl-D-glucose (3-O-MG) of ~ 17 mM has been obtained (Gould et al. , 1991). This 
agrees well with equilibrium exchange studies in human erythrocytes in which a range of 
Km values from 17-38 mM for D-glucose have been measured (see Carruthers, 1990 and 
references therein). Human erythrocytes display asymmetry and exchange acceleration, 
therefore, under net flux conditions, much lower Km values are measured. The Km for D- 
glucose uptake is ~  1.6 mM and for efflux 4.6 mM (Lowe & Walmsley, 1986). The Km
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for net D-glucose influx in most tissues expressing GLUT1 is «  1-2 mM (Thorens et al., 
1990c).
The expression of GLUT1 is increased by any factors that increase cellular 
activity, such as oncogene infection, cell division and growth factors (Kahn & Flier, 1990; 
Mueckler, 1990). This explains its inappropriate expression in most cell lines where it 
appears to be an adaptation to enhanced rates of growth and cell division. GLUT1 
expression can be increased in cultured cells starved of glucose. It has also been shown 
that a low insulin level in the blood, as occurs in diabetes, can increase expression of 
GLUT1 around the terminal hepatic venules in the liver (Tal et al., 1991).
1.2.4.2 GLUT2 - The liver/pancreatic-type glucose transporter
GLUT2 has been cloned and sequenced from rat (Thorens et al., 1988), mouse 
(Asano et al., 1989) and human liver (Fukumoto et al., 1988). The rat gene codes for a 
522 amino acid protein which shares 82% sequence identity with the 524 amino acid 
human protein (Gould & Bell, 1990). GLUT2 has also been cloned from human pancreatic 
tissue (Permutt et al., 1989), where it is found to be expressed solely in the 8-cells. In 
addition to being present in liver and 8-cells, GLUT2 mRNA has also been found in cells 
of the intestinal epithelium and proximal tubule cells of the kidney (Thorens et al., 1988; 
Thorens etal., 1990a; Thorens et al. , 1990b).
Analysis of the predicted primary structure of GLUT2 has indicated that the 
topological organisation of this isoform is identical to that predicted for GLUT1. The 
major differences between GLUT2 and the rest of the transporter family reside in the C- 
terminal 28 residues and the exofacial loop between Ml and M2 which is almost double the 
length in GLUT2. This loop contains a single asparagine-linked glycosylation site 
(Fukumoto et al., 1988). GLUT2 also contains a potential cAMP-dependent protein kinase 
phosphorylation site on the cytoplasmic face of the protein (Fukumoto et al., 1988).
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Overall, the transmembrane segments of GLUT2 display a 55-65% sequence identity with 
GLUT1, although a greater degree of similarity is seen in M5 and M10 which are 75% and 
80% sequence identical respectively (Thorens et al., 1990c).
The apparent molecular weight of rat GLUT2 varies from 53-61 kDa depending on 
the tissue in which it is expressed. In liver it has an apparent molecular weight of 53 kDa. 
In islet fi-cells its apparent molecular weight is 55 kDa, in the kidney it is 57 kDa and in 
the intestine 61 kDa (Thorens et al., 1988). These differences in size may be due to tissue- 
specific post-translational modifications such as glycosylation, phosphorylation or 
proteolysis (Thorens et al., 1990a; Thorens et al., 1990c).
Transport in liver is symmetrical and is not accelerated under exchange conditions 
(Craik & Elliot, 1979). In rat hepatocytes a Km of about 20 mM for 3-O-MG has been 
measured under both net flux and equilibrium exchange conditions at 20°C (Craik & 
Elliot, 1979). The Km for D-glucose transport in isolated hepatocytes is very high, 
approximately 60 mM (Elliott & Craik, 1982; Granner & Pilkis, 1990). This is similar to 
the Km of 50 mM measured for D-glucose uptake in pancreatic 6 -cells (Heilman et al., 
1971). When GLUT2 is expressed in Xenopus oocytes, Km values of 42 mM and 6 6  mM 
measured under equilibrium exchange conditions have been obtained for 3-O-MG and D- 
glucose respectively (Gould et al. , 1991).
GLUT2 is distinct from the other transporter isoforms in that it has a high Km and 
therefore a much lower affinity, but a much higher capacity for D-glucose. This means 
that in tissues expressing GLUT2, glucose transport is not limiting at high glucose 
concentrations. GLUT2 also differs from the other transporter isoforms by being able to 
transport D-fructose. This has been demonstrated in isolated rat hepatocytes (Okuno & 
Gliemann, 1986) and in Xenopus oocytes expressing GLUT2 (Gould et al., 1991). It has 
also been shown that the affinity of cyt B for glucose sensitive binding sites in liver 
membranes, which are now known to be GLUT2 transporters, is one order of magnitude
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lower than in adipocyte and erythrocyte membranes, now known to contain GLUT4 and 
GLUT1 respectively (Axelrod & Pilch, 1983).
i) The role and regulation of GLUT2 in liver
The glucose transporter proteins expressed in liver, in addition to supplying the 
glucose requirements of the hepatocytes themselves, play an important role in the glucose 
homoeostasis of the whole organism. GLUT2 is the predominant transporter in liver 
tissue, although GLUT1 can be detected in a subset of hepatocytes that lie within one row 
of the terminal hepatic venules (Tal et al., 1990; Tal et al., 1991).
The presence of GLUT2 in hepatocytes is important for their gluconeogenic 
function. Under conditions favouring net glucose release, liver hexokinase activity 
decreases, glucose accumulates and is exported via GLUT2. The high Km of this 
transporter ensures that intracellular glucose concentrations do not become rate limiting to 
efflux. During conditions favouring glucose uptake, the presence of large amounts of 
GLUT2 ensures that at high plasma glucose concentrations glucose transport does not 
become rate limiting for metabolism.
Although levels of GLUT2 mRNA are significantly altered by fasting and 
refeeding, levels of the corresponding protein remain unchanged (Chen et al., 1990). This 
indicates that the regulation of GLUT2 is not related to a transcriptional change in gene 
expression, but rather to post-transcriptional changes including functional alteration of the 
protein (Kahn & Flier, 1990; Seino et al., 1991). Contradictory results have been 
obtained on the effect of streptozotocin-induced diabetes on the level of GLUT2 in liver. 
Thorens et al. (1990d) found no alteration in liver GLUT2 in diabetic animals, whereas 
Oka et al. (1990c) found that diabetic animals had increased levels of liver GLUT2.
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ii) The role and regulation of GLUT2 in the kidney and intestine
GLUT2 is expressed in the kidney and intestine in association with other 
facilitative glucose transporter isoforms and the Na+ -glucose symporter. GLUT2 is 
localised in regions of these tissues involved in trans-epithelial glucose transport, in 
particular, glucose efflux.
In the intestine, GLUT2 is present only in the differentiated epithelial cells of the 
jejeunum, ileum and duodenum, where it is present in the basolateral membrane. It is not 
found on the brush border of the apical membrane which contains the Na+ -glucose 
symporter (Thorens et al., 1990a). Glucose is absorbed by the intestinal epithelium over 
the apical membrane by active transport. It is then passed into capillaries via the 
basolateral membrane facilitative glucose transporter. A high Km transporter such as 
GLUT2 is required to prevent glucose efflux being limited at high intracellular glucose 
concentrations.
In the kidney GLUT2 is present in cells where gluconeogenesis occurs, that is, in 
the basolateral membrane of cells from the proximal tubule. The remaining glycolytic 
regions of the kidney express GLUT1 (Thorens et al., 1990b). The factors regulating 
GLUT2 expression in the kidney and intestine are unknown.
iii) The role and regulation of GLUT2 in the pancreatic 6-cell
GLUT2 is expressed in pancreatic 6 -cells, where it is found at a higher density in 
the plasma membrane of the microvilli facing adjacent endocrine cells than in the flat 
regions of the plasma membrane. This localization may be mediated via interactions with 
the underlying cytoskeleton (Orci et al., 1989). The expression of the high Km GLUT2, 
which operates with pseudolinear kinetics over the physiological range of glucose 
concentrations, ensures that the intracellular 8 -cell D-glucose concentration rapidly
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approaches that of the blood enabling the 6 -cell to fulfil a "glucose sensor" function. Any 
defect in GLUT2 which limits glucose uptake may be expected to impair the normal 6 -cell 
response to hyperglycaemia.
6 -cell GLUT2 can be down regulated by a low plasma glucose concentration, as 
occurs in hyperinsulinaemia (Chen et al., 1990) and fasting (Koranyi et al., 1990), it is 
also decreased in cells cultured in low concentrations of glucose (Seino et al., 1991). The 
decreased GLUT2 expression in IDDM (Orci et al., 1990a) and NIDDM (Johnson et al., 
1990b; Orci et al., 1990b; Thorens et al., 1990e; Unger, 1991) is unknown, but it is 
apparently not mediated by hyperglycaemia (Orci et al., 1990b), since recent evidence has 
shown that in cultured islets GLUT2 expression is increased by high and decreased by low 
glucose concentrations (Yasuda et al. 1992).
1.2.4.3 GLUT3 - The brain-type glucose transporter
GLUT3 was cloned from human foetal skeletal muscle (Kayano et al., 1988). Its 
predominant site of expression is the brain, although it is also expressed at lower levels in 
fat, kidney, liver, muscle and placenta tissue. This may be due to the presence of 
fibroblasts and blood vessels, which contain GLUT3 mRNA, in all of these tissues. In 
rodent tissue GLUT3 expression seems to be restricted entirely to the brain (Yano et al., 
1991).
The human GLUT3 gene codes for a 496 amino acid protein which shares 64% 
identity with GLUT1. Under equilibrium exchange conditions a Km for 3-O-MG uptake 
of » 1 0  mM has been obtained for GLUT3 expressed in Xenopus oocytes (Gould et al.,
1991). The role of GLUT3 seems to be similar to that of GLUT1, that is, it is a low Km 
transporter supplying the basal glucose requirements of cells, particularly neural cells 
which have an absolute requirement for glucose.
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1.2.4.4 GLUT4 - The insulin-responsive glucose transporter
The GLUT4 insulin-responsive glucose transporter isoform was first cloned and 
sequenced in 1989 (Bimbaum, 1989; Charron etal., 1989; Fukumoto et al., 1989; James 
et al., 1989; Kaestner et al., 1989). The rat gene encodes a 509 amino acid protein with 
an apparent molecular mass of 43 kDa, or when deglycosylated, 38 kDa (James et al.,
1989). GLUT4 has 65% sequence identity with GLUT1 and there is a 95% homology 
between the rat and human GLUT4 (Gould & Bell, 1990). When expressed in Xenopus 
oocytes GLUT4 has a Km for 3-O-MG transport of 1.8 mM when measured under 
equilibrium exchange conditions (Keller et al., 1989).
GLUT4 is expressed only in tissues in which glucose transport can be acutely 
regulated by insulin, that is, in adipose tissue and cardiac and skeletal muscle (Gould & 
Bell, 1990). In these tissues under basal conditions, that is, in the absence of insulin, the 
major glucose transporter isoform in the plasma membrane is GLUT1. The addition of 
insulin causes a 20-30 fold increase in the rate of glucose transport by increasing the Vmax 
for uptake without altering the Km for transport (Taylor & Holman, 1981). The acute 
action of insulin does not involve de novo protein synthesis but is mediated by the 
translocation of the GLUT4 glucose transporter isoform from intracellular vesicles to the 
plasma membrane. The structural property of GLUT4 that enables it to respond to glucose 
has not yet been identified. The proposed translocation of GLUT4 has become known as 
the "recruitment hypothesis" (Cushman & Wardzala, 1980; Suzuki & Kono, 1980). 
Insulin increases the cell-surface availability of GLUT4 by 15-20 fold, but the amount of 
GLUT1 only increases 3-5 fold indicating that it is the GLUT4 isoform that is responsible 
for mediating the insulin-stimulated increase in glucose transport (Holman et al., 1990). 
There is some controversy over whether recruitment alone can quantitively account for the 
insulin stimulation of glucose transport. This has led to the proposal that insulin also acts 
to increase the intrinsic activity of the recruited GLUT4 proteins (Suzuki, 1988).
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In insulin-resistant states such as fasting, diabetes mellitus and obesity, there is a 
decreased expression of GLUT4 in adipocytes and muscle tissue which results in decreased 
glucose uptake in response to insulin. These changes can be corrected by refeeding, 
insulin therapy or weight reduction respectively (Kahn & Flier, 1990).
1.2.4.5 GLUT5 - The small intestine glucose transporter
GLUT5 was cloned from human small intestine (Kayano et a l ,  1990). The gene 
encodes a 501 amino acid protein which has 41.7% identity with human GLUT1 and is 
thus the most divergent member of the glucose transporter family so far described.
GLUT5 mRNA has been detected in kidney, adipose and skeletal muscle tissue, 
although it is predominantly expressed in the small intestine, where it is localised on the 
apical brush border on the luminal side of the intestinal epithelial cells (Holman & Gould,
1992). While the protein can transport glucose in a cyt B-inhibitable manner, it has 
recently become evident that the major role of this isoform is actually as a high affinity 
fructose transporter (Holman & Gould, 1992).
1.2.4.6 GLUT6 - A pseudogene
A facilitative-glucose transporter-like cDNA sequence has been designated GLUT6  
by Kayano et al. (1990). The gene has been identified in a number of tissues, but because 
of the presence of multiple stop codons and frame shifts the sequence cannot encode a 
functional transporter protein.
1.2.4.7 GLUT7 - A hepatic microsomal glucose transporter
The most recently identified member of the glucose transporter family, GLUT7 is 
found in the liver endoplasmic reticulum and nuclear envelope but not in the plasma
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membrane (Waddell et al., 1992). The cDNA clone for GLUT7 was obtained by screening 
a library with an antibody raised against a purified rat hepatic microsomal glucose 
transport protein (Waddell & Burchell, 1991).
GLUT7 codes for a 528 amino acid protein with a calculated mass of 53 kDa. 
GLUT7 is 6 8 % identical to GLUT2, with ~ 100% identity being observed in membrane- 
spanning regions M1-M4, M9 and M10. The loop between Ml and M2 is identical, but 
the C-terminus contains an extra 6  amino acids, which may function to retain the protein in 
the endoplasmic reticulum.
GLUT7 is believed to be the component T3  of the hepatic microsomal glucose-6 - 
phosphatase system. This is a complex located in the endoplasmic reticulum membrane 
which is made up of 3 transport proteins, T] (glucose-6 -phosphate transporter), T2  
(phosphate transporter) and T3  (glucose transporter), a Ca^ + regulatory protein and the 
catalytic glucose-6 -phosphatase protein itself. The enzyme is responsible for producing 
glucose as the terminal step of gluconeogenesis and glyconeolysis. The T3  transporter 
(GLUT7) enables the glucose produced by the enzyme to leave the endoplasmic reticulum . 
It may therefore play a role in the regulation of the hepatic output of glucose.
1.3 GLUCOSE HOMOEOSTASIS
In higher animals it is essential that the blood glucose concentration is maintained 
within a narrow range. Sustained hypo- and hyper-glycaemia , if uncorrected, can both be 
rapidly fatal. Homoeostatic mechanisms are normally able to maintain blood glucose 
concentrations in humans within the safe range of 4-7 mM (Matschinsky, 1990). A key 
organ in glucose homoeostasis is the liver. After eating, it rapidly reduces blood glucose 
by converting it into the storage carbohydrate glycogen by the process of gly coneogenesis. 
In periods of starvation the liver can release glucose immediately by glycogen degradation, 
and over longer periods by gluconeogenesis. The liver accounts for 90% of the body's
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gluconeogenesis, the kidney the remaining 10%. Important to the functioning of both of 
these tissues is the presence of the high Km facilitative glucose transporter protein, 
GLUT2, which does not limit the rate of glucose influx or efflux even at high glucose 
concentrations (Thorens et al., 1990a).
Glucose homoeostasis is under hormonal control. The two most important 
hormones are glucagon and insulin which respectively raise and lower blood sugar 
concentrations by acting upon liver, muscle and adipose tissue. These hormones are 
produced by the endocrine tissue of the pancreas namely, distinct clusters of about 5000 
cells known as the Islets of Langerhans, which make up 1-2% of the total weight of the 
pancreas (Montague, 1983). In the adult human, 60-70% of the cells within the islet are 
insulin-secreting 6 -cells (Montague, 1983). About 20% of the islet cells are a-cells which 
secrete glucagon. The remaining cells are 6 -cells (10%) which secrete somatostatin, and 
PP cells (2%) which secrete pancreatic polypeptide hormone, the exact function of which is 
unknown (Montague, 1983).
1.3.1 Insulin secretion from normal pancreatic B-cells
The only efficient means by which an organism can lower its blood glucose 
concentration is by the release of the hormone insulin from storage granules in the 6 -cell 
cytoplasm (Prentki & Matschinsky, 1987). The 6 -cell has a unique method of responding 
to its major agonists. The main 6 -cell secretagogues, which include the sugars D-glucose, 
D-mannose, the amino acids leucine, arginine and lysine and certain fatty acids share the 
common feature that they can all be metabolized by the 6 -cell to generate metabolic signals 
responsible for the initiation of the insulin secretory response. This is in contrast to the 
situation in other secretory tissues in which agonists generate signals via a receptor. Since 
D-glucose, the predominant physiological signal controlling insulin secretion, does not 
mediate its insulinotropic effect by interacting with a receptor at the cell surface, it is 
essential to the secretory function of the 6 -cell that uptake of D-glucose is not rate limiting
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to the signal generating metabolic pathways. The expression of the high Km glucose 
transporter GLUT2 ensures that fi-cells are effectively freely permeable to glucose 
(Thorens et al., 1988). Therefore, if a fairly high threshold level of intracellular glucose is 
required to initiate insulin-secretion, the expression of a high Km transporter would be 
required to ensure that the intracellular glucose concentration reached this threshold.
Understanding the factors involved in the normal recognition of D-glucose by fi- 
cells is important, since defects in these sites may be associated with the impaired ability of 
D-glucose to induce insulin secretion in the disease diabetes mellitus (Robertson & Porte, 
1973; Malaisse, 1988). Although it need not actually be located at the cell surface, a 
sensor or receptor component is necessary in any stimulus response pathway. In both liver 
and islet cells in addition to the normal low Km glucose phosphorylating enzyme 
hexokinase, there is also a unique high Km phosphorylating enzyme called glucokinase 
(ATP:D-glucose 6 -phosphotransferase [EC 2.7.1.2]), This enzyme is widely believed to 
play a pivotal role as the 6 -cell glucose sensor, since it is the activity of this enzyme that 
determines the rate of metabolic flux through the glycolytic pathway. (Bedoya et al., 1986; 
Matschinsky, 1990). Inhibition of glucose phosphorylation by mannoheptulose blocks 
glucose-induced insulin secretion indicating that the phosphorylation step is important 
(Ashcroft & Crossley, 1975; Hedeskov, 1980).
The 15 amino acids present at the amino terminus of islet glucokinase may, by 
virtue of their high number of positively charged residues, allow for an electrostatic 
interaction with islet GLUT2 (Newgard et al., 1990). This association may effectively 
compartmentalize the 8 -cell so that phosphorylation is carried out by glucokinase rather 
than hexokinase (MacDonald, 1990). This putative interaction may enable the 6 -cell 
glucose transporter and glucokinase to function in tandem as the 8 -cell glucose sensor 
(Thorens etal., 1988).
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Although there is a considerable amount of experimental evidence supporting the 
hypothesis that most 6 -cell agonists are metabolized, the identity of these proximal signals 
remains elusive. Most evidence favours energy parameters rather than specific metabolites 
as signals. The signals are probably unique to each individual secretagogue but may 
include the NAD+ (P):NAD(P)H ratio, pH, phosphorylation potential, guanine nucleotides 
and acyl-co-A (Prentki & Matschinsky, 1987). Much more is known about the distal 
components of the signalling system which appear to operate the same in fi-cells as in other 
secretory cells (MacDonald, 1990).
The proposed sequence of events that results in insulin secretion is as follows. The 
metabolism of glucose causes an increase in ATP which mediates the closure of K+ 
channels (Prentki & Matchinsky, 1987). This results in the depolarization of the 6 -cell 
causing voltage-gated Ca^+ channels to open and influx of Cs? + to occur. This transient 
rise in Ca? + is a prerequisite for glucose-induced insulin secretion as shown by the ability 
of Ca2+ channel antagonists to inhibit the sustained phase of glucose-induced insulin 
release. CaP + may mediate insulin secretion by a number of mechanisms including the 
activation of protein kinases which results in an alteration in the phosphorylation states of 
specific proteins which effect insulin secretion in an as yet unknown manner.
1.3.2 fi-cell lines as models of normal islet fi-cells
The study of the physiology of 6 -cells has been impeded by the fact that the normal 
method used to isolate them from pancreatic tissue is a time consuming and expensive 
procedure which results in the production of a small quantity of a heterogeneous population 
of islet cells. The development of 6 -cell lines, that can be maintained in tissue culture, has 
been of importance in studies of insulin secretion and 6 -cell antigenicity. Some of the 
similarities and major differences between 6 -cell lines and native 6 -cells are outlined 
below.
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1.3.2.1 The RIN 6-cell line
The RIN or rat insulinoma cell line was established in culture from radiation- 
induced transplantable islet tumours in rats (Gazdar et al., 1980). Several subclones have 
been established from the RIN cell line, including RINm5F a widely used clone.
RIN cells are abnormal fi-cells in that they do not secrete insulin in response to 
glucose, although alternative secretagogues including leucine, glyceraldehyde and arginine 
are able to induce insulin secretion (Lambert & Atkins, 1987). The defect is glucose- 
specific, suggesting a deficiency in the normal glucose transport or glucose- 
phosphorylating activity of the cell line. RIN cells are also resistant to the cytotoxic action 
of the diabetogenic drugs alloxan and streptozotocin which affect native /3-cells (Kawada et 
al., 1987; Malaisse, 1988). Most studies have shown that there is a deficiency in RIN 
cells which results in a slow uptake of 3-O-MG. In RIN 1046-38 cells a Km for D-glucose 
of 6  mM has been obtained (Powers et al., 1990). This contrasts with the behaviour of 
pancreatic fi-cells which have a high Km for D-glucose and equilibrate sugar within 2-3 
minutes (Meglasson et al., 1986; Malaisse, 1988). The abnormal expression in RIN cells 
of the GLUT1 transporter isoform (Thorens et al., 1988; Powers et al., 1990; Brant et 
al., 1992), may contribute to both the low rate of glucose transport in these cells and their 
abnormal glucose response (Thorens et al., 1988). A relationship between a reduction in 
glucose transport and decreased insulin secretion, has also been demonstrated by Shibaski 
et al. (1990) in an experiment in which insulin secretion in RIN cells was increased by 
transfecting the cells with GLUT1 mRNA. This indicated that an increase in glucose flux, 
regardless of the transporter isoform through which it occurred could mediate insulin 
release from RIN cells.
It has been shown that RIN cells have defects in addition to abnormal glucose 
transporter expression. Glucose metabolism in this cell line is 8-10 fold higher than in 
normal 6 -cells, therefore the rate of glucose transport may be limiting to glucose 
phosphorylation (Halban et al., 1983). It has also been shown that RIN cells do not
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express glucokinase (Halban et al., 1983; Shimizu et al., 1988) although the hexokinase 
enzyme is 8  times more active than in normal islets (Halban et al., 1983). How important 
the presence of glucokinase is to the normal glucose response is unclear, since although it 
has been shown that increasing the activity of RIN cell glucokinase does increase basal 
insulin secretion it does not make the cells responsive to glucose (Femandez-Mejia & 
Davidson, 1990).
Owing to their failure to secrete insulin in response to glucose despite having a 
normal response to other insulinotropic agents, RIN cells have become important models in 
which to investigate the glucose sensor function of 6 -cells. The essential deficiency in RIN 
cells has yet to be identified.
1.3.2.2 The HIT B-cell line
Another popular 8 -cell model, the HIT (hamster islet tumour) cell line was 
established by Simian virus 40 transformation of Syrian hamster pancreatic islet cells 
(Santerre et al., 1981). The clone used in most studies is the HIT-T15 line. HIT cells are 
important models of the 6 -cell since they retain the ability to secrete insulin in response to 
glucose. Although stimulation of glucose-induced insulin secretion is 3.5 fold lower than 
in hamster islets, peak stimulation of HIT cells by glucose occurs at 7.5 mM which is 
similar to the response of normal hamster islets (Santerre et al., 1981; Lambert et al., 
1986). HIT cells also be stimulated with leucine and arginine (Lambert et al., 1986) 
although the general responsiveness decreases with increasing passage number (Zhang et 
al., 1989).
HIT cells have been shown to contain glucokinase, but they differ from normal 8 - 
cells in their predominant usage of the low Km hexokinase enzyme (Shimizu et al., 1988). 
Since the glucose transport inhibitors cyt B and phloretin are able to block glucose-induced
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insulin secretion but mannoheptulose, an inhibitor of glucose phosphorylation, is not, 
glucose metabolism in HIT cells is limited by the rate of entry of glucose into the cell 
(Ashcroft & Stubbs, 1987). Therefore in contrast to native 6 -cells, glucose transport is the 
rate determining step and the glucose transporter is the "glucose sensor" that confers 
concentration dependence and specificity on the HIT cell line.
Western and Northern blotting of HIT cells has confirmed that like RIN cells they 
abnormally express GLUT1 (Powers et al., 1990; Brant et al., 1992) and exhibit slow 
glucose transport in which equilibration between internal and external sugar is not attained 
(Meglasson et al., 1986). Ashcroft & Stubbs (1987) have reported a Km for D-glucose of
4.3 mM.
HIT cells have been used to investigate the regulation of 8 -cell glucose transporter 
expression, the advantage being that, using cells in culture, a single regulatory factor can 
be investigated in isolation. Unfortunately, results obtained with cultured cells have been 
contradictory. Using isolated rat 8 -cells cultured in high concentrations of glucose, Orci et 
al. (1990b) found a slight, but not significant, increase in the GLUT2 protein. Similarly, 
in HIT cells, although GLUT2 mRNA was found to increase 3 fold when glucose was 
increased from 2.8-22.2 mM, no change in the level of the GLUT2 protein was detected 
(Seino et al., 1991). In contrast, in a study by Purrello et al. (1991) both GLUT1 and 
GLUT2 mRNA levels were shown to decrease when HIT cells were cultured in high 
glucose. This correlated with a decrease in glucose-induced insulin secretion and in the 
rate of 2 -deoxyglucose transport.
HIT cells express the low Km glucose transporter GLUT1, and have rates of 
glucose transport low enough to limit glucose metabolism, yet they can still secrete insulin 
in response to glucose. This implies that the ability of 6 -cells to respond to glucose is not 
simply dependent on a high rate of glucose transport or on exclusive expression of 
GLUT2 (Thorens et al., 1988). Possibly of more importance, is the ratio of GLUT2 to
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glucokinase. These two proteins may interact to form functional "glucose sensing units" 
which may be involved in the 6 -cell response to glucose (Newgard et al., 1990; Unger, 
1991).
1.3.2.3 The MIN 6-cell line
Two permanent cell lines have recently been developed which may help to solve 
the question of the importance of the GLUT2 transporter in glucose-induced insulin 
secretion. The MIN (mouse insulinoma) cell lines were established from insulinomas 
obtained by targeted expression of the Simian virus 40 T antigen gene in transgenic mice. 
MIN cells produce insulin and have the morphological characteristics of pancreatic 6 -cells 
(Miyazaki et al., 1990). The MIN 6  cell line is reported to express a high level of 
GLUT2, but GLUT1 is said to be barely detectable. These cells exhibit glucose-induced 
insulin secretion comparable with that found in normal mouse islets . In contrast, the MIN 
7 line, in addition to high levels of GLUT2, also expresses high levels of GLUT1 and does 
not respond to glucose.
MIN 6  cells are therefore a useful model of native 6 -cells being unusual in that 
they have reportedly been immortalized without the induction of GLUT1. The exclusive 




Diabetes mellitus is a chronic metabolic disorder affecting normal glucose 
homoeostasis. It is characterised by hyperglycaemia, caused by a relative or absolute 
deficiency in insulin. Only recently was it realized that diabetes mellitus is not a single 
disease but a group of syndromes in which hyperglycaemia is the common feature. In
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1979, the National Diabetes Data Group developed a nomenclature and classification 
system for diabetes mellitus which has now been universally accepted.
Type I diabetes is also known as insulin-dependent diabetes mellitus, abbreviated 
as IDDM. It was formerly called juvenile onset diabetes since it occurs mainly, but not 
exclusively in younger people, typically those less than 30 years old. The type I diabetic 
patient is absolutely dependent on an exogenous supply of insulin, required because the 
insulin secreting 8 -cells in the pancreas have been completely destroyed.
Type II diabetes is also known as non-insulin dependent diabetes mellitus 
(NIDDM). It was formerly called maturity or adult onset diabetes since it generally occurs 
in older people, although it is also known in the young. Approximately 70-80% of all 
diabetic patients have the non-insulin dependent form of diabetes and in many cases it is 
linked to obesity and insulin resistance in the peripheral tissues (Lefebvre, 1988). In 
NIDDM patients, 8 -cells are still present, therefore these patients are not dependent on 
exogenous insulin. However, since the 8 -cell response to glucose is usually impaired 
(Robertson & Porte, 1973), insulin may be administered to relieve symptomatic 
hyperglycaemia. In many cases oral hypoglycaemic drugs, such as the sulphonylureas, can 
reduce hyperglycaemia by acting as alternative insulin secretagogues and by improving 
glucose uptake in peripheral tissues.
Important features of these two types of diabetes are illustrated in Table 2.
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Type I insulin dependent 
diabetes mellitus (IDDM)
Type II non-insulin dependent 
diabetes mellitus (NIDDM)
Age at onset Usually < 30 Usually > 40
Appearance of symptons Usually rapid Insidious
First functional abnormality Reduced glucose induced Reduced glucose induced
insulin secretion insulin secretion
Ketoacidosis Common Uncommon
Obesity Uncommon Common
Concordance in monozygotic 
twins
*50% *  100%
HLA association Present Absent
Percentage of diabetic patients *20% *80%
Insulin resistance Rare Common
Initial pathology of the pancreas Insulitis Usually none
Late pathology of the pancreas Absence of 6-cells 6-cell mass usually normal 
Amyloid deposition & fibrosis
Disease aetiology Autoimmune destruction of 6- 
cells
Unknown
Anti-islet cell antibodies Present at onset 
Reduction in 6-cell mass
Absent
Table 2 A comparison of the features of Type I and Type II diabetes mellitus.
1.4.1 The pathogenesis of diabetes mellitus
In type I diabetes the absence of insulin means that glucose cannot be taken up by 
insulin-sensitive tissue. This causes an increase in the blood glucose concentration. When 
this exceeds the renal threshold of 10 mM, glycosuria occurs and with it, dehydration 
(Montague, 1983). This results in a decrease in the peripheral circulatory volume, tissue 
anoxia occurs and lactic acid is produced. If untreated, acidosis occurs and patients can 
become comatose and die. Since, in the absence of insulin, glucose cannot be utilized by 
adipose cells, fat depots are mobilized and taken up by the liver which produces acetoacetic 
acid and 6 -hydroxybuturic acid. This results in ketoacidoisis and excretion of ketone 
bodies. Not long ago death from ketoacidoisis at the onset of diabetes was very common, 
today it accounts for less than 1% of all diabetes related deaths (Terranova et al., 1982). 
Symptoms at the onset of diabetes include extreme thirst, hunger, polyuria and weight loss.
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Until 1921 when insulin was discovered, type I diabetes was rapidly fatal. Today 
diabetics can lead relatively normal lives, although insulin therapy cannot be considered a 
"cure" since the administration of exogenous insulin never exactly mimics normal insulin 
secretion. In an attempt to keep blood sugar within the normal range too much insulin can 
be administered, the resulting hypoglycaemic episode can lead to coma and death if 
untreated. Less intensive insulin therapy resulting in hyperglycaemia has been linked with 
the long term complications of diabetes. Current diabetic therapy therefore aims for a 
compromise between these two extremes.
Much of the mortality and morbidity associated with diabetes is caused by the 
chronic complications arising from long-term metabolic disturbances. After 3-15 years of 
diabetes 80-90% of all patients exhibit microangiopathy arising from a thickening of the 
capillary basement membrane (Williamson & Kilo, 1982). This change causes blood 
vessels to become blocked, oxygen exchange cannot occur and tissue hypoxia results. 
When microangiopathy occurs in the extremities of the limbs it can cause gangrene. In the 
kidney it can result in nephropathy and kidney failure, which is responsible for the death of 
a third of all patients with IDDM (Cullinan, 1982). When microangiopathy occurs in the 
eye it can cause retionopathy which is the commonest cause of blindness in people of 
working age in the U.K. (Connor & Boulton, 1989). Heart disease and neuropathy are 
also commonly associated with diabetes. The precise way in which diabetes causes such 
widespread organ damage is not known but the risks seem to be associated with sustained 
hyperglycaemia and increased duration of diabetes.
The complications of diabetes mellitus are therefore both numerous and serious. 
According to some estimates more than 60 million people today may be suffering from 
diabetes (Zimmet, 1991). This is a problem not only in terms of personal suffering but in 
the burden that it places on society in terms of expensive health care and lost working 
days. At present, diabetes affects about 5% of the population of the Western world 
(Lefebvre, 1988), but there is evidence that it is an increasing problem. It has even been
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suggested that the rise in incidence of NIDDM in developing countries is best described as 
an epidemic (Zimmet, 1991).
1.4.2 The aetiology of NIDDM
Type II diabetes is probably not a single disease but a collection of syndromes. 
Relatively little is known about the basic defects and even less about the underlying causes 
of the disease.
There is a strong hereditary component since concordance between monozogotic 
twins is almost 100% (Lefebvre, 1988) and the risk for siblings of diabetic patients is 29%. 
In certain populations, for example the Pima Indians of Arizona, prevalence can reach BO- 
35 %. NIDDM may be associated with poor diet, decreased physical activity, increased 
smoking, obesity and increased alcohol consumption.
Morphologically the pancreas of a type II diabetic appears almost normal. The fi- 
cells however seem to have a specific functional deficiency, that is, a decreased ability to 
secrete insulin in response to stimulation with glucose. NIDDM is therefore characterised 
by abnormal insulin secretion from the pancreas, with the additional problem of insulin 
resistance in the peripheral tissues which in many cases is augmented by obesity. The 
precise biochemistry of the insulin resistance is unknown.
1.4.2.1 Evidence for abnormal glucose transport in NIDDM
Although in the type II diabetic pancreas D-glucose does not stimulate insulin 
secretion, alternative insulinotropic agents such as arginine and the sulphonylureas can still 
produce an insulin response. The abnormality must therefore be confined to the "glucose 
sensor" component of the 6 -cell insulin secretory pathway. A down-regulation of the high
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Km 6 -cell GLUT 2 could potentially cause this altered glucose sensitivity. This has been 
investigated in several animal models of NIDDM.
A reduction in 6 -cell GLUT2 has been detected in Zucker diabetic fatty (ZDF) rats 
(Johnson et al., 1990b; Orci et al., 1990b), in insulin-resistant diabetic Wistar Kyoto rats 
(Orci et al., 1990b), in GK rats, which exhibit a selective inhibition of glucose-stimulated 
insulin secretion, (Orci et al., 1990b) and in rats that developed NIDDM as a result of 
neonatal injection of streptozotocin (Thorens et al., 1990e). In severely diabetic animals 
reductions in GLUT2 of 75% and 85% were found respectively in ZDF rats and in rats 
made diabetic with streptozotocin (Johnson et al., 1990b; Thorens et al., 1990e). In 
diabetic animals the transport of 3-O-MG was also reduced to less than 40% of that found 
in control animals (Johnson et al., 1990b). Destruction of about 60% of the total 6 -cell 
population was shown to be sufficient to prevent the secretion of insulin in response to 
glucose, although it did not affect the arginine response (Johnson et al., 1990b).
Orci et al. (1990b) investigated whether the reduction in GLUT2 could be caused 
by hyperglycaemia. The conclusion reached was that both in vitro and in vivo, exposure to 
high glucose could not induce a deficiency in 6 -cell GLUT2 nor could elimination of 
hyperglycaemia in prediabetic animals prevent the GLUT2 deficiency. Since it does not 
occur in response to diabetic hyperglycaemia, the decrease in the expression of GLUT2 
may play a role in the development of NIDDM.
A scenario for the development of NIDDM could therefore be as follows. An 
unknown primary event, genetic or environmental, reduces 6 -cell GLUT2. This reduction 
causes a decrease in glucose transport and reduces glucose-induced insulin secretion which 
leads to hyperglycaemia. The condition is aggravated by the insulin resistance of the 
peripheral adipose and muscle tissues which are normally responsible for insulin-stimulated 
glucose disposal. This insulin resistance may be partially attributable to decreased 
expression of the GLUT4 glucose transporter in these tissues (Friedman et al., 1991; Vogt
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et al., 1991). The level of blood glucose is not therefore reduced by uptake into these 
tissues, hyperglycaemia increases, the 15-cell is unable to respond and NIDDM results 
(Unger, 1991).
1.4.3 Insulin dependent diabetes mellitus (IDDM)
The disease IDDM arises from a specific necrosis of islet 6 -cells. Although the 
onset of the disease is generally sudden and occurs when the 6 -cell mass has decreased 
below 90%, the destruction process is insidious and can have started many years 
previously. During this pre-overt period patients often have an abnormal insulin response 
to an oral or intravenous glucose challenge.
The mediator of this destruction is the immune system, which attacks self antigens 
present on the islet 6 -cell. The antigenic target of the immune response has still to be 
unequivocally identified, as have the factors leading to the breakdown of normal self 
tolerance. The autoimmune process may be initiated by environmental factors or may be 
the result of a genetic defect.
1.4.3.1 Environmental or genetic aetiology ?
Although diabetes can be induced experimentally by chemicals such as alloxan and 
streptozotocin which are selectively toxic to 6 -cells, there is very little evidence that any 
specific chemical is associated with the normal aetiology of IDDM.
There is some evidence for an association between infection with certain viruses, 
including the mumps virus, rubella and Coxsackie B4, and the development of IDDM 
(Yoon, 1990). The evidence for viral involvement has stemmed largely from work on 
experimental animals. However, epidemiological studies have also shown that there is a 
seasonal variation in the clinical onset of IDDM with relatively more cases diagnosed
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during the autumn and winter months, when viral infections are more common (Green, 
1990). There is also a peak in incidence at the ages of 12-15 years and 5-6 years, the times 
when children start or change schools and thereby meet new viruses (Bottazzo, 1986). 
Viruses could act as primary injurious agents of 8 -cells or they could alter the structure or 
expression of normal 8 -cell proteins. The anti-8 -cell antibodies detected in diabetic 
patients could therefore be generated in response to antigens produced by the damaged or 
infected 8 -cells. Alternatively, a viral infection could indirectly trigger an autoimmune 
response against the 8 -cell if antigenic epitopes present on the virus were also contained in 
8 -cell proteins. There is some evidence that an epitope on RIN 8 -cells, recognised by 
antibodies in diabetic serum, is shared with the rubella virus (Karounos et al. 1990).
Genetic factors also play a role in the development of IDDM, since first-degree 
relatives of diabetic patients have a risk of developing the disease that is about 1 0 - 2 0  fold 
higher than in the general population (Green, 1990). However, the fact that the 
concordance rate for monozygotic twins is only 50% means that an environmental factor is 
also likely to be involved. There is evidence that genes within the major histocompatibility 
complex (MHC) contribute to the development of IDDM, since there is an association with 
the HLA-D region which contains the DP, DQ, and DR genes that code for the class II 
molecules found on cells of the immune system (Bottazzo, 1986; Atkinson & Maclaren, 
1990). The serologic types HLA-DR3 and -DR4 are positively associated with IDDM, 
since about 95% of Caucasian diabetics have DR3 or DR4 alleles compared with about 
50% of the general population.
The inheritance of the DR3 or DR4 haplotype is a marker for about 100 genes that 
are in linkage disequilibrium with the DR3 and DR4 genes. Potentially, any one of these 
genes could confer susceptibility to IDDM. However, the observed association of other 
autoimmune diseases with the inheritance of certain HLA haplotypes means that the class II 
loci themselves must be considered the strongest candidates for the disease genes in 
autoimmune diabetes (Green, 1990). The genes encoding DR3 and DR4 probably do not
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confer susceptibility themselves, but are linked to genes in the DQ region that do (Atkinson 
& Maclaren, 1990; Nepom, 1990).
It has been proposed that the presence of an aspartic acid residue at codon 57 in the 
6 -chain of the protein encoded by HLA-DQ could help to prevent the development of 
IDDM (Todd et al., 1987). This negatively charged residue seems to play a role in the 
formation of a salt bridge between the a  and 6  chains of the DQ molecule (Green, 1990). 
The substitution of valine, a non-charged amino acid, at codon 57 has been shown to cause 
susceptibility to diabetes. If this substitution affects the structure of the DQ molecule it 
may facilitate the autoimmune response that results in IDDM (Atkinson & Maclaren, 
1990).
Since there are no unique class II sequences found only in diabetics, there are 
probably many genes both within and outside the MHC that contribute IDDM 
susceptibility.
1.4.3.2 Autoimmune aetiology
Although during development immunoreactive cells that recognise many different 
epitopes are generated randomly, the normal immune system is able to distinguish self 
from non-self with great precision, mounting immune responses only against foreign 
antigens. Self tolerance may be achieved by the elimination during early ontogeny of T- 
cell clones possessing receptors recognising self antigens. If potentially autoreactive clones 
leave the thymus they can be held in a state of long-term unresponsiveness known as clonal 
anergy. Alternatively, peripheral autoreactive T cells can be inactivated or inhibited by 
suppressor T (Ts) cells.
There is evidence that the autoimmune response in IDDM occurs against a normal 
6 -cell antigen, since autoantibodies from diabetic serum recognize antigens in normal
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pancreas. This implies that the defect in IDDM that allows a response to occur against a 
self antigen is in the regulatory component of the immune system. A failure to correctly 
regulate other autoreactive clones could also explain the increased incidence of other 
autoimmune disorders, such as idiopathic Addisons disease and autoimmune thyroid 
disease, in diabetic patients.
Although an impaired regulatory response may predispose to IDDM susceptibility, 
an initiating factor is still be required to trigger the immune attack against the 6 -cells. It 
has been shown that in pancreatic tissue taken from diabetics who died shortly after 
diagnosis of IDDM, some of the remaining 6 -cells within the islets abnormally express 
MHC class II molecules (Bottazzo et al., 1985) and seem to have a hyper-expression of 
MHC class I molecules. Bottazzo et al. (1985) proposed that the abnormal expression of 
class II antigens could initiate an autoimmune response by cytotoxic T cells (Tc) by 
enabling helper T (Tjj) cells to be directly activated by the islet 6 -cells, without the need 
for the processing of 6 -cell antigens by antigen presenting cells. Class II molecules have 
been shown to be induced by interferon (Bottazzo et al., 1983; Bottazzo, 1986). When 6 - 
cells were made to over-express this cytokine, pancreatic inflammation and insulitis 
occurred and 6 -cells increased their expression of MHC molecules (Sarvetnick, 1990). It 
is not however known whether or not the production of class II molecules on 6 -cells 
precedes insulitis and therefore whether it is a consequence or cause of the autoimmune 
response against the 6 -cells.
Although the factor initiating the autoimmune attack on 6 -cells is unknown, the 
agents of destruction appear to be both humoral and cell mediated.
1.4.3.2.1 Cell-mediated autoimmunity
In the Biobreeding (BB) rat and the non-obese diabetic (NOD) mouse, both models 
of autoimmune diabetes, as well as in 78% of human IDDM patients, insulitis can be
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detected in pancreatic islets at the onset of diabetes (Foulis & Bottazzo, 1988; Lo, 1990). 
The infiltrating cells are mononuclear lymphocytes the majority being activated T-cells of 
the CD8 + type (Tc). Small numbers of CD4+ (Tjj) are also detected (Bottazzo et al., 
1985). There is evidence from animal studies that autoimmune diabetes is essentially T- 
cell mediated since neonatal thymectomy can stop development of the disease as can 
treatment with cyclosporin A, which affects the function of T cells. Diabetes can also be 
transferred from diabetic animals by adoptive transfer of CD4+ and CD8 + cells (Lo, 
1990). Antibodies directed against these cell types can prevent disease onset (Cooke,
1990). The other major cell types that can be detected in the islet infiltrate are natural 
killer (NK) cells, macrophages and B lymphocytes. In animals, depletion of NK cells and 
inhibition of macrophages can prevent the development of diabetes (Cooke, 1990; 
Mandrup Poulsen et al., 1990).
Although the specific destruction of 8 -cells is generally deemed to be effected by a 
specific class II-restricted immune response, it is also possible that non-specific 
immunological events are involved. The selective killing of the 8 -cells is possible because 
of the unusual susceptibility of this cell type. For example, the effect of cytokines on 8 - 
cells is dramatic. Active 8 -cells can readily be killed by interleukin 1 which causes cell 
lysis. 8 -cells are also susceptible to free oxygen radicals, produced by the respiratory burst 
of phagocytic cells, because of their low levels of superoxide dismutase and other 
scavengers (Mandrup Poulsen et al., 1990).
The following scenario summarises some of the putative mechanisms involved in 8 - 
cell destruction. In individuals with a genetic predisposition to IDDM, a triggering factor 
causes inflammation in the islets. This factor may be a virus which cross-reacts with a 8 - 
cell autoantigen. Macrophages could present the foreign antigen in association with MHC 
class II molecules, thereby activating specific Tjj cells. These in turn could activate Tc 
cells which would kill the islet 8 -cells expressing the cross reacting autoantigen. 
Alternatively, the 8 -cells themselves could be induced to express class II molecules and
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could then initiate the autoimmune response by self-presentation of autoantigens. It is also 
possible that autoantigens released from injured 8 -cells could be presented by macrophages 
to generate specific T cell help. Once specific Tjj cells are activated, B lymphocytes may 
also be activated. The presence of cytokines and antibodies would attract more 
macrophages and natural killer cells. 6 -cells could be killed specifically by Tc cells and 
antibody- or complement-mediated cytotoxicity, as well as by direct cytokine sensitivity. 
8 -cell lysis would release autoantigens which would generate more autoantibodies thereby 
enhancing the ongoing 6 -cell destruction (Atkinson & Maclaren, 1990).
1.4.3.2.2 Antibody-mediated autoimmunity
At the onset of IDDM about 91% of patient have circulating antibodies reactive 
with components of islet cells (Lemmark et al., 1981). Although these antibodies can be 
present in patient's serum many years before the onset of the clinical symptoms of diabetes, 
their relevance to the pathogenesis of IDDM remains a matter of debate, since experimental 
transfer of diabetic antibodies has never been shown to cause the disease. Similarly there 
are no transplacental effects on neonates born to diabetic mothers.
Islet cell specific antibodies found in the serum of patients with IDDM have 
traditionally been divided into two groups according to the method by which they are 
detected:
i) ICCA - Islet cell cytoplasmic antibodies
ii) ICSA - Islet cell surface antibodies
i) Islet cell cytoplasmic antibodies (ICCA)
Studies have shown that between 50-90% of patients with IDDM have ICCA 
(Sigurdsson & Baekkeskov, 1990). Initially, the lack of standardized methodology for the
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ICCA assay made inter-laboratory comparisons of ICCA titres difficult. Recently, 
international workshops have established standardized protocols, which by use of standard 
sera enable titres to be reported in standard JDF (Juvenile Diabetes Foundation) units.
The conventional ICCA assay uses immunofluorescence to detect antibodies 
binding to cytoplasmic islet cell antigens in cryostat sections of human blood group O 
pancreas (Lernmark et al., 1981; Marner et al., 1984). The ICCA which are of the IgG 
class (Millward et al., 1988) do not only recognise species-specific antigens, since they 
have also been shown to detect antigens present in rodent pancreas (Dib et al., 1987). 
ICCA react with all of the four islet cell types and not specifically with 6 -cells (Doniach et 
al., 1985). The target antigen of ICCA has neither been isolated nor fully identified, 
although it has been suggested that it may be a glycolipid with the characteristics of a 
sialoglycoconjugate (Nayak et al., 1985; Marshall et al., 1991). Living cells are not 
permeable to immunoglobulins and since ICCA recognise cytoplasmic antigens it seems 
likely that they were generated following the death of the 8 -cell and therefore that they do 
not play a major role in the aetiology of IDDM.
However, prospective studies have shown that ICCA can appear up to 8  years 
before diabetic symptoms (Srikanta et al., 1983). About 80% of patients have ICCA at 
diagnosis, this figure drops to about 62% after the first year, 37% after 2-4 years and after 
4 years only 11% of patients are still ICCA positive ( Lernmark et al., 1981; Braining et 
al., 1984). This decrease probably reflects the diminishing prevalence of 8 -cells and 
therefore a decrease in antigenic stimulation. Other studies have found ICCA to be more 
persistent with 62% of patients still having antibodies 3 years after diagnosis (Kolb et al., 
1988).
Although the prevalence of ICCA in the general population is low (~0.4% ), 
approximately 25% of first degree relatives of IDDM patients have persistent ICCA in 
their serum. This high prevalence questions the validity of using these antibodies as
43
predictors of IDDM, since only about a quarter of these ICCA-positive relatives will 
actually become diabetic (Lernmark, 1980). Although approximately 99% of relatives 
developing IDDM have ICCA up to 8  years previously, this still leaves 30-60% of 
relatives positive for ICCA who do not develop IDDM in an 8  year follow up period 
(Johnston et al., 1989). Some studies have suggested that high titres of ICCA (>  80 JDF 
units) are predictive for IDDM development, whereas low titres (<  4 JDF units) are less so 
(Bonifacio et al., 1989; Johnson et al., 1989; Karjalainen, 1990). Other studies have 
however found no correlation with the ICCA titre and 8 -cell damage (Neifing et al., 1990). 
In conclusion, the role of ICCA as markers of ft-cell damage and IDDM pathogenesis 
remains controversial.
ii) Islet cell surface antibodies (ICSA)
Islet cell surface antibodies are, by definition, antibodies which react with surface 
antigens on viable islet cells. They are non-species specific and traditionally have been 
detected in an indirect immunofluorescence assay using dispersed viable rat or mouse islets 
as the antigen (Lernmark et al., 1978; Lernmark et al., 1981; Mamer et al., 1984). 
Human pancreas has also been used to detea ICSA both in an indirect immunofluorescence 
assay using cultured foetal islets (Pujol-Borrell et al., 1982) and in an assay using single 
human islet cells in which immunofluorescence is deteaed by flow cytometry (Peakman et 
al., 1990; Vergani et al., 1991). Quantification of ICSA titres has been improved by 
using 125i protein A to detea the bound antibodies (Lernmark et al., 1980). ICSA have 
also been detected using rat plasma membrane in an ELISA which is reported to detect 
higher binding by diabetic compared with control sera (Peakman et al., 1989). Cultured 15- 
cells can be used to detea ICSA, for example, RIN cells (Lander et al., 1989), human 
insulinoma cells (Maclaren et al., 1975) and HIT cells (Matsuba et al., 1987) have been 
used in indirea immunofluorescence and ^ 5 i  protein-A binding assays to demonstrate the 
presence of higher levels of ICSA in diabetic compared with normal serum. RIN cells have 
also been successfully used to detea ICSA in a cell surface ELISA (Thomas et al., 1987)
44
and in an assay which has shown that 94% of diabetic sera contain antibodies that can 
displace a specific monoclonal antibody from the surface of RIN cells (Keilacker et al., 
1988; Thomas etal., 1990; McEvoy etal., 1991).
As there is no standardizable assay for ICSA, reports of the prevalence of these 
antibodies have been variable. Between 30-80% of patients with new onset IDDM have 
ICSA (Lernmark et al., 1978; Lernmark et al., 1981; Pujoll-Borrell et al., 1982). They 
are found independently of ICCA, with 49% of patients being discordant for the two types 
of antibody (Freedman et al., 1980; Lernmark et al., 1981). Using an indirect 
immunofluorescence assay on rat islet cells Lernmark et al. (1981) reported that 53% of 
seventeen young diabetic patients had ICSA at the onset of IDDM. This decreased to 30% 
after 6  months and to 2 0 % after 18 months indicating the evanescent nature of these 
antibodies. Between 2-4% of the general population have ICSA (Lernmark et al., 1978; 
Lernmark et al., 1981). ICSA have been detected in 44% of children with glucose 
intolerance, which is often an indication that they will progress to overt diabetes, although 
the significance of ICSA to the pathogenesis of IDDM has not yet been established since 
ICSA titre at diagnosis does not seem to correlate with residual 6 -cell function.(Todd & 
Bottazzo, 1985).
In vitro, ICSA have been shown to kill 8 -cells by complement-dependent and cell- 
mediated cytotoxicity (Dobersen et al., 1980; Maruyama et al., 1984). As discussed in 
section 1.4.3.2.3 (iii) these antibodies may also affect 8 -cell function. Therefore, there is 
some evidence that ICSA are involved in the pathogenesis of human IDDM. Further 
experimental evidence is provided by the detection of ICSA in three animal models of 
diabetes. ICSA have been found in the BB rat (Dyrberg et al., 1982), in mice in which an 
autoimmune form of diabetes was induced by multiple low doses of streptozotocin (Itoh et 
al., 1984), and in the NOD mouse (Karounos & Thomas, 1990).
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The antigens recognised by ICSA have not been identified, but since they are 
expressed on the surface of viable 6 -cells they are potentially accessible to attack by 
autoantibodies and are therefore of putative pathological significance in the aetiology of 
IDDM.
1.4.3.2.3 Identification of putative autoantigens
Only two target antigens of islet cell antibodies have been positively identified. 
The first is insulin, the second, a 64 kDa protein recently identified as glutamic acid 
decarboxylase (GAD) (Baekkeskov et al., 1990). It has also been proposed that the 6 -cell 
glucose transporter protein GLUT2 may be an autoantigen although this has yet to be 
proven (Johnson et al., 1990a). A number of other antigens have been identified by 
molecular mass only.
i) Insulin as an autoantigen.
Insulin autoantibodies (IAA) can be detected in some newly diagnosed diabetic 
patients prior to their treatment with exogenous insulin. IAA are especially prevalent in 
young children, but they do not seem to be important in the pathogenesis of IDDM, since 
their presence before diagnosis does not affect the clinical course of the disease 
(Karjalainen et al. , 1988).
ii) The 64 kDa antigen.
The best characterised islet cell autoantigen is a 64 kDa protein first described in 
1982 by Baekkeskov and co-workers. It has been identified as the enzyme glutamic acid 
decarboxylase (GAD) (Baekkeskov et al., 1990). This enzyme converts glutamic acid to 
the inhibitory neurotransmitter gamma-aminobutyric acid (GAB A). It is found in GAB A 
secreting neurones of the central nervous system and in pancreatic 6 -cells where it has been
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speculated that its role is as an endocrine transmitter involved in glucose-induced insulin 
secretion (Baekkeskov et al., 1990). This is supported by the failure to detect GAD in 
insulinoma cell lines which have an abnormal response to glucose (Baekkeskov et al., 
1988).
The initial interest in this 64 kDa antigen was aroused by the discovery that 
between 70-80% of serum samples from patients with recently diagnosed IDDM, but not 
from control individuals, had IgG antibodies that immunoprecipitated a 64 kDa protein 
from crude detergent lysates of methionine labelled human islets (Baekkeskov et al., 
1982). The assay was later modified to enable rat islets to be used, by the inclusion of an 
additional detergent extraction step (Baekkeskov et al., 1987; Christie et al., 1988). 
Unfortunately, this method of detecting anti-64 kDa antibodies , although highly specific, 
is too expensive and of too low a capacity to be suitable for routine screening of serum 
samples.
The subcellular location of 8 -cell GAD has not been finally resolved although it 
has been shown to exist in a 65 kDa hydrophilic form and a 64 kDa hydrophobic form 
which can be both membrane bound and soluble (Baekkeskov et al., 1990; Christgau et 
al., 1991). Most evidence, including the inability to label the protein with the cell surface 
label (Colman et al., 1987), suggests that GAD is not expressed at the 6 -cell
surface but is probably present in cytoplasmic, synaptic-like vesicles (Baekkeskov et al., 
1990; Reetz et al., 1991). This does not preclude the involvement of anti-64 kDa 
antibodies in the pathogenesis of IDDM, since peptides derived from the GAD protein 
could be expressed on the 8 -cell surface where they could initiate an autoimmune response 
against the healthy 8 -cells.
The prevalence of anti-64 kDa antibodies amongst healthy control individuals is 
about 3% (Sigurdsson & Baekkeskov, 1990). At the onset of IDDM approximately 70% 
of diabetics have autoantibodies against both the 64 and 65 kDa GAD proteins. Antibodies
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against the 64 kDa protein are also present in the pre-diabetic period as would be expected 
if they are of aetiological importance. In one familial study they have been detected in 
79% of patients up to 8  years before the onset of IDDM (Baekkeskov et al., 1987). The 
antibodies seem to be of higher predictive value than either IAA or ICCA which cannot 
always be detected when anti-64 kDa antibodies are present (Atkinson et al., 1990). Anti- 
64 kDa antibodies have also been detected in animal models of autoimmune diabetes. In 
the BB rat a 64 kDa islet protein was immunoprecipitated by ICSA-positive serum from 
prediabetic animals (Baekkeskov et al., 1984) and approximately 87% of newly diabetic 
NOD mice have also been found to have anti-64 kDa antibodies (Atkinson & Maclaren, 
1988).
Most evidence suggests that anti-64 kDa antibodies are predictive for IDDM. The 
recent cloning of the protein should therefore facilitate the development of a screening test 
for pre-overt IDDM. If GAD turns out to be a major target of the autoimmune attack in 
IDDM it could also become a major tool for prevention of the disease.
iii) fi-cell GLUT2 as a putative autoantigen in IDDM.
One of the earliest clinical symptoms of both type I and II diabetes, which can 
antedate the overt disease by 5-8 years, is a selective loss of the first phase insulin release 
in response to intravenous glucose challenge. In this pre-diabetic period before the 
occurrence of overt hyperglycaemia, the response to other secretagogues remains normal 
(Rabinowe & Eisenbarth, 1984). This suggests that although viable 8 -cells are present at 
this stage, they exhibit a functional defect in the glucose-specific component of the 6 -cell 
insulin secretion pathway.
Circulating 8 -cell autoantibodies can be detected prior to the onset of the glucose 
intolerance that will lead to overt type I diabetes. These antibodies have been 
demonstrated to affect 6 -cell function both in vivo and in vitro. ICSA-positive serum from
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diabetic children has been shown to inhibit glucose-induced insulin secretion from 
perifused rat islets (Kanatsuna et al., 1982; Kanatsuna et al. , 1983; Alden etal., 1984; 
Kitagawa et al., 1990). This inhibition occurred in the absence of complement and without 
6 -cell lysis and was specific for glucose-induced insulin secretion with no effect on 
arginine- or tolbutamide-stimulated insulin release (Kitagawa et al., 1990). ICSA positive 
sera were found to produce a similar effect in vivo. When serum from diabetic children 
was passively transferred into animals, in most cases it did not cause outright diabetes, it 
did however lead to a reduced insulin secretory response which was detected by 
experimental perfusion of the pancreases (Svenningsen et al., 1983).
The complexity of the pathway that enables the 8 -cell to respond to glucose, means 
that antibodies directed against any of the components involved in this sequence of events 
could potentially have an inhibitory effect on insulin secretion. For example, a monoclonal 
antibody which bound to a glycolipid on the 8 -cell surface was able to block glucose- 
induced insulin secretion, possibly by covering the surface of the carbohydrate rich 8 -cell 
and blocking external signals (Ziegler et al., 1988). However, one of the strongest 
candidates for the autoantigen is the 8 -cell glucose transporter GLUT2, the presence of 
which is believed to be essential for normal glucose-induced insulin secretion.
As previously discussed, down-regulation of GLUT2 has been proposed to play a 
role in the pathogenesis of NIDDM (Unger, 1991). There is some experimental evidence 
from both IDDM patients and animal models which supports the theory that the 6 -cell 
GLUT2 protein is also involved in the pathogenesis of autoimmune diabetes. In the first 
fortnight following onset of diabetes in BB/W rats the pancreas can still secrete insulin in 
response to arginine, but the glucose response is absent. It has been possible to show that 
this correlates temporally with a >90% reduction in the rate of 8 -cell 3-O-MG transport. 
The rate is significantly lower than in control animals even when corrected to account for 
the reduction in mass of the islet endocrine tissue (Tominaga et al., 1986). More recent 
studies on the BB rat have shown that the reduction in glucose transport, that occurs in
49
diabetic animals, can be correlated with a halving in the quantity of 6 -cell GLUT2 (Orci et 
al., 1990a). The observed 6 -cell insensitivity to glucose and reduction in the rate of 
glucose uptake probably arise as the result of a number of factors including an 80% 
reduction in the number of 6 -cells, a 50% decrease in GLUT2 expression and the action of 
putative inhibitory autoantibodies (Orci et al., 1990a). The reduction in GLUT2 alone 
may be sufficient to account for the loss of glucose-induced insulin secretion even in the 
absence of inhibition of the high Km glucose transport by immunoglobulins (Unger, 1991). 
The factors causing a reduction in GLUT2 remain unknown, but the reduction does not 
appear to be a consequence of hyperglycaemia (Orci et al., 1990b). It could result from a 
specific autoimmune attack against GLUT2 itself or from a non-specific autoimmune injury 
of 6 -cells that affects their ability to express GLUT2.
It has yet to be established whether the reduction in 6 -cell GLUT2 observed in BB 
rats also occurs in human IDDM, but results consistent with the hypothesis that GLUT2 is 
a target of the autoimmune process in patients with IDDM have been obtained by Johnson 
et al. (1990a). It was demonstrated that 95% of IgG samples from patients with new onset 
IDDM, but not from NIDDM patients or control subjects, were able to halve the rate of 3- 
O-MG transport via the high Km glucose transporter in rat islets. Transport in the liver 
was unaffected. The inhibition was completely abolished by incubation of the diabetic IgG 
with cells or cell membranes containing GLUT2, for example, hepatocytes or 6 -cells. 
Incubation with cells or membranes that did not express GLUT2, such as erythrocytes or 
kidney brush border cells, did not remove the inhibitory activity. These findings strongly 
suggest the presence of an antibody reaction against either GLUT2 or an as yet unidentified 
protein that influences 6 -cell function (Johnson et al., 1990a).
The relevance of the putative GLUT2 antibodies to the pathogenesis of IDDM is 
not known. In particular it has not been established whether a 50% reduction in glucose 
transport would actually affect insulin secretion in vivo since glucose transport capacity 
normally exceeds by 4 fold the rate of glucose phosphorylation (Johnson et al., 1990c). It
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is therefore unknown whether anti-GLUT2 antibodies are an epiphenomonen or whether 
they initiate a chain of events that results in the loss of glucose-induced insulin secretion in 
vivo.
iv) Other 6-cell autoantigens.
Numerous 6 -cell autoantigens have been described but most have not been fully 
characterised. Many are probably produced as a response to antigens exposed following 8 - 
cell injury and therefore are unlikely to be relevant to the early pathogenesis of IDDM.
Monoclonal antibodies have been produced that react with both 6 -cell surface and 
cytoplasmic components, although it is not known whether or not these antigens are 
important in IDDM pathogenesis (Eisenbarth et al., 1981; Srikanta et a l,  1986). 
Potentially of more relevance to the aetiology of autoimmune diabetes are the monoclonal 
antibodies that have been produced from lymphocytes of diabetic animals. Some 
monoclonal antibodies have been generated which recognise a 64 kDa 8 -cell antigen and 
are able to inhibit insulin release from islets ( Hari et al., 1986; Zlobina et al., 1989). 
Human monoclonal antibodies have also been produced from patients with new onset 
IDDM. The first report was of an antibody that reacted with a cytoplasmic antigen 
(Eisenbarth et al., 1982). A human monoclonal antibody has also been produced that 
reacts with a 8 -cell surface monosialoganglioside (Spitalnik et al., 1988). Western blotting 
has also enabled the identification of antigens in islets and 8 -cell lines that are specifically 
recognised by antibodies present in diabetic serum. The antigens are a heterogeneous 
group of proteins and glycoproteins for which a range of molecular weights have been 
reported (Karounos et al., 1988; Buchs et al., 1990).
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1.4.3.3 Screening for IDDM
The interest in diabetes-specific autoantibodies, that appear in individuals many 
years before the symptoms of diabetes, has largely stemmed from their potential to be used 
as markers for ongoing autoimmune destruction of pancreatic 6 -cells enabling early 
identification of individuals with pre-clinical diabetes. At present, since the incidence of 
IDDM in the general population is low, screening of the whole population is not 
considered to be cost effective. The advantages of knowing that you are at risk of 
developing diabetes are currently minimal, because even early treatment cannot cure the 
disease nor produce any long-term improvements in metabolic control.
The most obvious reason for wanting to predict diabetes is the hope that if detected 
in the early stages, before complete 6 -cell destruction occurs, it may be possible to actually 
slow or halt the immune response against the 6 -cells. If treatments, which may have 
serious side effects are to be initiated before evidence of clinical symptoms, then it follows 
that the screening assay must be sufficiently sensitive and accurate so that individuals are 
neither inadvertently omitted from treatment nor treated unnecessarily.
The ideal screening assay would be cheap, the reagents would have a long shelf 
life, it would be standardizable, quantitative and suitable for screening large numbers of 
samples. None of the currently available immunofluorescence or radioactive assays fulfil 
these criteria. It is for this reason that much research has been dedicated to the 
identification and purification of 6 -cell autoantigens. These could then be used to develop 
the ideal assay for IDDM.
Identification of autoantigens may be useful in the short term for developing a 
screen for IDDM. In the long term the knowledge of 6 -cell autoantigens may be applied to 
the development of a specific therapy for IDDM. Diabetes is an autoimmune disease and 
therefore if detected early enough, before total 6 -cell destruction has occurred, it should
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theoretically be possible to halt the disease process by the use of treatments that suppress 
the immune system. The results of this type of immunosuppressive therapy have however 
generally been disappointing (Lernmark, 1985). Even considering the serious nature of the 
complications that are likely to arise after several years of conventional insulin therapy this 
type of general immunosuppression is unjustifiable as a treatment for IDDM. What is 
required is a specific therapy that could block just the single autoimmune reaction 
responsible for initiating the disease and which is safe enough to be given to symptomless 
individuals before the onset of IDDM. Therapies that can be envisaged require the 
identification of the 6 -cell autoantigen or autoreactive lymphocyte clones responsible for 
initiating 6 -cell destruction. For example if the autoantigen could be identified, labelled 
with a toxin or radioactive isotope and administered to a patient, its interaction with 
autoreactive T or B lymphocytes could cause their death thereby preventing further 6 -cell 
destruction.
Identification and cloning of autoreactive T or B lymphocytes could enable anti- 
idiotypic antibodies to be raised against them. When administered to patients, these 
antibodies should specifically destroy the autoreactive lymphocyte clones. Antibodies 
against specific Tjj cells may also prevent triggering of a specific anti-6 -cell immune 
response (Lernmark, 1985). One method of identifying anti-6 -cell lymphocytes is to 
isolate them using the antigen with which they interact (Bergman et al., 1990; Sobel et al., 
1990; Elias et al., 1991). It may then be possible to immunize against diabetes by using 
peptides derived from autoreactive T or B cell receptors to generate antibodies that react 
against the autoreactive lymphocyte clones. It has been demonstrated that a peptide 
recognised by T lymphocytes can be used as a vaccine to prevent development of diabetes 
in mice. Alternatively the autoreactive T-cells can be attenuated and themselves used as a 
therapeutic T-cell vaccine (Elias et al., 1991). It is not yet known whether the same 
approach would work for human IDDM.
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Many researchers now believe that IDDM will become a preventable disease. 
Exactly how this will be achieved is currently only a matter for speculation. What is 
certain is that until a diagnostic test which predicts IDDM with 100% certainty has been 
developed and autoantigens responsible for initiating the disease have been identified, then 
the research into 6 -cell autoantigens must continue.
1.5 AIMS
The major aims of the work described in this thesis are as listed below: -
1) To determine whether the exofacial photoaffinity probe ATB-BMPA, which has 
previously been used to label the glucose transporter isoforms GLUT1 and GLUT4 (Clark 
& Holman, 1990; Holman et al., 1990) could be used to photolabel the GLUT2 
transporter isoform in liver plasma membranes and thus provide an alternative to the 
endofacial label cyt B. To use ATB-BMPA to compare GLUT2 with the other transporter 
isoforms.
2) To identify the glucose transporter isoforms that are expressed in cultured (3 -cell lines 
by using Western blotting and ATB-BMPA photolabelling followed by 
immunoprecipitation with specific anti-GLUTl and GLUT2 peptide antibodies.
3) To develop a simple /3-cell line plasma membrane ELISA which could be used to screen 
for the presence of anti-islet cell surface antibodies (ICSA) in serum from children with 
recently diagnosed IDDM.
4) To investigate the targets of the autoantibodies present in the serum of patients with 
IDDM and to attempt to establish the presence of diabetes-specific autoantibodies directed 
against the GLUT2 glucose transporter isoform which is expressed in islet /3-cells.
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2.0 MATERIALS AND METHODS
2.1 GENERAL REAGENTS
Unless otherwise stated all standard laboratory reagents were obtained from Fisons 
pic (Loughborough, UK), BDH Laboratory Supplies (Poole, Dorset, UK), Sigma Chemical 
Co. (Poole, Dorset, UK) or Aldrich Chemical Co. Ltd (Gillingham, Dorset, UK).
2.2 BUFFERS AND SOLUTIONS
Gey and Gey medium pH 7.4
120 mM NaCl
27 mM NaHC03
1 mM Na2 HP04
5 mM KC1
0.2 mM KH2 P0 4
1 mM MgCl2  6H20  
0.3 mM MgS04 *7H20  
4 mM D-glucose
2 mM CaCl2 -2H20
Prepare just before use and aerate with 5% C 02  95% 0 2
Hanks balanced salts solution (HBSS) pH 7.4
5.4 mM KC1
0.44 mM KH2 P0 4
0.813 mM MgS04 -7H20
138 mM NaCl
4.17 mM NaHC03
0.35 mM Na2 HP04
5.55 mM D-glucose
1.27 mM CaCl2 *2H20  -as required
Hepes-buffered balanced salts solution pH 7.4
132 mM NaCl
4.76 mM KC1
1.24 mM MgS04 -7H20
1.95 mM CaCl2 -2H20
2.19 mM NaH2 P0 4 *2H20
10 mM Hepes
55
Krebs Ringer Bicarbonate (KRB) pH 7.4
119 mM NaCl 
5.94 mM KC1 
2.54 mM CaCl2
1.19 mM MgS04
1.19 mM KH2 P04  
25 mM NaHC03  
10 mM Hepes
0.1-0.2% bovine serum albumin (BSA)
Phosphate buffered saline (PBS) pH 7.3
140 mM NaCl 
2.7 mM KC1
1.5 mM KH2 HP04
8.1 mM Na2 HP04
Sodium phosphate buffer pH 7.4
5 mM Na2 HP04
TRIS-buffered saline (TBS) pH 7.4 
154 mM NaCl 
10 mM TRIS
TRIS/EDTA/sucrose buffer pH 7.4
10 mM TRIS 
1 mM EDTA 
250 mM sucrose
Transfer buffers
For wet transfer pH 8.3
25 mM TRIS
192 mM glycine
2 0 % (v/v) methanol
For semi-dry transfer 
39 mM glycine 
48 mM TRIS 
0.0375% (w/v) SDS 
2 0 % (v/v) methanol 
In double distilled water
Electrophoresis stock reagents
30% (w/v) Acrylamide Stock 
60 g acrylamide
1.6 g N'N methylene bis acrylamide 
60 g sucrose
Adjust volume to 200 ml with double distilled water
Resolving gel buffer pH 8 . 8
1.5 M TRIS 
0.4% (w/v) SDS
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Stacking gel buffer pH 6 . 8  
0.5 M TRIS 
0.4% (w/v) SDS
Electrophoresis buffer pH 8.3 
25 mM TRIS 
192 mM glycine 
0.1% (w/v) SDS
2.3 HUMAN SERUM SAMPLES
Serum samples designated "Set 1" were provided by Dr. Pennock (Pediatric Dept., 
Bristol Royal Infirmary). Diabetic serum samples were obtained from children admitted to 
the hospital with recently diagnosed IDDM, and control samples were obtained from non­
diabetic children who had been admitted to the hospital for other reasons. Some of these 
samples were very cloudy and had to be centrifuged before use to remove a white 
precipitate.
Additional samples, designated "Set 2” were obtained from 21 children recently 
diagnosed as having IDDM. These samples were shown to contain ICCA by a standard 
immunofluorescence assay. Control samples were obtained from the non-diabetic siblings 
of diabetic children, these samples did not contain ICCA. Set 2 samples were kindly 
provided by Dr. P. Bingley (Dept, of Diabetes and Metabolism, St. Bartholomews Hospital 
Centre for Clinical Research, London). Preliminary studies were carried out using samples 
provided by Dr. J. Reckless (Royal United Hospital, Bath) from adults attending the 
outpatient's diabetic clinic. Serum samples from Pima Indians with NIDDM were obtained 
from Dr. C. Bogardus (Clinical Diabetes and Nutrition Section, National Institutes of 
Health, Phoenix, Arizona, USA).
A large volume of serum which was used as an internal standard in ELISAS was 
obtained from a healthy blood donor. All serum samples were received frozen. On receipt
57
they were defrosted and aliquoted into small working volumes. All samples were then 
stored at -2 0 °C.
2.4 PROTEIN ESTIMATIONS
The concentration of membrane or total cell protein was estimated using either the 
Bio-Rad assay based on the Coomassie Brilliant Blue dye-binding method of Bradford 
(1976) or with a modification of the Lowry protein assay (Lowry et al., 1951; Markwell 
etal., 1981).
2.4.1 Modified Bio-Rad assay
The protein content of samples was estimated by comparison with a standard curve 
ranging from 0-15 fig of protein (BSA) in 775 fd of sodium phosphate buffer (pH 7.4). 
The addition of 25 fi 1 of 0.1 M NaOH to all standards and test samples aided the 
solubilization of membrane proteins. 200 fi\ of Bio-Rad dye-binding reagent (Bio-Rad 
Laboratories Ltd, Hemel Hempstead, UK), were added and the samples were mixed. After 
5 min the absorbance was measured at 595 nm. All samples and standards were measured 
in duplicate.
2.4.2 SDS-modified Lowry
The protein content of samples was estimated from a standard curve ranging from
0-100 fig of BSA adjusted to a volume of 200 fi\ with water. Protein was solubilized by a 
10 min incubation at room temperature with 1 ml of a 100 fold dilution of solution B (4% 
(w/v) Q 1SO4 .5 H2 O) in solution A (2% (w/v) Na2 CC>3 in 0.4% (w/v) NaOH, 0.16% (w/v) 
KNa tartrate, 3% (w/v) SDS). Colour was developed over a 30 min period following the 
addition of 100 fil of a 1:1 dilution of Folin and Ciocalteau's phenol reagent (BDH) in
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water. Absorbance was measured at 750 nm. All samples and standards were tested in 
duplicate.
2.5 CELL CULTURE
Four immortal pancreatic B-cell lines were cultured. The HIT-T15 cell line 
(Santerre et al., 1981) was a gift from Dr. R.F. Santerre (Lily Research Laboratories, 
Indianapolis, USA). The HITm2.2 sub-clone (Edlund et al., 1985) and RINm5F line were 
both kindly provided by Dr. D. Boam (Queen Elizabeth Hospital, Birmingham Medical 
School, UK). MIN 6 cells (Miyazaki et al., 1990) were obtained from Dr. J-I. Miyazaki 
(Kumamoto University Medical School, Japan).
3T3-L1 fibroblasts, used as a control in some experiments, were cultured by Dr. J. 
Yang (Dept., of Biochemistry, University of Bath) as previously described (Frost & Lane, 
1985).
Growth medium, serum, reagents and tissue culture plasticware were purchased 
from ICN Flow (High Wycombe, Bucks., UK) or Gibco Ltd (Paisley, Scotland). Serum 
was heat-inactivated (HI) at 56°C for 30 min before use. Dulbecco's A phosphate-buffered 
saline (PBS) was prepared from tablets (Oxoid). All reagents and equipment which were 
not purchased sterile were autoclaved at 20 Ib/in^ for 30 min.
2.5.1 HIT-T15 culture
HIT-T15 cells were cultured in HAMS-F12 medium containing 2 mM glutamine, 
100 U/ml penicillin and 100 /ig/ml streptomycin which was supplemented with either 10% 
(v/v) Hl-foetal calf serum (FCS) or 15%(v/v) Hl-donor horse serum (DHS) plus 2.5% 
(v/v) HI-FCS. The cells were routinely seeded in 25 cm^ flasks at a density of 2x10^ cells 
per 8 ml of medium. If seeded at lower densities cell growth was poor. Within an hour of
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plating out, the cells reaggregated into small clumps which reached a maximum size after 
4-5 days growth. If left longer than this the cells started to detach. Cultures were 
maintained at 37°C in 5% CO2  and 95 % air. The medium was changed every 2 days.
To subculture, the medium was removed and the cells were rinsed briefly with 
PBS. The cells were then incubated for about 8 min at 37°C in a film of 0.05% (w/v) 
trypsin and 0.02% (w/v) EDTA in PBS until the cells just started to lift off the surface. 
The action of trypsin was inhibited by the addition of 5 ml of serum-supplemented medium 
and the cells were detached by gentle aspiration. The cells were washed by centrifugation 
for 3 min at ~ 200 gav, the pellet was resuspended in growth medium and a count of viable 
cells was carried out by mixing an equal volume of resuspended cells with 0.02% Trypan 
Blue in PBS, dead cells stained blue. Under these conditions the cultures were split 1:2 or 
1:3 after 4-7 days growth.
For storage, cells were resuspended at a density of 1x10^ cells/ml in cold 
lactalbumin hydrolysate medium containing 10% (v/v) Hl-newbom calf serum (NCS) and 
10% (v/v) dimethyl-sulphoxide (DMSO). After slow-cooling overnight in the vapour 
phase of liquid nitrogen, the cells, in cryotubes, were transferred to liquid nitrogen tanks 
for storage. When required again, the cells were rapidly defrosted at 37°C and washed 
immediately in 20 ml growth medium before plating out as usual.
2.5.2 MIN 6 culture
MIN 6 cells were cultured in DMEM supplemented with 2 mM glutamine, 100 
U/ml penicillin, 100 /zg/ml streptomycin, 20% (v/v) HI-FCS and 7 /d/L 2- 
mercaptoethanol.
These cells were grown at 37° C in an atmosphere of 5% CO2  and 95% air in 25 
cm^ flasks containing 5-8 ml of medium or in 9 cm diameter plates containing 10 ml of
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medium. MIN 6 cells grew in small clusters, they were subcultured after 7-8 days growth. 
Trypsinization was carried out as described for HIT-T15 cells except that the incubation 
was at room temperature. It was important not to make a single cell suspension, but to 
leave small aggregates of several cells. The cells were routinely split 1:5 and the medium 
was changed every 3 days. MIN 6 cells were frozen in FCS containing 10% DMSO. 
Since recovery was relatively low, it was important to start the culture after thawing at a 
high cell density.
2.5.3 HITm2.2 and RINm5F culture
Cells were cultured in RPMI-1640 medium supplemented with 2 mM glutamine, 
100 U/ml penicillin, 100 jig/ml streptomycin and either 10% (v/v) HI-FCS or 5% (v/v) HI- 
FCS plus 5% (v/v) HI-NCS. RIN cells could also be grown in medium supplemented with 
10% HI-NCS. Cultures were maintained in a humidified incubator at 37°C in an 
atmosphere of 5% CO2  and 95% air. The cells were seeded in 9 cm dishes at a density of
1-1.5x10^ cells per dish. RIN cells reached «90% confluence after about 7 days and HIT 
cells reached 70-80% confluence after 4-6 days. The cells were routinely split 1:7. The 
cells were fed every 2 days and subcultured as described for HIT-T15 cells. Cells were 
frozen in FCS containing 10% DMSO and stored in liquid nitrogen.
2.6 DETECTION OF INSULIN
2.6.1 Indirect immunofluorescence
HITm2.2, RINm5F and HIT-T15 cells were grown in 1 ml wells. The cells were 
washed briefly in warm PBS and fixed overnight at 4°C in a buffer containing 4% (v/v) 
formaldehyde, 46 mM Na2 HP0 4  and 26 mM NaH2 P0 4 -2 H2 0  (pH 7.4). The cells were 
washed in PBS and blocked for 1 hour at room temperature (or 37 °C) in PBS containing 
5% (v/v) normal goat serum (NGS). The cells were then incubated for 2 hr at 37° C with
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150 fd of a pre-diluted monoclonal anti-insulin antibody (Amersham International, 
Amersham, UK). Control wells were incubated with PBS only. After 3 washes with PBS, 
200 /d of fluorescein isothiocyanate (FITC) conjugated goat anti-mouse IgG antibody, 
diluted 1:50 in PBS/5 % (v/v) NGS, were added to each well and incubated for 1 hour at 
37°C in the dark. The cells were washed in PBS, mounted in a PBS:glycerol (1:1) buffer 
and examined with a fluorescence microscope. Cytoplasmic fluorescence indicated the 
presence of insulin.
2.6.2 Insulin radioimmunoassay (RIA)
HITm2.2 and RINm5F cells were grown in 1 ml wells. In order to determine the 
mean number of cells present per well, two wells per experiment were trypsinized and the 
cells counted. Following a brief wash with KRB buffer (see section 2.2), the cultures were 
incubated at 37°C for 60 min (RINm5F) or 90-130 min (HITm2.2) with 1 ml of fresh KRB 
to which the secretagogues D-glucose, L-arginine or L-D-isoleucine had been added at the 
indicated concentrations.
After incubation, the supernatant was removed, centrifuged to remove any cell 
debris and stored at -70°C until assayed with a commercial insulin RIA kit (Amersham 
International), which detected insulin over the range 0-160 /zU/ml. The protocol 
recommended by the manufacturers was followed and results were expressed in terms of 
fdJ insulin secreted per 60 min per 2x10^ cells.
2.7 MEASUREMENT OF 2-DEOXYGLUCOSE UPTAKE IN CULTURED B- 
CELLS
Uptake of 2-deoxyglucose, which is phosphorylated but not further metabolised, 
was measured in HITm2.2 and RINm5F cells. Cells were detached from culture plates by 
incubation at 37°C in PBS containing 1 mM EDTA. The cells were resuspended in a
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Hepes-buffered balanced salts solution (see section 2.2), washed briefly by centrifugation 
and aliquoted into round bottomed plastic tubes. Each tube contained 200 /xl of a cell 
suspension containing 5x10^ HIT or 1x10^ RIN cells respectively. Transport assays were 
performed at 37°C. At time zero, 50 /d of a cocktail containing 250 /iM 2-deoxyglucose 
and a tracer amount of 2-deoxyglucose (0.1 jiCi/assay) were added to the cell 
suspension. The final concentration of 2-deoxyglucose was 50 fiM. Sugar uptake was 
stopped after the indicated intervals by the addition of 2 ml of stopping solution (0.1 mM 
phloretin in balanced salts solution). The cells were immediately pelleted by a brief low 
speed centrifugation and the washing step was repeated. The supernatant was removed by 
briskly inverting the tubes and traces of liquid around the rim were wiped away.
The cell pellet was solubilized in 0.1 M NaOH and a small aliquot was removed 
for estimation of protein using the Bio-Rad protein assay. The remainder of the sample 
was added to scintillation fluid and the incorporated radioactivity was determined. Results 
were expressed in terms of nmol 2-deoxyglucose transported/mg protein/min.
2.8 ISOLATION OF RAT ISLETS OF LANGERHANS
Islets were isolated using a modification of the collagenase digestion procedure 
first described by Lacy & Kostianovsky (1967). The present protocol was developed from 
the method used at Kings College Hospital, London (Dr. M. Peakman - personal 
communication). Islets were separated from exocrine tissue on a Ficoll (Sigma) gradient 
essentially as described by Lemmark (1976) and McDaniel et al. (1983).
4-6 Wistar rats (200-250 g) were stunned and killed by cervical dislocation, the 
pancreas was removed from each animal and placed in a petri-dish containing ice-cold Gey 
and Gey medium (see section 2.2). The exocrine tissue was disrupted by the injection of 
about 20 ml of ice-cold Gey and Gey medium into multiple sites under the capsule of the 
pancreas. After inflation, the organ was chopped into 1-2 mm pieces in a small volume of
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medium and the pieces were allowed to settle. The supernatant, containing autolytic 
enzymes and fatty tissue, was removed by aspiration. The tissue pieces were washed three 
times in this way. Tissue from 2 pancreases was transferred to a plastic universal tube 
with 8 ml of medium containing 14 mg of Type XI collagenase (Sigma) or 10 ml of 
medium containing 10 mg of collagenase P (Boehringer Mannheim). The tissue was 
digested by vigorous manual shaking for 5-6 min in a 37°C water bath. When the mixture 
appeared homogeneous, digestion was terminated by the addition of ice-cold medium. The 
digested tissue was washed 3 times by centrifugation for 3 min at 300 gav.
After washing, the digested tissue from 2 pancreases was vortex-mixed with 4 ml 
of 27% (w/w) Ficoll in Gey and Gey medium at room temperature. 23%, 20.5% and 11 % 
solutions of Ficoll in Gey and Gey medium were made by appropriate dilution of the 27% 
Ficoll stock. 4 ml of each were carefully layered onto the 27% layer in order of decreasing 
Ficoll concentration. The resulting gradient was centrifuged at room temperature (10 min, 
800 gav) which caused the islets to separate out at the interfaces of the 11% and 20.5% 
layers. The islets were hand-picked from the Ficoll with a fine-ended silicanized pipette 
under the low magnification of a stereomicroscope. Islets stood out as solid "pearl-like" 
structures when illuminated from above against a dark background. Generally, the islets 
separated on Ficoll gradients were small, the average yield was about 100-200 islets per 
pancreas.
2.9 ISOLATION OF RAT HEPATOCYTES
Hepatocytes for use in photolabelling studies were isolated from rat liver 
essentially as described by Howard et al. (1967).
The liver of a freshly killed rat was perfused in situ via the hepatic portal vein with 
ice-cold Ca2 + -ffee HBSS (see section 2.2). Perfusion was continued until the liver was 
blanched. The liver was then removed and about 3 g of tissue were chopped finely with
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scissors. The chopped tissue was distributed between 3 plastic capped pots containing 7 ml 
of digestion buffer (Ca^ + -free HBSS containing 0.15% collagenase (Type 1) and 0.15% 
hyaluronidase). The tubes were incubated at 37 °C in a shaking water bath for 60 min. 
Large pieces of undigested tissue were removed by filtration through gauze. The resulting 
cell suspension was washed in ice-cold HBSS by centrifugation at 1000 rpm. The pelleted 
liver parenchymal cells were removed from the erythrocytes which remained in the 
supernatant. Washing was repeated three times. The viability of the parenchymal cells 
was assessed by Trypan Blue staining. Typically, viability was =78%.
2.10 PREPARATION OF CELL MEMBRANES
2.10.1 Preparation of rat adipocyte plasma membranes
Adipocyte plasma membranes were used as a control in some experiments. They 
were kindly prepared by A.E. Clark (Dept, of Biochemistry, University of Bath) according 
to the method described by Holman et al. (1988).
2.10.2 Preparation of human erythrocyte ghosts
Human blood was washed with PBS by centrifugation for 10 min at 3000 g (4°C). 
The "buffy coat" of leukocytes and platelets that sedimented above the erythrocytes was 
removed by aspiration. Approximately 5 ml of washed erythrocytes were added to 250 ml 
ice-cold haemolysing buffer containing 5 mM Na2 HPC>4 , 1 mM EDTA and 1 /xg/ml PMSF 
(phenylmethylsulphonylfluoride). After 20 min on ice the membranes were pelleted by 
centrifugation for 20 min at 16,000 gav (4°C). The pellet was re-haemolysed and the 
centrifugation repeated. The resulting ghosts were disrupted by resuspending the 
membrane pellet in 5 mM sodium phosphate buffer (pH 7.4).
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2.10.3 Preparation of rat liver membranes
2.10.3.1 Method I - Liver plasma membranes
Liver plasma membranes for use in photolabelling experiments, Western blotting, 
ELISAS and GLUT2 purification were isolated on a Percoll (Pharmacia LKB, Uppsala, 
Sweden) gradient essentially as described by Prpic et al. (1984).
The liver was removed from one male 200 g Wistar rat and placed in 150 ml of 
ice-cold isolation medium (250 mM sucrose, 5 mM Hepes, 1 mM EGTA pH 7.4) 
containing the proteinase inhibitors aprotinin, antipain, leupeptin and pepstatin A (Sigma) 
each at a concentration of 3 ptg/ml. The liver was minced, then homogenised with 10 
strokes of a loose-fitting Potter-Elvejhem homogeniser, followed by 4 strokes of a tight- 
fitting homogeniser. The homogenate was filtered through 2 layers of nylon mesh and 
centrifuged at 1464 gav (Sorval RC5B, SS-34 rotor, 3500 rpm) for 10 min at 4°C. The 
resulting pellet was resuspended in isolation medium and homogenised with 4 strokes of 
the tight-fitting homogeniser. The volume was adjusted to 124.5 ml with isolation buffer 
and the homogenate was mixed thoroughly with 16.8 ml Percoll and centrifuged at 34,540 
gav (Sorval RC5B, SS-34 rotor, 17,000 rpm) for 35 min at 4°C. The plasma membrane 
was identified as a fluffy white layer close to the top of the gradient, lying just beneath a 
broader band containing nuclei, which was discarded. The plasma membrane was 
aspirated and washed by centrifugation at 100,000 gav (Beckman Ti60 rotor, 40,000 rpm) 
for 30 min at 4°C in 5 mM sodium phosphate buffer (pH 7.4), which prevented the 
formation of membrane vesicles. 2-4 mg of plasma membrane protein were obtained per 
rat liver. Membranes were stored at -70°C in small aliquots.
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2.10.3.2 Method II - Crude liver membranes
Liver membranes were obtained from rat liver essentially as described by Thorens 
et al. (1988). The liver was homogenized in 0.3 M sucrose and centrifuged for 10 min at 
5900 gav. The pellet was discarded and the centrifugation was repeated. The resulting 
supernatant was centrifuged at 120,000 g av for 40 min to obtain the membrane pellet.
2.10.4 Preparation of B-cell line and islet membranes
2.10.4.1 Method 1 - Preparation of B-cell plasma membranes
Plasma membranes were prepared from /3-cell lines as described by Kunze et al. 
(1987) and as modified by Karounos & Thomas (1990).
Confluent cell cultures (5-25 dishes) were washed twice with warm PBS. The cells 
were then scraped into 4 ml of ice-cold buffer containing 5 mM TRIS, 2 mM EDTA and 1 
jig/ml PMSF. The cells were lysed on ice for 40 min, then homogenised by 20 strokes of a 
Potter-Elvejhem homogenizer. The homogenate was centrifuged for 10 min at 3000 gav to 
remove mitochondria and nuclei. The supernatant was centrifuged at 100,000 gav for 40 
min at 4°C (Beckman Ti60 rotor, 40,000 rpm) to pellet the plasma membranes. 
Membranes were stored at -70°C in 10 mM TRIS, 100 mM NaCl and 2 mM EDTA (pH
7.4) containing the proteinase inhibitors aprotinin, antipain, leupeptin and pepstatin A 
(Sigma) each at a concentration of 3 f i g / m i .
2.10.4.2 Method II - Preparation of B-cell plasma membranes using a Ficoll gradient
This method was based on a protocol for the isolation of adipocyte plasma 
membrane as described by McKeel & Jarett (1970) and as modified by Rees (1981).
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Confluent cell cultures (10-20 dishes) were washed briefly with PBS. The cells 
were then detached by incubation at 37 °C in PBS containing 1 mM EDTA and pelleted by 
centrifugation. The cell pellet was transferred to 10-20 ml of ice-cold TES buffer (see 
section 2.2). Cells were homogenised in a very tight-fitting Potter-Elvejhem homogeniser 
using 10 strokes of a motor driven pestle rotating at 1500 rpm. In order to minimize the 
clearance between the plunger and glass vessel, homogenization was carried out at room 
temperature.
The homogenate was centrifuged at 500 gav for 5 min to pellet unbroken cells. 
The supernatant was then centrifuged at 4°C for 20 min at 11,200 gav (Sorval RC5B, SS34 
rotor, 11,000 rpm). The resulting pellet was resuspended in 0.5-1.0 ml TES by 
homogenization with 10-15 strokes of a loose-fitting homogenizer and 300-500 p\ of the 
homogenate were layered onto a 4 ml Ficoll gradient. The gradient was prepared by 
dissolving Ficoll in TES to a concentration of 18% (w/w) . Before use, the Ficoll solution 
was filtered and cooled to 4°C. A plasma membrane-containing fraction was separated 
from the remaining nuclei and mitochondria by centrifugation of the gradient at 4°C for 45 
min at 37,000 gav (Beckman, SW50.1 rotor, 20,000 rpm). The plasma membrane fraction 
was removed from the interface and washed in TES by centrifugation at 4°C for 60 min at 
70,000 g (Beckman, SW50.1, 27,000 rpm). The resulting pellet was resuspended in 5 mM 
sodium phosphate buffer and stored at -70 °C.
2.10.4.3 Method III - Preparation of total B-cell membranes
Cultured cells were washed with PBS and detached from petri-dishes by incubation 
at 37°C for 5-10 min in PBS containing 1 mM EDTA. The cells or islets were then 
homogenized in ice-cold 5 mM sodium phosphate buffer or TES (see section 2.2). The 
homogenate was centrifuged at 100,000 gav for 40 min at 4°C and the pelleted membranes 
were resuspended in a small volume of 5 mM sodium phosphate buffer and stored at 
-70°C.
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2.11 TRITON X-114 EXTRACTION OF B-CELL MEMBRANE PROTEINS
The phase extraction of amphiphilic membrane proteins from HITm2.2 and 
RINm5F cells was based on the protocols described for the Triton X-l 14 extraction of the 
64 kDa autoantigen from methionine-labelled islets (Baekkeskov et al., 1987; Christie 
et al., 1988; Baekkeskov et al. , 1989).
HITm2.2 or RINm5F cells were detached from their culture dishes by incubation 
in PBS containing 1 mM EDTA. The cells were washed in PBS and approximately 3x10^ 
cells were homogenized with 10 strokes of a tight-fitting Potter-Elvejhem homogenizer in 
0.25 M sucrose/10 mM Hepes (pH 7.4) containing 1 /zg/ml aprotinin, 0.1 mM p- 
chloromercuribenzene sulphonic acid and 10 mM benzamidine hydrochloride. The 
homogenate was centrifuged at 75,000 gav at 4°C for 30 min and the pelleted membranes 
were resuspended by homogenization in 1 ml of extraction buffer (20 mM TRIS, 150 mM 
NaCl, 1 /ig/ml aprotinin, 20 mM NEM, 0.1 mM Na vanadate, 5 mM EDTA, 5 mM NaF 
and 2% (v/v) Triton X-114. Proteins were solubilized for 2 hours on ice, then insoluble 
material was removed by centrifugation at 16,000 gav at 4°C for 20 min.
The supernatant was subjected to a phase separation procedure as described by 
Bordier (1981) and Christie et al. (1988). The Triton X-l 14 detergent had a cloud point of 
20°C, therefore when warmed above this temperature the detergent separated into an 
aqueous and a detergent-enriched phase with the amphiphilic membrane proteins 
partitioning into the detergent phase. 150 /xi of the Triton X-114 extracted proteins were 
overlaid onto 250 /d of a sucrose cushion which contained 6% (w/v) sucrose in the 
extraction buffer prepared without the Triton X-114 detergent. Tubes were incubated at 
30°C for 3 min which caused the detergent extract to become cloudy. Aggregated 
detergent micelles and associated integral membrane proteins were pelleted by 
centrifugation at 1500 gav for 3 min at 25°C. A small cloudy droplet appeared below the 
sucrose cushion. The aqueous phase above the cushion was removed and Triton X-114
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was added to a concentration of 2% (v/v). Proteins were re-extracted by incubation for 10 
min on ice. The solubilized proteins were again overlaid on a sucrose cushion. This phase 
separation procedure was repeated twice.
The final detergent pellet was removed from beneath the sucrose cushion and was 
diluted in extraction buffer without added Triton X-114. Extracted proteins were 
solubilized by boiling for 1 min in sample buffer containing 80 mM TRIS, 3% (w/v) SDS, 
15% (w/v) sucrose, 5% (v/v) 2-mercaptoethanol and 0.005 % (w/v) Bromophenol Blue. 
Proteins were analysed by SDS-PAGE and Western blotting. Approximately 20-40 /zg of 
protein (from 2x10^ cells ) were loaded per lane.
2.12 ASSAY OF 5* NUCLEOTIDASE ACTIVITY
The method used to measure 5’ nucleotidase (EC 3.1.5.3) activity in membranes 
was modified from the protocol described by Newby et al. (1975). 50 /zl of a membrane 
suspension adjusted to 0.6 mg of protein/ml in 5 mM sodium phosphate buffer were added 
to 200 /d of a solution containing 1 mM adenosine monophosphate (AMP), a tracer amount 
of [^C]AMP, 5 mM MgS0 4  ^  50 mM TRIS (pH 8.0). The reaction was initiated by 
incubation at 37°C for 30 min and terminated by the addition of 200 jzl of 0.15 M ZnSC>4 . 
The subsequent addition of 200 /zl of 0.15 M Ba(OH) 2  precipitated the charged AMP 
molecules leaving any radiolabelled adenosine, formed by the nucleotidase activity, in the 
supernatant. The precipitate was pelleted by centrifugation and samples of the supernatant 
were taken for liquid scintillation counting. Blanks were included in which membranes 
were added to the incubation mixture at the same time as the ZnSC>4 . The specific activity 
was calculated from a control to which buffer was added instead of ZnSC>4 and Ba(OH)2 - 
Results were expressed as /zmol adenosine produced/mg protein/30 min.
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2.13 PRODUCTION OF ANTI-GLUCOSE TRANSPORTER PEPTIDE 
ANTIBODIES
Table 3 gives details of the rabbit anti-glucose transporter peptide antibodies used 
in this study, these include antibodies raised against the GLUT1, GLUT2 and GLUT4 
glucose transporter isoforms.
2.13.1 GLUT2 C-terminal peptides
The C-terminal sequence of GLUT2 is unique to this transporter isoform, therefore 
antibodies raised against it should be specific for GLUT2. Antisera have been used that 
were raised against three slightly different peptides from the C-terminal region of rat 
(Thorens et al., 1988) and human GLUT2 (Fukumoto et al., 1988). Sequences are shown 
in Table 3.
Peptide A - This peptide corresponds to the 13 C-terminal amino acids with an additional 
cysteine incorporated for the purpose of coupling to the protein carrier. This peptide was 
purchased from Multi-Peptide Systems.
Peptide B - This peptide has the same sequence as peptide A except that it is longer by 3 
amino acids. 20 mg of the peptide were kindly provided by Dr. S. Baldwin.
Peptide C - This peptide corresponds to the upper C-terminal region of GLUT2, 18 amino 
acids away from the putative transmembrane region (M12). Antiserum raised against this 
peptide was kindly provided by Hoffmann La Roche.
Peptide D - This peptide corresponds to the 18 terminal amino acids of the human GLUT2 
sequence. Antiserum raised against this peptide was kindly provided by Dr. S. Cushman.
Antiserum raised against peptide B was routinely used in all experiments unless 
otherwise stated.
Antiserum Amino acids Peptide sequence (* denotes amino acids incorporated for 
coupling to carrier protein)
Acknowledgements




C E E L F H P L G A D S Q V
Cys Glu Glu Leu Pbe His Pro Leu Gly A lt Asp Ser Gin V tl
Antiserum provided by A.E. Clark (Dept, of 
Biochemistry, University of Bath.)




C T V Q M E F L G S S E T V
Cys Thr V tl Gin Met Glu Phe Leu Gly Ser Ser Glu Thr Vtl
Peptide A




C R K A T V Q M E F L G S S E T V
Cys Arg Lys A lt Thr V tl Gin Met Glu Phe Leu Gly Ser Ser Glu Thr V tl
Peptide B
Peptide donated by Dr, S. Baldwin (Dept, of 
Biochemistry and Chemistry, Royal Free Hospital 
School of Medicine, London.)
Anti-rat GLUT2 C- 
terminal peptide (C)
499-508 K K S G S A P P R K
Lys Lys Ser Gly Ser Ala Pro Pro Arg Lys
Peptide C
Antiserum provided by Hoffmann La Roche, USA.
Anti-human GLUT2 C- 
terminal peptide (D)
507-524 H R P K A A V E M K F L G A T E T V
His Arg Pro Lys Ala Ala Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val
Peptide D






C G V P L D D R R A T I N Y D
Cys Gly Val Pro Leu Asp Asp Arg Arg Ala Thr De Asn Tyr Asp




C G S T E L E Y L G P D E N D
Cys Gly Ser Thr Glu Leu Glu Tyr Leu Gly Pro Asp Glu Asn Asp
Antiserum provided by A. E. Clark (Dept, of 
Biochemistry, University of Bath.)
Table 3 Details of anti-glucose transporter peptide antibodies.
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2.13.2 Synthesis of anti-rat GLUT2 exofacial loop peptide
The exofacial loop peptide corresponded to part of the amino acid sequence 
predicted from the nucleotide sequence of the large exofacial loop between membrane 
spanning regions Ml and M2 of rat GLUT2. This sequence is found in GLUT2 and 
GLUT7, but is absent from the shorter extracellular loops found in the other transporter 
isoforms.
The peptide was synthesised under the guidance of Dr. R. Kinsman (Dept, of 
Chemistry, University of Bath) using a Cambridge Research Biochemicals Pepsynthesiser
II. The synthesis was performed using the Fmoc (9-fluorenylmethoxycarbonyl) polyamide 
method of solid phase synthesis. The solvent used for all couplings was freshly distilled 
N,N-dimethylformamide (DMF). All reagents were used in a 4 fold excess.
The carboxy-terminal amino acid was coupled to 0.5 g of the supporting resin 
(Pepsyn KA) via an ester bond which was generated by the recirculation of the active ester- 
derivatised amino acid and the catalyst (4-dimethylaminopyridine in DMF) through the 
resin for 7 hours. A sample of the resin was washed and subjected to Fmoc analysis by 
cleavage of the Fmoc group in 20% piperidine in DMF. Free Fmoc groups were 
quantified by measuring the absorbance at 190-300 nm. This demonstrated that maximum 
loading of the resin had been achieved. The carboxy-terminal amino acid was 
"deprotected" by washing for 10 min in 20% piperidine in DMF followed by a 15 min 
wash in DMF. All subsequent amino acids were coupled stepwise by recirculation of the 
active ester derivative and the catalyst 1-hydroxybenzotriazole through the resin plus its 
growing peptide chain for 25 min. The resin was then washed in DMF for 25 min, 
deprotected, then the coupling cycle was repeated with the following amino acid.
In order to check for completion of the coupling reaction, Kaiser or Istatin tests 
were performed on small samples of resin following coupling. The resin was washed in
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DMF, dichloromethane and diethyl ether then dried under a stream of nitrogen. For the 
Kaiser test, 6-10 beads of resin were heated at 100°C for 5 min in 2 drops of each of 5% 
ninhydrin in ethanol, 400% phenol in ethanol and 2% 0.001 M KCN in pyridine. 
Complete coupling, indicated by the absence of uncoupled primary amino acids was 
confirmed by a pale yellow colour. When coupling to a secondary amino acid (e.g. 
proline) the Kaiser test was modified by the addition of 2 drops of Istatin reagent (3.3% 
(w/v) Istatin in benzyl alcohol stirred for 2 hours at room temperature and filtered to 
remove insoluble Istatin). Complete coupling was confirmed by the absence of colour on 
the resin beads.
Following the coupling of the amino terminal residue, the resin was washed in 
DMF, tertiary amyl alcohol and glacial acetic acid to remove any by-products of the 
synthesis. This was followed by a wash with tertiary amyl alcohol, dichloromethane and 
diethyl ether to dry the resin. Cleavage of the peptide from the resin and removal of side- 
chain protecting groups were performed at the same time by incubating the resin in 
trifluoroacetic acid (TFA). 3% (w/v) phenol and 3% (v/v) ethanedithiol (EDT) were 
included as scavengers to prevent side-reactions occurring with the released peptide. The 
optimum time for cleavage and deprotection was determined by shaking a small sample of 
resin with the TFA, phenol and EDT reagent and removing samples of the supernatant 
after 1, 2, 4, 8 and 24 hours. The sample was added to diethyl ether on ice and the 
precipitate that formed was pelleted by centrifugation at 800 gav for 10 min. The 
precipitated peptide was washed 4 times in diethyl ether.
The peptide was subjected to analytical reverse phase high-performance liquid 
chromatography (HPLC) using a Cqg column. The sample components were fractionated 
by a gradient of acetonitrile (5-70%) in TFA:water and compounds were detected by 
measurement of their absorbance at 215 nm. The peptide peak reached a maximum size 
after incubation with the cleavage reagent for 8 hours, this time also minimised the 
generation of by-products. Large scale cleavage of the peptide was performed under
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identical conditions. Approximately 200 mg of peptide were produced which were stored 
at -20°C under nitrogen. Analytical HPLC showed the peptide to be at least 80% pure, it 
was therefore used for immunization without further purification.
2.13.3 Coupling of peptides to the carrier protein
2.12.3.1 Ellman's test for thiol groups
Cysteine groups were required for the coupling of the peptide to the carrier 
protein. The content of thiol groups in the cysteine residue of each peptide was determined 
by Ellman's method, as described by Davies (1990)
A stock solution of Ellman's reagent was prepared containing 10 mM 5,5' 
dithiobis-<2-nitrobenzoic acid (DTNB) in 100 mM Na2 HPC>4 , 18 mM NaHCC>3 (pH 7.5). 
For each assay 67 fi\ of the DTNB stock were added to 600 fi\ of 100 mM Na2 HPC>4 (pH
7.5) and the volume was adjusted to 1.0 ml with water and the thiol-containing standard or 
sample. A standard curve ranging from 0.01-0.33 jimol/ml of cysteine hydrochloride was 
prepared by dilution of a 1 mM stock. Each peptide was dissolved at a concentration of 8 
mg/ml in a buffer found to maximise its solubility. For peptide A, which dissolved poorly 
in all buffers, solubilization was maximised in 0.1 M sodium borate (pH 9.0). The loop 
peptide was soluble in 100 mM Na2 HPC>4 (pH 7.2) and Peptide B was soluble in both of 
these buffers. 10 /d of each peptide solution were added to each assay tube. After a 10 
min incubation at room temperature the absorbance of all samples was measured at 412 
nm. The content of thiol groups in the peptide sample was then estimated from the 
standard curve.
Peptide A was poorly soluble and contained only 19% of the total number of 
expected thiol groups. Peptide B was estimated to have 79% of the expected number of 
thiol groups and the loop peptide had 100% of the thiol groups available. When the thiol
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content was low, peptides were either coupled using the glutaraldehyde method (see section 
2.13.3.2) or were reduced using dithiothreitol (DTT). To reduce the peptide, 8 mg were 
solubilized in 500 /zl of 50 mM Na2 HPC>4 (pH 7.2), DTT was added to a concentration of 
100 mM and the reaction was allowed to proceed at room temperature. The reaction 
mixture was separated by passing through a Sephadex G10 column equilibrated with 50 
mM Na2 HPC>4 (pH 7.2). The peptide-containing fractions, which had a high absorbance 
at 236 and 280 nm, were added immediately to KLH-MB as described in section 2.13.3.3.
2.13.3.2 Glutaraldehyde coupling of peptide and carrier protein
Glutaraldehyde was used to couple peptide A which had a low number of available 
thiol groups. The coupling procedure was a modification of the method described by 
Walter et al. (1980). 5 mg of peptide A in 200 /zl of 0.1 M sodium borate (pH 9.0) were 
mixed with 6 mg of Keyhole Limpet haemocyanin (KLH) dissolved in 400 /zl of 10 mM 
Na2 HPC>4 (pH 7.4). 200 /zl of a 20 mM glutaraldehyde solution were added dropwise and 
the mixture was stirred at room temperature for 30 min. Unreacted products were 
separated on a Sephadex G25 column (20x1 cm) equilibrated with 50 mM sodium 
phosphate buffer (pH 6.0) at 4°C. Fractions emerging after the void volume contained the 
peptide-KLH conjugate as determined by turbidity and absorbance at 280 nm. The protein 
concentration of the conjugate was determined, it was aliquoted and stored at -20°C.
2.13.3.3 MBS coupling of peptide and carrier protein
The use of N-maleimidobenzoic acid-N-hydroxysuccinimide ester (MBS) to couple 
a peptide to a protein was first described by Liu et al. (1979). The protocol used in the 
present study has been adapted from Green et al. (1982) and Davies (1990).
A 16 mg/ml solution of KLH in 10 mM Na2 HPC>4 (pH 7.2) was dialysed 
overnight at 4 °C against the same buffer. 500 /zl of the protein solution were added to
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10 /zl of a 50 mM solution of N-ethyl maleimide (NEM) and the mixture was stirred at 
25°C for 10 min in order to block any thiol groups on the KLH. The dialysis and blocking 
steps could be omitted with no obvious effect on the quality of the antiserum produced. 2 
mg of MBS were solubilized in the minimum volume of DMF (* 5 0  /zl) and added 
dropwise to 250 /zl of the KLH solution. The reaction mixture was stirred for 30 min at 
25°C. The products were passed down a Sephadex G25 or G50 column (1x20 cm ) 
equilibrated at 4°C with 50 mM Na2HP04 (pH 6.0) or 10 mM Na2HP04/145 mM NaCl 
(pH 7.4). Unreacted MBS was retained on the column, the KLH-MB conjugate emerged 
after the void volume. Turbid fractions with a high absorbance at 280 nm were pooled, 
giving a final volume of * 2  ml. The KLH-MB was added to about 5 mg of the peptide 
dissolved in 1 ml of 50 mM Na2HP04 (pH 7.2) or 0.1 M sodium borate (pH 9.0). After 
adjustment of the pH to 7.0, the mixture was stirred at room temperature for three hours. 
The coupled peptide-KLH conjugate was dialysed overnight against PBS and the protein 
concentration was determined. The conjugate was stored in aliquots at -20°C.
2.13.4 Immunisation protocol
Antisera were raised against the GLUT2 peptide-KLH conjugates in sandy half- 
lop-eared rabbits. Each animal was injected with 200-400 fig of conjugate in 500 /zl of 
PBS emulsified with 0.5-1.5 ml of Freund's complete adjuvant (FCA). All injections were 
given intramuscularly into 2-4 sites in the thigh. This first injection was followed 2-3 
weeks later with an injection of 200-400 fig of conjugate in 500 /zl of PBS emulsified with 
0.5-1.5 ml of Freund's incomplete adjuvant (FIA). 2-4 weeks later a boost injection was 
given consisting of 100-200 fig of protein in 1 ml of PBS containing 6 mg of aluminium 
ammonium sulphate (alum). These boost injections were repeated every 4-6 weeks, or 
whenever the antibody titre fell. Small test bleeds were taken from an ear vein and the 
antibody titre was measured using an ELISA (see section 2.18.2). At 4-6 week intervals 
30 ml of blood were obtained by cardiac puncture under general anaesthesia. Blood was 
allowed to clot in glass tubes at room temperature for *  4 hours. The clot was loosened
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and the sample was left at 4°C overnight. The serum was obtained by centrifugation at 
— 2000 gav for 10 min and stored in small aliquots at -70°C.
2.13.5 Purification of antibodies from anti-GLUT2 peptide antiserum
2.13.5.1 Affinity Purification of anti-GLUT2 C-terminal peptide antibodies
Rat C-terminal peptide was immobilized on a Reacti Gel 6X matrix of 6% cross- 
linked agarose, derivatised with l-l'carbonyl-diimidazole carbonate (Pierce Chemical 
Company, Illinois, USA ). 2 ml of Reacti Gel slurry were washed in ice-cold buffer (0.9% 
(w/v) NaCl, 0.1 M boric acid, pH 8.3). The gel cake was then added to 4 mg of peptide 
solubilized in 8 ml of the same buffer and was stirred at 4°C for 44 hours. The gel was 
washed briefly, then incubated in 8 ml of 1 M ethanolamine (pH 9.0) for 3 hours in order 
to block remaining active groups. The gel was washed with water and packed into a 
column. Antiserum was purified following the method described by Oka et al. (1988).
The peptide column was equlibrated with PBS at room temperature, then 5-10 ml 
of antiserum were re-circulated through the column for ~ 2  hours. The column was 
washed with «  20 ml of PBS followed by 20 ml of 10 mM Na2HP04/2 M NaCl (pH 7.4). 
Anti-peptide antibodies were eluted by washing the column with 10 ml of 3.5 M sodium 
thiocyanate in 10 mM Na2HPC>4 (pH 6.6). The antibody-containing fractions were 
dialysed against PBS and concentrated using polyethylene glycol 20,000 (PEG). All 
column washes were tested for the presence of anti-peptide antibody using an ELISA (see 
section 2.18). Antibody was only detected in the sodium thiocyanate wash. Between 50- 
100 ng of pure antibody were obtained per ml of serum. The antibody was stored at 
-70°C.
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2.13.5.2 Purification of IgG from anti-GLUT2 antiserum
IgG was purified from rabbit anti-GLUT2 C-terminal peptide (B) antiserum 
according to the method described by Johnstone & Thorpe (1987). 10 ml of serum were 
warmed to 25°C and 1.8 g Na2 SC>4 were added to make an 18% (w/v) solution. The 
serum was stirred for 30 min at 25°C then centrifuged at 3000 gav for 30 min at 25°C. 
The supernatant was discarded and the volume of the precipitate was noted. The pellet was 
dissolved in water and the volume was adjusted to 5 ml. Sufficient Na2S0 4  was added to 
make a 14% (w/v) solution (accounting for the salt carried over in the first precipitate). 
The serum was stirred at 25 °C for a further 30 min and the centrifugation step was 
repeated. The precipitate was redissolved in water to give a volume of 3 ml and dialysed 
overnight against PBS at 4°C. The protein yield was calculated from the absorbance at 
280 nm in a 1 cm light path.
_ „  . . A280 nm x 10IgG (mg / ml) in sample =  ------------------
13.6
2.14 IMMUNOAFFTNITY PURIFICATION OF LIVER GLUT2
2.14.1 Preparation of immunoaffinity columns
i) Coupling of IgG to Sepharose-4B
The cyanogen bromide activation of Sepharose-4B and subsequent coupling of 
antibody were performed as described by March et al. (1974). 10 ml of settled Sepharose- 
4B beads were washed with water then added to 20 ml of 1 M Na 2 CO3  and stirred slowly. 
1 ml of a 2  g/ml solution of cyanogen bromide in acetonitrile was added and the slurry was 
stirred vigorously for 2 min in a fume cupboard. The slurry was washed under a vacuum 
in a course sintered glass funnel with 200 ml of each of 0.1 M NaHCC>3 (pH 9.5), water 
and 0.2 M NaHCC>3 (pH 9.5). The moist cake of beads was rapidly transferred to a large
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plastic tube containing 30 mg of IgG in 20 ml of 0.2 M NaHCC>3 (pH 9.5). IgG was 
prepared from anti-GLUT2 C-terminal peptide antiserum as described in section 2.13.5.2. 
Coupling was performed by a rotation for 20 hours at 4°C. It was calculated that *  1.5 
mg of IgG were coupled per ml of gel. Any remaining active sites on the gel were blocked 
by mixing the coupled gel cake with 2 M ethanolamine for »1.5 hours at room 
temperature. The coupled Sepharose-4B beads were washed with 200 ml of NaHCC>3 (pH 
10.0) and rotated overnight at 4°C with 40 ml of 0.2 M NaHCC>3 /l% (w/v) casein. The 
beads were washed successively with 100 ml of 50 mM glycine/50 mM NaCl (pH 3.0), 10 
mM sodium phosphate/50 mM NaCl (pH 7.4), 50 mM glycine/50 mM NaCl (pH 10.0) and 
10 mM sodium phosphate/50 mM NaCl (pH 7.4). The immunosorbent was used to affinity 
purify GLUT2 using method I described in section 2 .14.2.(i).
ii) Coupling of purified anti-GLUT2 antibody to Reacti Gel 6X
Affinity purified anti-GLUT2 C-terminal peptide (A) antibodies (see section 
2.13.5.1) were coupled to Reacti Gel 6X as recommended by the manufacturers and as 
described in section 2.13.5.1 for the coupling of peptide with the following exceptions: 1 
ml of gel was coupled to 3 mg of antibody in 4 ml of coupling buffer. The gel was then 
washed in 2 M TRIS (pH 8.0) to block remaining active sites. The efficiency of antibody 
coupling was about 70%, as estimated from an SDS-Lowry protein assay. The antibody 
loading was therefore about 2 mg/ml gel. The immunosorbent was used to affinity purify 
GLUT2 using method II described in section 2 .14.2.(ii).
2.14.2 Affinity purification of GLUT2
i) Method 1 - (Momoi & Lennon, 1982)
#
The method used was essentially as described by Momoi and Lennon (1982). 7-8 
mg of liver plasma membrane, prepared as described in section 2.10.4.1, were solubilized
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by a rotation for 3 hours at 4°C, in 40 ml of buffer containing 2% Triton X-100, 10 mM 
sodium phosphate and 50 mM NaCl (pH 7.4) . Insoluble material was removed by 
centrifugation for 30 min at 20,000 gav. The solubilized liver plasma membrane proteins 
were mixed with the antibody-coupled Sepharose 4B beads which had been fully 
equilibrated with buffer A (0.5% Triton X-100, 10 mM Na2 HPC>4 , 50 mM NaCl, pH 7.4). 
Following an overnight rotation at 4°C, the beads were packed into a column and the gel 
was washed sequentially with 400 ml of buffer A, 100 ml of buffer B (0.2% Na cholate, 10 
mM TRIS, 100 mM NaCl, pH 7.4) and 50 ml of buffer B containing 0.25 M NaCl. The 
bound GLUT2 was recovered by alternating elutions with 25 ml volumes of 1 M NaCl and 
2 M NaCl in buffer B which were repeated 4 times. The fractions were concentrated with 
PEG and dialysed extensively against 10 mM sodium phosphate buffer (pH 7.4). Proteins 
were analysed by SDS-PAGE and Western blotting. The column was washed with 50 ml 
of 50 mM glycine/50 mm NaCl containing 0.2% Na cholate (pH 3.0). This was followed 
by 50 ml of 50 mM glycine/50 mM NaCl containing 0.5% Triton X-100. The column was 
finally washed and stored in 10 mM Na2HPC>4/50 mM NaCl buffer (pH 7.4).
ii) Method II - (Davies, 1990)
The method used was essentially as described by Davies (1990). Before use the 
coupled Reacti Gel 6 X was washed extensively with buffer A (50 mM sodium phosphate, 
100 mM NaCl, 1 mM EDTA, pH 7.4) and buffer B (0.2 M glycine, 1 mM EDTA, 100 
mM NaCl, pH 2.4). The gel was then packed into a small glass column and equilibrated at 
4°C with buffer A containing 1% n-octyl B-D-glucopyranoside.
2 mg of liver plasma membrane protein were solubilized for 1 hour on ice in 15 ml 
of buffer B containing 1 % n-octyl fi-D-glucopyranoside and proteinase inhibitors (details 
and concentrations are given in section 2.10.4.1). Insoluble material was removed by 
centrifugation for 20 min at 20,000 gav. The solubilized material was loaded onto the 
column and pumped slowly through until it had recirculated ~ 5  times. The unbound
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fraction was collected and the column was washed with 15 ml of equilibration buffer. The 
bound proteins were eluted by washing with ~  2 ml of buffer B containing 1 % n-octyl B- 
D-glucopyranoside. 2 ml fractions were collected and neutralized immediately by the 
addition of 1 M sodium phosphate. The fractions were dialysed overnight against buffer A 
and after concentration with PEG were analysed by SDS-PAGE and Western blotting. The 
column was washed with PBS and 50 mM diethanolamine (pH 11.0) and was stored at 4°C 
in PBS containing 0.02% azide.
2.15 PHOTOLABELLING WITH ATB-BMPA
2.15.1 Preparation of ATB-[2-^H]-BMPA and ATB-BMPA
The [2-^H] and non-radioactive ATB-BMPA were prepared by Dr. G.D. Holman 
as previously described (Clark & Holman, 1990). ATB-[2-^H]-BMPA had a specific 
activity of 10 Ci/mmol) and was stored at -20°C in PBS in the dark at a concentration of 
0.5 mM (5 mCi/ml).
2.15.2 Photolabelling of liver plasma membranes
Suspensions containing 100 fig of liver plasma membrane protein were mixed with 
100 / i d  of ATB-[2-3h]-BMPA and competing substrates and inhibitors as required. D- 
glucose, D-mannitol, D-fructose and 4,6-0-ethylidene-D-glucose were prepared as 1 M 
stock solutions in double distilled water. Phloretin and cytochalasin B (Sigma) were 
dissolved in ethanol as concentrated stock solutions. The final ethanol concentration in 
assays did not exceed 5 %. These inhibitors were added to cells or membranes just prior to 
the addition of the photolabel to give the concentrations indicated in the figure legends. 
The final sample volume was adjusted to 100 /d with 5 mM sodium phosphate buffer (pH 
7.4). Samples were irradiated for 60s in polystyrene dishes using a Rayonet RPR-100 
photoreactor with RPR-3000 lamps. The labelled membranes were washed 3 times by
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centrifugation (20 min, 20,000 gav 4°C) in 5 mM sodium phosphate buffer. Washed 
membranes were either analysed directly by SDS-PAGE or were used for 
immunoprecipitations.
2.15.3 Photolabelling of whole cells
The conditions used for photolabelling cells are described in detail in the figure 
legends. Just prior to labelling, cells were washed to remove any glucose-containing 
medium. Photolabelling was carried out at room temperature in a Hepes-buffered balanced 
salts solution pH 7.0 (see section 2.2), which was also used for the washing steps. 
Hexoses were added from concentrated stock solutions to give the concentrations indicated 
in the figure legends. When cell suspensions were labelled, between 5x10^ and 2.5x10^ 
cells in 500 /d of buffer were irradiated in the presence of 100-400 /xCi of ATB-BMPA. 
Cells were initially irradiated for 30 s, the suspension was then agitated and the irradiation 
continued for a further 30 s. Cells were washed = 5 times by low speed centrifugation. 
Monolayers of cultured B-cell lines in 35 mm dishes were irradiated for 60s in 0.5 ml of 
buffer containing 100 f id  ATB-BMPA. The cell monolayers were also washed 5 times.
2.15.4 Immunoprecipitation of ATB-BMPA labelled proteins
Photolabelled proteins were immunoprecipitated from liver, islets and fi-cells with 
rabbit antisera raised against GLUT2 or GLUT1 peptide sequences. Preimmune rabbit 
serum was used in control experiments. Unless otherwise stated, the GLUT2 antiserum 
used routinely for immunoprecipitations was anti-rat GLUT2 C-terminal peptide (B) 
antiserum. Serum samples from human diabetic patients or normal controls were also used 
to immunoprecipitate labelled proteins from liver plasma membranes.
For each immunoprecipitation, 5 mg of Protein A-Sepharose (Sigma) were 
conjugated to 50 fi\ of serum. When the amount of Protein A-Sepharose was altered details
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have been given in the figure legends. The Protein A-Sepharose was swollen for 30 min in 
PBS. It was then washed three times by low speed centrifugation to remove stabilizers. 50 
fi 1 of human or rabbit serum were diluted in 500 /xl of PBS and mixed with the Protein A- 
Sepharose beads by rotation for 3-16 hours at 4°C. Excess antibody was removed by 
washing the beads four times in PBS.
The pellets of washed photolabelled cells or membranes were solubilized for 1 
hour on ice in 0.5-1 ml of 5 mM sodium phosphate buffer containing 2% nonaethylene 
glycol dodecyl ether (C1 2 E9 ) detergent (Boehringer Mannheim) and the proteinase 
inhibitors pepstatin A, leupeptin, antipain and aprotinin each at 5 /zg/ml. In some 
experiments, as indicated in the figure legends, the C1 2 E9  detergent was replaced by 1% 
n-octyl 6-D-glucopyranoside (Sigma) or 4% Triton X-100 and 0.5% SDS. Any insoluble 
material was removed by centrifugation for 20 min at 20,000 gav at 4°C. The solubilized 
material was incubated with the Protein A-Sepharose antibody-complex for 2*A-3 hours by 
a rotation at 4°C. The Protein A-Sepharose immunoprecipitates were pelleted by low 
speed centrifugation. In some experiments the supernatant was removed and added to 
another Protein A-Sepharose antibody complex for a second 2 xh  hour rotation.
The Protein A-Sepharose immunoprecipitates were washed five to seven times with 
1 ml of ice cold 5 mM phosphate buffer containing 0.2% C\2^9- Labelled proteins were 
released from the conjugate by incubation for 30 min at room temperature in 
electrophoresis sample buffer (see section 2.16). Following a low speed centrifugation to 
remove the Sepharose beads radiolabelled proteins were analysed by SDS-PAGE (see 
section 2.16).
As a control, identical immunoprecipitations were also performed using labelled 
material which was then analysed by Western blotting. To prevent interference between 
the —55 kDa glucose transporter protein and the —51 kDa IgG heavy chain polypeptide, 
SDS-PAGE was performed under non-reducing conditions on 8% polyacrylamide gels.
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In some experiments the non-precipitated proteins in the supernatant were also 
saved for analysis by electrophoresis. An aliquot was either mixed directly with 
electrophoresis sample buffer and analysed by SDS-PAGE. Alternatively, the protein was 
removed from the detergent-containing buffer by precipitation with chloroform and 
methanol (Wessel & Fliigge, 1984). A 1 ml sample of detergent-solubilized proteins was 
mixed with 3.6 ml of methanol and 900/d of chloroform were added. The sample was 
vortex-mixed and 2.7 ml water were added. The sample was mixed again and centrifuged 
at 9000 gav for 1 min. The upper phase was carefully removed, discarded and replaced 
with 2.7 ml of methanol in order to precipitate the protein from the lower chloroform 
phase and interphase. Following vortex mixing, the protein was pelleted by centrifugation 
for 2 min at 9000 gav and the supernatant was removed by aspiration. The precipitated 
proteins were solubilized in electrophoresis sample buffer and analysed by SDS-PAGE.
2.15.5 Analysis of ATB-BMPA labelled samples
Photolabelled samples were analysed by SDS-PAGE, the gels were stained briefly 
with Coomassie Blue, then destained and cut into 6 . 6  mm wide slices. Each slice was 
placed in a scintillation vial and dried at 80°C for 2 hours. Slices were then solubilized in 
capped vials for a further 1-2 hours at 80°C in 0.5 ml of hydrogen peroxide containing 2 % 
(v/v) ammonia solution. 8  ml of scintillation fluid were added to each vial and the 
radioactivity was then counted. The position of the radiolabelled peak was compared with 
the molecular weight marker proteins. The size of the peak was quantified by summing the 
radioactivity present in each slice under the peak and subtracting a background value based 
on the average amount of radioactivity in the slices on either side of the peak (Calderhead 
& Lienhard, 1988).
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2.15.6 Estimation of the binding constant of ATB-BMPA for liver GLUT 2
The binding constant of ATB-BMPA was determined by the displacement of 
radiolabelled ATB-[23 H]-BMPA by non-labelled ATB-BMPA. Photolabelling of 100 /zg 
samples of liver plasma membrane protein using 100 /xCi ATB-[2-3 H]-BMPA was 
performed in the presence of a range of concentrations of unlabelled ATB-BMPA. The 
final ATB-BMPA concentrations used were 100 /zM (no added unlabelled ATB-BMPA), 
300 /zM, 500 /zM, 700 /zM and 900 /zM. The radioactive and unlabelled ATB-BMPA 
compounds were mixed together in a final volume of 100 /zl of 5 mM phosphate buffer 
before the addition of membranes. Samples were then irradiated, immunoprecipitated and 
subjected to electrophoresis. The size of the GLUT 2 peak was calculated for each 
concentration of ATB-BMPA. A background value was then subtracted to take account of 
the binding and immunoprecipitation which was non-specific. The background value used 
was calculated from the average amount of radioactive protein precipitated by preimmune 
rabbit serum. Values for the binding constant (K^) and the total number of binding sites 
(Bmax) were obtained from non-linear regression (weighted for relative error) of the 
equation: B=(Bmax/K(j)«F/( 1 + F/K^)
where B and F are the bound and free ATB-BMPA. The data were graphically presented 
as F/B against F plots which were used to calculate the binding constant K^. The number 
of pmol of ATB-BMPA bound per 100 /zg of liver plasma membrane protein were 
calculated from the peak areas (in dpm) which, based on the known specific radioactivity of 
ATB-BMPA were converted into moles of ATB-BMPA bound.
2.16 SDS-PAGE
Proteins from whole cells, membrane preparations, affinity purifications or 
immunoprecipitates were analysed by SDS-PAGE using the Protean II gel system (Bio- 
Rad).
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The samples were solubilized by incubation at room temperature for 30-60 min in 
sample buffer containing 10% (w/v) SDS, 6 M urea, 0.05% (w/v) Bromophenol Blue and 
10% (v/v) 2-mercaptoethanol. For analysis of Protein A-Sepharose immunoprecipitates 
*  100 /d of solubilization buffer were added directly to the washed beads. For analysis of 
membrane preparations, samples were diluted 2  fold in solubilization buffer such that there 
was at least 1 /d of solubilization buffer per fig protein. When sample buffer was added 
directly to whole cells, solubilization was aided by passage of the samples through a fine 
needle. In some experiments, when the samples were analysed under non-reducing 
conditions, the 2-mercaptoethanol was omitted and replaced with 0.1 M iodoacetamide 
(Johnstone & Thorpe, 1987). Proteins extracted from HIT and RIN cells with the 
detergent Triton X-114 were prepared for electrophoresis as described in section 2.11.
SDS-PAGE was carried out essentially as described by Laemmli (1970). Gels 
were prepared from stock solutions, details of which are given in section 2.2. The 
resolving gel contained 8  or 10% acrylamide, 0.55 M TRIS (pH 8 .8 ) and 0.15% (w/v) 
SDS. The gel was polymerised chemically by the addition of 0.6 /d/ml N, N, NT, N', 
tetramethylethylene-diamine (TEMED) and 6  /d/ml of a 10% solution of ammonium 
persulphate. The poured gel was overlaid with a layer of water-saturated butanol and left 
to polymerize (~1 hour). Following removal of the butanol, the resolving gel was 
overlaid with a stacking gel containing 3.75% acrylamide, 125 mM TRIS (pH 6 .8 ) and 
0.1 % SDS which was polymerized as described above.
Electrophoresis was generally carried out overnight at 25 mA for a 3 mm gel or at 
12 mA for a 1.5 mm gel in buffer containing 25 mM TRIS, 192 mM glycine and 0.1% 
SDS (pH 8.3). Molecular mass protein standards (Sigma) were included on each gel. 
Myosin (205 kDa), 6 -galactosidase (116 kDa), phosphorylase (97.4 kDa), BSA ( 6 6  kDa), 
ovalbumin (45 kDa) and carbonic anhydrase (29 kDa). Prestained markers with 
approximate molecular masses of —116 kDa (B-galactosidase) and -2 9  kDa (carbonic
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anhydrase) were also added to some samples so that the positions of the lanes could be 
easily identified.
For analysis of proteins by Western blotting, samples were subjected to 
electrophoresis on 1.5 mm thick gels with 40-50 p,g of protein per lane. ATB-BMPA 
labelled samples were subjected to electrophoresis on 3 mm thick gels and following 
staining were processed as described in section 2.15.5.
2.16.1 Staining polyacrylamide gels for protein
Gels were agitated at room temperature in 0.2% (w/v) Coomassie Brilliant Blue in 
10% (v/v) acetic acid, 30% (v/v) methanol and 60% (v/v) water for »15 min. Excess 
stain was removed by destaining in several changes of 10% (v/v) acetic acid, 30% (v/v) 
methanol and 60% (v/v) water.
2.17 WESTERN BLOTTING
2.17.1 Electrophoretic transfer of proteins to nitrocellulose
Proteins separated by electrophoresis on 1.5 mm thick polyacrylamide gels were 
transferred to nitrocellulose paper (Gelman Sciences pore size 0.4 pm) using one of two 
alternative electrophoretic transfer methods.
i - Wet transfer
The polyacrylamide gel was soaked for 10-15 min in transfer buffer (see section 
2.2). Wearing gloves, a sandwich was then constructed in which the gel was overlaid with 
a piece of wet nitrocellulose paper, care was taken to exclude all air bubbles. This 
sandwich was surrounded on each side by a layer of filter paper and a nylon pad, both
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soaked in transfer buffer. The whole sandwich was placed between two plastic plates 
which were taped together tightly and slotted into a transfer tank with the nitrocellulose 
paper facing the anode. The blotting apparatus used was the Bio-Rad "Trans-Blot" cell or 
a similar tank which had graphite plates as the electrodes. It contained »  1.5 L of transfer 
buffer at 4°C. Electrophoretic transfer was carried out for 6  hours at 29 Volts at 4°C 
which optimized the transfer of proteins with molecular masses between 116 and 29 kDa.
ii - Semi-dry transfer
Proteins were transferred to nitrocellulose paper using a semi-dry blotting 
apparatus (Novablot, Pharmacia LKB), and following the manufacturers instructions. 
Briefly, this involved layering a stack of buffer-soaked filter papers onto the anode plate, 
covering it with a piece of nitrocellulose paper followed by the polyacrylamide gel and a 
final stack of filter papers. All layers were cut to the same size and smoothed out to 
exclude any air bubbles. Once the cathode plate had been replaced, the gel was transferred 
at 0.8 mA/cm^ for 105-120 min.
2.17.2 Staining nitrocellulose filters for total protein
Proteins were visualised by staining the washed nitrocellulose paper by agitating it 
for ~ 2  min in 0.1% (w/v) Ponceau S in 3% (w/v) trichloroacetic acid prepared in double 
distilled water. Background staining was removed by washing in double distilled water. 
Although relatively insensitive and having a tendency to fade, this stain was useful for 
marking the positions of molecular weight marker proteins, since it did not distort the 
nitrocellulose paper. It also confirmed that satisfactory transfer of proteins had occurred. 
Ponceau S staining could be removed completely by washing in several changes of PBS or 
TRIS-buffered saline (TBS) - see section 2.2.
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Once the temporary stain was removed, identification of the position of transferred 
proteins was facilitated if pre-stained molecular weight marker proteins with weights of 
about 116 and 29 kDa were included on the polyacrylamide gel. These could be seen as 
blue bands on the nitrocellulose paper.
2.17.3 Immunoblotting of nitrocellulose-bound protein
Nitrocellulose paper was cut either into blocks or single tracks which were placed 
(using forceps) in plastic dishes or trays divided into longitudinal wells. The nitrocellulose 
was blocked, and primary antibody added using either protocol I, II or III described below 
and as indicated in the figure legends.
Bound primary antibodies were detected by the addition of one of the secondary 
antibody conjugates listed below. In order to prolong their life, the antibody-enzyme 
conjugates were diluted 1 :1  with glycerol and then stored at -2 0 °C.
i) Horse radish peroxidase (HRP)-conjugated goat-anti-human (or rabbit) IgG antibody 
(Sigma). Diluted 1:1000 in the appropriate blocking buffer and incubated for 2 hours at 
room temperature.
ii) Alkaline phosphatase conjugated goat-anti-human (or rabbit) IgG antibody (Sigma) 
diluted 1:2000-1:4000 in blocking buffer and incubated at room temperature for 2 hours.
iii) 125i_iabened donkey anti-rabbit IgG antibody (Amersham International), diluted in 
blocking buffer to give a specific activity of 0.2-0.35 fiCi/ml and incubated for 3 hours at 
room temperature.
2.17.3.1 Blocking protocol I
The protocol followed was modified from that described by Thorens et al. (1988). 
Nitrocellulose filters were washed for 20 min in TBS containing 0.1% Tween-20. This
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was followed by an incubation for 30 min at 37°C in blocking buffer containing 5% (v/w) 
non-fat dried milk (Marvel) and 0.2% (v/v) Nonidet P-40 (NP-40 - Sigma). At this stage 
the blocked filters could be air-dried and stored at -20°C until required. The blocked 
filters were shaken with rabbit or human serum overnight at room temperature in blocking 
buffer to which 0.05% (w/v) thiomerosal was added to inhibit microbial growth. The 
serum was used at dilutions ranging from 1:20-1:5000, although 1:500 was the standard 
dilution used.
Blots were washed (2x20 min) at room temperature in TBS containing 0.2% NP-40 
and 0.1% Tween-20 respectively. The filters were then reblocked in the blocking buffer 
for 30 min at 37°C. Following an incubation with one of the secondary antibody 
conjugates listed above, the nitrocellulose was washed for 3x10 min in TBS containing 
0.2% NP-40 and for 3x10 min in TBS/0.1 % Tween-20. The blots were then developed as 
described in Section 2.17.4.
2.17.3.2 Blocking protocol II
This method was based on the protocol used by Dr. S. Cushman and co-workers 
(personal communication). Nitrocellulose filters were blocked for 1 hr at 37°C with TBS 
containing 3% (w/v) BSA. The filters were then shaken for »2-16 hr with antiserum 
diluted 1:50-1:5000 in blocking buffer. The filters were washed in TBS alone (2x5 min), 
followed by washes with TBS containing: 0.1% (v/v) NP-40 (5 min), 0.2 M NaCl (5 
min), and 0.1% (v/v) NP-40 (5 min). This was followed by two final 5 min washes in 
TBS alone. Following incubation with one of the antibody conjugates listed above, the 
same series of washes was repeated and the blots were developed as described in section 
2.17.4.
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2.17.3.3 Blocking protocol III
This blocking protocol was essentially as recommended by Amersham International 
for use with the enhanced chemiluminescence (ECL) detection system.
The nitrocellulose was blocked for 1 hour at room temperature in TBS containing 
5% (w/v) non-fat dried milk and 0.2 % (v/v) Tween-20. Antisera diluted 1:8000 in the 
blocking buffer were incubated with the nitrocellulose for a further hour at room 
temperature. The nitrocellulose was washed with TBS/0.2% Tween-20 (2x10 min), 
TBS/0.2 M NaCl (5 min) and finally in TBS/0.2% Tween (20 min). Bound antibodies 
were detected by incubation for 1 hour at room temperature with alkaline phosphatase 
conjugated goat-anti-rabbit IgG antibodies (Sigma), diluted 1:4000 in blocking buffer. 
Following washing as described above, the blots were developed using the enhanced 
chemiluminescence system.
2.17.4 Development of immunoblots
2.17.4.1 125I-labelled anti-IgG
Following washing, the nitrocellulose was air-dried, wrapped in cling-film and 
exposed to photographic film at room temperature for 2-5 days. When quantification was 
required, the nitrocellulose blots were aligned with the developed film and 5 mM slices 
were cut from the region of interest on the blot. Radioactivity was measured in a gamma- 
counter.
2.17.4.2 HRP-conjugated anti-IgG
The nitrocellulose blots were washed briefly with 50 mM sodium acetate (pH 5.0) 
in double-distilled water. The substrate was freshly prepared by a 20 fold dilution in
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sodium acetate buffer of a stock of 0.4% 3-amino-9-ethylcarbazole (AEC) in DMF. 
Hydrogen peroxide was added to give a final concentration of 1 fig/ml. The blots were 
then incubated with the substrate at room temperature for about 30 min or until the pink- 
coloured bands appeared. The developed blots were then washed thoroughly with water.
2.17.4.3 Alkaline phosphatase conjugated anti-lgG
Two stock solutions were prepared, which were stable for about I year at 4°C.
i) 0.5 g of Nitroblue Tetrazolium (NBT - Sigma) in 10 ml of 70% DMF.
ii) 0.5 g of Bromochloroindyl phosphate p-toluidene salt (BCIP - Sigma) in 10 ml of DMF.
Immediately prior to use 6 6  fil of NBT stock, 33 fi\ of BCIP stock and 20 fi\ of a 2 
M MgCl2  stock were added to 10 ml of a 10% (w/w) diethanolamine buffer (pH 9.5). The 
nitrocellulose blot was shaken in this solution until purple bands appeared, usually within 
5-10 min. The blots were then washed thoroughly with water.
2.17.4.4 Enhanced chemiluminescence (ECL)
Blots were exposed to the chemiluminescent substrate for 1 min as recommended 
by the manufacturers (Amersham International). They were then wrapped in cling film and 
exposed to ECL film (Amersham International) for 10-30 s.
2.18 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
An ELISA was used to confirm the presence of anti-GLUT2 peptide antibodies in 
serum samples from immunized rabbits. ELISAS were also developed to screen serum 
samples from type I diabetic patients for the presence of anti-fi-cell surface antibodies.
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2.18.1 Islet cell surface antibody ELISAS
Flat bottomed polystyrene microtitre plates (Titertek, Flow 1CN) were coated with 
fi-cell line plasma membrane antigens by the addition to each well of 1 0 0  /d of a 1 0  /-ig/ml 
membrane protein suspension in 50 mM NaHCC>3 buffer (pH 9.6). The plates were 
covered and incubated overnight at 4°C. Membranes were prepared from HITm2.2 cells 
using either method I or II described in sections 2.10.4.1 and 2.10.4.2 respectively; 
details are given in the figure legends. Membranes were prepared from MIN 6  cells using 
method I described in section 2.10.4.1. Some serum samples were also assayed against 
liver plasma membranes prepared as described in section 2.10.4.1.
Excess antigen was removed by sharply tapping the inverted plate. Each well was 
washed (3x10 min) with 200 /d of PBS/0.1% (w/v) casein/0.05% Tween-20 (Kenna et al. 
1982). Serum, diluted 1:100 in PBS/1 % casein/0.05% Tween was added (100 /d/well) and 
incubated for 2 hours at 37°C. Each sample was tested in triplicate on one plate and on 1- 
5 separate occasions. Samples were coded so that their identity was unknown at the time 
of assaying.
A standard serum serially diluted 1:12.5-1:12589 was used to obtain a standard 
curve which was included on every plate. This enabled absorbance values of test sera to be 
expressed as a percentage of the absorbance given by the standard serum, allowing 
comparisons to be made between results obtained on different occasions. A reference 
sample was also assayed on every plate and it was checked to see that its titre did not 
deviate greatly from the mean.
After incubation, the plate was washed as previously described and 100 fd of HRP- 
conjugated goat-anti-human IgG antibodies were added to each well (diluted 1:1000 in 
PBS/1% casein/0.05 % Tween). After incubation for 1-1.5 hours at 37°C the wells were 
washed 3 times with PBS/0.05% Tween and 100 fd of substrate were added per well. The
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substrate was prepared from TMB (3 5' 5 5' tetra-methylbenzidene) dissolved in DMSO to 
give a 1% (w/v) stock solution. This stock was then diluted 1:100 in 0.1 M sodium 
acetate/citrate buffer prepared in double-distilled water (pH 6.0) and hydrogen peroxide 
was added to a concentration of 0.25 /zl/ml.
The colour was allowed to develop for 10-30 min, then the reaction was stopped by 
the addition of 50 /xl of 2 M H2 SO4 . Absorbances were measured at 450 nm using a 
Titertek Multiskan MCC (Flow ICN) and were corrected for non-specific conjugate 
binding by measuring against a blank in which antiserum was omitted.
2.18.2 Anti-GLUT2 peptide antibody ELISAS
The procedure was identical to that described above, except that the plates were 
coated either with 10 /xg/ml of liver plasma membranes or 0.2 /zg/ml of peptide. All 
washings and incubations were carried out using PBS/0.1% casein/0.05% Tween. Rabbit 
sera were typically tested in duplicate at dilutions from 1:50-1:6400. Binding was 
compared with that shown by the serum taken from the same animal prior to immunization. 
The second antibody used was HRP-conjugated goat anti-rabbit IgG at a 1:1000 dilution.
2.19 STATISTICAL ANALYSIS
The Kolmogorov-Smimov (K-S) two sample test (Siegel, 1956) was used to 
compare levels of antibodies in type I diabetic patients and non-diabetic controls. The K-S 
test is a non-parametric test which makes no assumptions about the distributions from 
which the samples were drawn (Sprent, 1981). It is also suitable for the analysis of a small 
number of samples (Siegel, 1956).
A cumulative frequency distribution was calculated for control and diabetic 
samples using the same intervals for both distributions. By subtraction of one step function
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from the other, the two tailed K-S test identifies the part of the distribution in which the 
maximum difference (Dmax) occurs. By comparison with a theoretical value of D, which 
varies depending on the number of samples, it could be determined whether there was any 
significant difference in the population distributions from which the samples were drawn.
n[ =# in sample 1 
n2 =# in sample 2
The null hypothesis that the 2 samples came from the same population was rejected 
if Dmax exceeded the theoretical value of D at the required level of significance.
Level of significance Critical value of D
. „  \m +m
p  = 0 . 1  1.2 2 ,
m .m
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PART I CHARACTERIZATION OF LIVER GLUT2 USING ATB- 
BMPA AND ANTI-PEPTIDE ANTIBODIES
It has previously been shown that the exofacial photoprobe ATB-BMPA {2-N-[4- 
(l-azi-2,2,2-trifluoroethyl)benzoyl]-l ,3-bis-(D-mannos-4-yloxy)-propyl-2-amine} can be 
used to specifically label the glucose transporter isoforms GLUT1 (Clark & Holman, 1990) 
and GLUT4 (Holman et al., 1990). The aim of the present investigation was to 
demonstrate that ATB-BMPA could be used to label GLUT2, thereby providing an 
alternative to the [^HJcytochalasin B photolabel, which has a low affinity for GLUT2 and 
the use of which is limited to studies of membranes rather than whole cells (Ciaraldi et al. , 
1986; Hellwig & Joost, 1991).
This section of results describes the use of ATB-BMPA to label GLUT2 and the 
optimization of the labelling and immunoprecipitation conditions. The work involved the 
production of anti-GLUT2 peptide antibodies and the demonstration that they specifically 
recognised GLUT2 in liver plasma membranes.
The characteristics of GLUT2 have been compared with those of the other 
transporter isoforms and results produced and techniques developed which could 
potentially be used to detect GLUT2 in 15-cells (Part II), and putative anti-GLUT2 
autoantibodies in the serum of patients with IDDM (Part III).
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3.1 PRODUCTION OF ANTI-GLUT2-PEPTIDE ANTIBODIES
The immune response of rabbits immunized with GLUT2 peptides was monitored 
by testing each serum sample in an ELISA using the immunising peptide as the antigen. A 
typical response is shown in Figure 5. The IgG titre increased rapidly up to about week 14 
when a maximum response was attained. Regular boosting maintained the titre at this 
level. All antisera contained antibodies that bound strongly to the peptide against which 
they were raised, but not all peptides generated equally high titres of antibodies able to 
recognise the intact GLUT2 protein.
The levels of antibodies binding to the GLUT2 protein were estimated from 
ELISAS in which liver membranes were used as the antigen. Western blotting was then 
used to confirm that the membrane antigen recognised was GLUT2, and that the antisera 
were specific for this protein. The ability to detect anti-GLUT2 antibodies by ELISA and 
Western blotting was dependent on the method used to prepare the membranes. When 
crude liver membranes were used (section 2.10.3.2), no specific binding of any anti-rat 
GLUT2 peptide antiserum could be detected either in an ELISA or in a Western blot 
(results not shown). However, antibodies raised against the human-GLUT2-C-terminal 
peptide sequence did bind to a protein in the crude liver membranes, which had an apparent 
molecular mass of ~ 64-66 kDa. This protein was not however GLUT2, since a band of 
the same molecular mass was also recognised by this serum in membranes from cells 
known not to contain GLUT2, for example, human erythrocytes and adipocytes (results not 
shown). The identity of the 64-66 kDa protein was not known, but it was not recognised 













Fig. 5 Typical rabbit IgG response to a GLUT2 C-terminal peptide-KLH conjugate 
administered with adjuvant.
Rabbit antiserum (1:100 dilution) was tested in an ELISA in which the peptide antigen was
coated onto the plates at a concentration of 0.2 jig/ml. The results are means obtained by assaying
samples in triplicate. The error bars shown represent ± S.E.M.
Fig. 6 Immunochemical detection of GLUT2 in purified rat liver plasma membranes
Proteins from rat liver plasma 
kDa membranes were separated by SDS-PAGE, 
transferred to nitrocellulose and 
immunoblotted using blotting protocol III 
and the ECL detection system. The antisera 
used were:
I .preimmune serum
2.anti-rat GLUT1 C-terminal peptide
3.anti-rat GLUT2 C-terminal peptide (B) 
preabsorbed by incubation overnight with 
peptide (B)
4.anti-rat GLUT2 C-terminal peptide (B)
5.anti-rat GLUT2 exofacial-loop peptide
6.anti-human GLUT2 C-terminal peptide .
1 2 3 4 5 6
All anti-GLUT2 antisera detected a band with an apparent molecular mass of *  57 kDa. 
This was recognised more strongly by antisera raised against the rat sequence than the human 
sequence. A non-specific band with an apparent molecular mass of *51 kDa was also recognised 
by all sera. In addition the anti-GLUTl antibody and the anti-GLUT2 exofacial loop antibody 














Liver plasma membranes were prepared as described in section 2.10.3.1. The 5' 
nucleotidase activity was consistent between different batches of membrane and did not 
decrease during the time that the membranes were stored at -70°C. The value obtained for 
the activity of this enzyme at 37°C was 6.15 /imol/mg protein/30 min. Membranes 
prepared by this method did contain immunodetectable GLUT2 as demonstrated by the 
binding of anti-GLUT2 peptide antisera in ELISAS and Western blots.
Figure 6  shows the results obtained by Western blotting liver plasma membranes 
with the antisera that were used in immunoprecipitation experiments. The major band 
recognised by both the anti-rat GLUT2 C-terminal peptide (B) antiserum and the anti-rat 
GLUT2 exofacial loop peptide antiserum had an apparent molecular mass of about 57 kDa. 
Antibodies directed against this protein could be removed by pre-absorption with the 
immunising peptide. The same protein was recognised, albeit less strongly, by the anti­
human GLUT2 C-terminal peptide (D) antiserum. In addition to the major 57 kDa protein, 
anti-GLUT2 peptide antisera also detected other proteins in liver plasma membranes with 
apparent molecular weights of =81, 51, and 36 kDa. As shown in Figure 7, this was 
evident particularly when high concentrations of serum were used for blotting. The 81 
kDa band appeared to be recognised non-specifically since antibodies directed against it 
were not removed by pre-absorption with the immunizing peptide (results not shown). The 
other bands were recognised by antibodies directed specifically against the peptide, since 
they were detected by peptide-affinity-purified antibody (Figure 7, lane 6 ) and could 
largely be removed by pre-absorption with the immunising peptide. However, as shown in 
Figure 6  some of the binding to the 51 kDa band may have been non-specific since this 
protein was also recognised by anti-GLUTl and preimmune serum. The nature of these 
minor bands was unknown. The strong 57 kDa band appeared to be the whole GLUT2 
protein since a band of the same apparent molecular mass was also detected in rat islets 
(Figure 8 ).
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Fig. 7 Western blotting of liver plasma membrane with antisera raised against GLUT2 C- 
terminal peptides A, B and C.
Proteins from rat liver plasma membranes (section 2.10.3.1) were separated by SDS-PAGE 
in sample buffer containing 5 mM DTT instead of mercaptoethanol, transferred to nitrocellulose 
using a wet transfer method and immunoblotted using blotting protocol II (2.17.3.2). Blots were 
developed with an alkaline phosphatase conjugated anti-rabbit IgG antibody.
Lanes 1-5 were blotted with anti-rat GLUT2 C-terminal peptide (B) antiserum at dilutions of 
1:100, 1:500, 1:1000, 1:2000 and 1:5000. Lane 6 was blotted with 2 pig/ml of affinity purified C- 
terminal peptide antiserum. Lane 7 was blotted with a 1:500 dilution of anti-rat GLUT2 C-terminal 
peptide (A) antiserum, and lane 8 with a 1:500 dilution of anti-rat GLUT2 C-terminal peptide (C) 
antiserum. All sera were obtained from rabbits when the anti-peptide antibody titre was at its peak. 
All antisera detected three bands with apparent molecular weights of =57 kDa, =51 kDa and =36 
kDa. The =57 kDa band was still detected at a 1:5000 dilution, the other bands were recognised 




kDa Fig. 8 Comparison of the apparent molecular mass of GLUT2 in
liver and Islets.
Proteins from rat liver plasma membranes (lane 2) and 
whole rat islets (lane 1) were solubilized in electrophoresis sample 
buffer containing 5 mM DTT instead of mercaptoethanol and were 
separated by SDS-PAGE then transferred to nitrocellulose using a wet 
transfer method. Proteins were immunoblotted with anti-GLUT2 C- 
terminal peptide (B) antiserum at a 1:500 dilution using blotting 
protocol II (methods section 2.17.3.2). Binding was detected by 
incubation with 0.2 n Ci/ml ^ 1  Gf anti-rabbit IgG conjugated 
antibody. A strong broad band was detected at *57 kDa in both 
liver and islets. The serum also detected bands at *35 kDa, 51 kDa 


















Numbers of animals immunized 3 3 1 1 2
% increase in absorbance of test 
serum compared to a 
preimmune control





200 45 3, 17 
mean= 10
Table 4 Comparison of the levels of anti-rat liver plasma membrane antibodies in four 
different anti-GLUT2 peptide antisera.
Anti-GLUT2 peptide antisera were tested in an ELISA in which liver plasma membranes (10 
fig/mi) were used as the antigen. All sera were obtained from rabbits when the anti-peptide antibody 
titre was at its peak. Values for the percentage increase in antibody binding (measured as absorbance 
at 450 nm) of test serum (1:100 dilution) compared to a preimmune control (1:100 dilution) are 
shown for each individual animal and a mean value is also given for all antisera raised against the 
same immunogen. The results show variability in the response of individual animals to the same 
immunogen. It is also shown that antisera raised against the C-terminal peptides B and C produce 
antibodies that bind strongly to liver plasma membranes.
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The anti-rat GLUT2 antisera were all specific for GLUT2 and did not bind to any 
proteins in 3T3-L1 aidipocytes or human erythrocytes, therefore they did not recognise 
either the GLUT1 or GLUT4 transporter isoforms. This is illustrated in Figure 24a-d.
As shown in Table 4 not all of the rat GLUT2 peptides produced equally high 
levels of antibodies recognising the whole GLUT2 protein. The antisemm raised against 
the loop peptide reacted very weakly with liver plasma membranes in an ELISA and 
although antibodies were present which recognised the denatured GLUT2 transporter in a 
Western blot, a very sensitive ECL detection system was required to detect them (Figure 
6 ). They could not be detected using an alkaline-phosphatase colour detection system 
(results not shown). Sera raised against the rat C-terminal peptides B and C (residues 507- 
522 and 499-508 respectively) produced the highest titres of antibodies binding to liver 
plasma membranes in an ELISA (Table 4). These antisera also bound strongly to GLUT2 
in a Western blot (Figure 7). Peptide A (residues 510-522) appeared to be a poor 
immunogen, since it produced antiserum containing only low levels of antibodies that 
bound to GLUT2 in either ELISAS (Table 4) or Western blots (Figure 7).
The regions of the peptide sequences that appeared to be most important in forming 
immunogenic epitopes were identified using peptide ELISAS. As shown in Table 5, all 
antisera contained antibodies that bound strongly to the peptide against which they were 
raised, this is indicated by a > 2 0 0 0 % increase in antibody binding in the test serum 
compared to a preimmune control. Although peptides A (510-522) and B (507-522) 
differed only in that peptide B contained an additional 3 residues, less than half of the 
antibodies that were raised against peptide A recognised peptide B and vice versa. 
Antiserum raised against peptide A also showed negligible binding to peptide D (human 
507-524), although 8/13 residues were identical. Although peptides B and D shared only 
10/16 amino acids, a high percentage of antibodies were present in antiserum B that 
recognised peptide D and vice versa.
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% increase in binding of test antiserum (1:100 
dilution) to test peptide compared to a preimmune 
control (1:100). Mean±S.E.M. (n).
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(3)
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Table 5 Comparison of the cross-reactivity of three GLUT2 anti-C-terminal peptide 
antisera with the three corresponding GLUT2 C-terminal peptides.
Antisera were tested in an ELISA in which plates were coated with the appropriate 
peptide at a concentration of 0.2 fig /ml. The number of samples tested from different 
animals is shown in parentheses. The * indicates amino acids in the human sequence that 
are different from the corresponding residues in rat GLUT2. The values given show the 
average (±S.E.M ) percentage increase in binding (measured as absorbance at 450 nm) 
given by a 1:100 dilution of the test serum compared to the same dilution of a preimmune 
control. Very high binding antisera gave values >2000%, high binding sera gave values 
of -500-1000% and sera that gave values < 200  were considered to show negligible 
binding to the test peptide.
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Neither of these sera bound as strongly to peptide A. The only residues common to 
peptides B and D not also shared with peptide A were the arginine and lysine residues at 
positions 507 and 508 (rat) and 510 and 511 (human). Therefore suggesting that these 
residues formed part of a strongly immumogenic region of the GLUT2 C-terminal peptide.
Since antibodies against rat-GLUT2 C-terminal peptide B produced a strong, 
relatively specific, response to the 57 kDa GLUT2 protein, this was the antiserum chosen 
for routine use in the following investigation of GLUT2.
3.2 ATB-BMPA PHOTOLABELLING OF RAT LIVER PROTEIN
3.2.1 Photolabelling of liver plasma membranes
When ATB-[2-3 H]-BMPA was irradiated in the presence of purified rat liver 
plasma membranes, analysis of the proteins by SDS-PAGE revealed that the photolabel was 
incorporated into a protein (or proteins) which migrated as a broad band with an apparent 
molecular mass of 45-66 KDa. This was usually detected as a single peak, occasionally as 
shown in Figure 9, as a double peak. This variability probably arose from the method used 
to slice the gels, which did not enable two very close peaks to be resolved all of the time. 
The second peak may have been due to labelling of the ~  5 1 kDa protein detected by anti- 
GLUT2 antibodies in Western blots of liver plasma membranes. ATB-BMPA could be 
displaced from liver plasma membranes by 43 ±1.6% (mean and S.E.M. from three 
independent experiments) when irradiation was carried out in the presence of 500 mM 4,6- 
O-ethylidene-D-glucose. From two independent experiments it was demonstrated that the 
addition of 500 mM D-glucose did not significantly reduce the incorporation of ATB- 
BMPA. 500 mM D-mannitol, included as a control, also caused no displacement of the 
photolabel. The result of a typical displacement experiment is shown in Figure 9.
105
TO TO TO TO TO TO
Q Q Q Q o QJSC JC
to to r^ - <o lO o>o •»— CT> CO CM
CM
▼ T  ▼ ▼ ▼ ▼




















— i----------- 1------------------ 1----------- 1--------------1--------------1-------------1------------- 1
2 4  6 8 10  12 14 16
Slice number
Fig. 9 Photolabelling of liver plasma membranes with ATB-BMPA.
Liver plasma membranes were photolabelled by irradiation in the presence of ATB-BMPA. 
After washing by centrifugation, labelled proteins were analysed by SDS-PAGE and a broad peak of 
labelled protein with an apparent molecular mass of =» 45-66 kDa was obtained. In the illustrated 
example labelled proteins appeared as a double peak, in replicate experiments a single peak has also 
been obtained. Arrowheads indicate the position of molecular weight marker protems. Labelling in 
the presence of 500 mM D-mannitol (•), which was included as a control, or 500 mM D- 
glucose (A) caused no significant displacement of ATB-BMPA. Irradiation in the presence of 500 
mM 4,6-0-ethylidene-D-glucose (O) inhibited ATB-BMPA binding to liver plasma membranes by 
43%.
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3.2.2 Immunoprecipitation of ATB-BMPA labelled proteins from liver plasma 
membranes
In order to identify the proteins labelled by ATB-BMPA in liver plasma 
membranes, immunoprecipitations were carried out using antibodies raised against short 
peptide sequences of GLUT I and GLUT2. The specificity of these antisera was 
determined by Western blotting as described in Section 3.1.
When used to immunoprecipitate photolabelled liver plasma membrane proteins 
solubilized in buffer containing the detergent C 1 2 E9  (nonaethylene glycol dodecyl ether), 
both the anti-rat-GLUT2 C-terminal peptide (B) and the anti-rat-GLUT2 exofacial loop 
peptide antisera, immunoprecipitated approximately equivalent amounts of a labelled 
protein with an apparent molecular weight of 45-66 kDa. Anti-human GLUT2 C-terminal 
peptide antiserum precipitated only about half of the amount of the same labelled protein 
that was precipitated by the rat GLUT2 antisera. These results are shown in Figure 10a.
In order to establish whether the 45-66 kDa precipitated protein was recognised 
specifically by anti-GLUT2 peptide antibodies, or non-specifically by antibodies present in 
normal rabbit serum, preimmune serum was used to immunoprecipitate ATB-BMPA 
labelled proteins from liver plasma membrane. As shown in Figure 10b, non-immune 
serum precipitated a small amount of labelled protein with a similar molecular mass to that 
of the protein precipitated by the anti-GLUT2 antiserum. On average, this non-specific 
immunoprecipitation, was calculated to account for 32±9.2% (mean and S.E.M. from six 
independent experiments) of the total amount of protein precipitated by anti-rat-GLUT2 C- 
terminal-peptide antiserum. All results were therefore corrected to account for this non­
specific precipitation.
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Fig. lOa-b Immunoprecipitation of photolabelled liver plasma membrane proteins.
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Liver plasma membranes were photolabelled by irradiation in the presence of ATB-BMFA, 
washed then solubilized in buffer containing the detergent C^E*)- Solubilized labelled proteins were 
immunoprecipitated with 5 mg of Protein A-Sepharose coupled to 50 /d of the indicated anti-GLUT2 
antisera: Labelled immunoprecipitates were analysed by SDS-PAGE. Arrowheads indicate the
position of molecular weight marker proteins, 
a : Anti-rat GLUT2 C-terminal peptide antiserum (#)
Anti-rat GLUT2 exofacial loop peptide antiserurtn (■)
Anti-human GLUT2 C-terminal peptide antiserum (▲)
Both of the anti rat-GLUT 2 antisera precipitated a similar amount of a protein with an 
apparent molecular weight of 45-66 kDa. The anti-human GLUT2 antiserum immunoprecipitated 
approximately 60% of the amount of the same labelled protein that was precipitated by the anti-rat 
GLUT2 antisera.
b: Anti-rat GLUT2 C-terminal peptide antiserum (•)
Anti-rat GLUT1 C-terminal peptide antiserum (A)
Preimmune serum O)
All sera precipitated some labelled protein with an apparent molecular mass of 45-66 kDa. 
In the illustrated experiment non-specific immunoprecipitation (as determined from the amount of 
protein precipitated with non-immune rabbit serum), accounted for *27% of the labelled protein 
precipitated by the anti-GLUT2 antiserum. When corrections were made to account for this non­
specific precipitation, anti-GLUT2 serum precipitated * 3  fold more labelled protein than anti- 
GLUT1 serum.
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Anti-GLUTl C-terminal peptide antiserum also immunoprecipitated radiolabelled 
liver protein with an apparent molecular weight of 45-66 kDa. The quantity precipitated 
was 47±13.9% (mean and S.E.M. from four independent experiments) of the amount 
precipitated by anti-GLUT2 antiserum. However, when corrected for non-specific 
immunoprecipitation only 15% of the protein precipitated by anti-GLUTl antiserum was 
specific compared with 6 8 % of that precipitated by anti-GLUT2 antiserum. The average 
ratio of immunoprecipitable GLUT2 to GLUT 1 was therefore approximately 5:1. This 
confirmed the results obtained by immunoblotting, that GLUT1 was not a major 
component of liver plasma membrane (Figure 6 ).
3.2.3 Quantification of the recovery of immunoprecipitated GLUT2
The amount of GLUT2 immunoprecipitated was low. On average only
4.6±0.87% (mean and S.E.M from five independent experiments) of the 45-66 kDa 
proteins labelled by ATB-BMPA in whole liver plasma membranes, were 
immunoprecipitated by anti-GLUT2 C-terminal peptide antiserum. Corrections were made 
to account for the fact that 32% of the labelled protein was also precipitated non- 
specifically by preimmune serum and that only 43% of the labelling was displaceable with 
4,6-0-ethylidene-D-glucose. It was therefore calculated that approximately 7% of the 
proteins labelled in a 4,6-0-ethylidene-D-glucose displaceable manner were 
immunoprecipitated by the anti-GLUT2 C-terminal peptide antiserum. The above 
calculation assumes complete detergent solubilization of photolabelled GLUT2. The 
possibility was considered that the low precipitation of GLUT2 could have resulted from 
incomplete solubilization of GLUT2 in the C 1 2 E9  detergent. However, as shown in 
Figure 11, when analysed by Western blotting, an approximately equivalent amount of 
GLUT2 was detected in both whole and detergent-solubilized liver plasma membranes. 
Solubilized proteins were precipitated with chloroform and methanol, which enabled them 




Fig. 11 Detection of GLUT2 in detergent-solubilized liver plasma membranes.
Liver plasma membranes (50 jag) were 
solubilized in 1 ml of buffer containing 2% of the 
detergent C^Ec)- The insoluble material was removed 
by centrifugation and analysed directly by SDS-PAGE 
(lane 3). The solubilized proteins were precipitated by 
treatment with chloroform and methanol (section 2.15.4) 
and analysed by SDS-PAGE (lane 2 ). As a control 50 
fig of liver plasma membranes were also analysed by 
SDS-PAGE (lane 1). Proteins were transferred 
electrophoretically to nitrocellulose and immunoblotted 
with anti-GLUT2 C-terminal peptide antiserum using the 
ECL method of detection. GLUT2 was detected as a 57 
kDa band in liver plasma membranes and solubilized 
liver plasma membranes but was not present in the non­
solubilized fraction.
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Liver plasma membranes were solubilized in buffer 
containing the detergents Triton X-100 (4%) and SDS 
(0.05%). Solubilized proteins were immunoprecipitated 
with 5 mg of Protein A-Sepharose coupled to 50 n 1 of 
anti-GLUT2 C-terminal peptide antiserum. Liver 
plasma membrane (lane 1), immunoprecipitated proteins 
(lane 2) and supernatant (lane 3) were analysed by 
electrophoresis under non-reducing conditions on an 8% 
polyacrylamide gel. Following electrophoretic transfer 
of the proteins to nitrocellulose, samples were 
immunoblotted with anti-GLUT2 C-terminal peptide 
antiserum (1:500 dilution) following protocol II (section 
2.17.3.2) and developed with alkaline phosphatase 
conjugated anti-rabbit IgG antibodies. GLUT2 was 
detected in both the immunoprecipitate and supernatant 
as a *5 7  and 51 kDa band. The colourimetric method 
of detection used did not allow quantification of the 
relative amounts of GLUT2 present in each sample.
n o
GLUT 2 could not however be clearly detected in the non-solubilized protein fraction, 
indicating that under the conditions used, GLUT2 was almost completely solubilized by the 
detergent C ^E g .
Using Western blotting it was shown that immunodetectable GLUT2 was 
immunoprecipitated by anti-GLUT2 C-terminal peptide antiserum, although GLUT2 could 
also be detected in the supernatant that remained following the immunoprecipitation. 
These results were obtained by electrophoresis under non-reducing conditions on 8% 
polyacrylamide gels, conditions that largely enabled the broad band of IgG to be separated 
from the lower molecular weight GLUT2 band. However, the presence of large quantities 
of IgG gave such a high background on Western blots developed with a ^ 5 i  detection 
system that it prevented the quantification of the total amount of GLUT2 precipitated. 
Although not quantitative, the results shown in Figure 12, which is a typical example of 
other similar experiments in which proteins were solubilized in buffers containing either 
2% C 1 2 E9  or 4% Triton X-100 and 0.05% SDS, clearly show that the 
immunoprecipitation of GLUT2 was incomplete. The same result was obtained whichever 
detergent was used.
Comparable results were obtained using ATB-BMPA photolabelling to quantify the 
amount of GLUT2 precipitated following solubilization of liver plasma membrane proteins 
in different detergents. There was no significant difference in the amount of GLUT2 
precipitated when proteins were solubilized in 1% n-octyl 8-D-glucopyranoside, 2% 
C 1 2 E9  or 4% Triton X-100 and 0.05% SDS (results not shown).
It was also attempted to increase the amount of GLUT2 immunoprecipitated, by 
increasing the amount of precipitating antibody. However, a 4-fold increase in the amount 
of Protein A-Sepharose-antibody conjugate used, resulted in only a further 1.1 fold 
increase in the amount of labelled protein precipitated by anti-GLUT2 antiserum (Figure 
13a).
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Fig. 13a-b Immunoprecipitation of ATB-BMPA labelled GLUT2 from liver plasma 
membranes: The effect of increasing the amount of anti-GLUT2 antiserum.
Liver plasma membrane proteins were photolabelled with ATB-BMPA, washed then 
solubilized in buffer containing the detergent C^Ec)- Solubilized labelled proteins were 
immunoprecipitated and analysed by SDS-PAGE. Arrowheads indicate the position of molecular 
weight marker proteins.
a: Proteins were precipitated with:
5 mg of Protein A-Sepharose coupled to 50 fi[ of anti-GLUT2 C-terminal peptide antiserum (#)
20 mg Protein A-Sepharose coupled to 200 /d of anti-GLUT2 C-terminal peptide antiserum O
Increasing the amount of Protein A-Sepharose and immunoprecipitating antibody 4-fold 
resulted in a ~  10% increase in the amount of immunoprecipitated GLUT2 protein.
b: Solubilized labelled proteins were immunoprecipitated for 2.5 hours with 5 mg of Protein
A-Sepharose coupled to 50 /x\ of anti-GLUT2 C-terminal peptide antiserum (#). The supernatant 
was then incubated for a further 2.5 hours with another 5 mg of Protein A-Sepharose coupled to 
GLUT2 antiserum (O). The anti-GLUT2 antibody removed 82% of the total immunoprecipitated 
labelled protein after a single treatment.
2 4 6 8 10 12 14 16
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As illustrated in Figure 13b, most of the labelled protein was precipitated in a single 
treatment with 5 mg of Protein A-Sepharose coupled to 50 fii of anti-GLUT2 antiserum. A 
second treatment with the same amount of antibody removed an additional quantity of 
labelled protein equivalent to 18% of that already precipitated.
ATB-BMPA was also used to label viable rat hepatocytes. A broad band of protein 
with an apparent molecular mass of 45-66 kDa was radiolabelled, solubilized in the 
detergent C ^E g  and immunoprecipitated with an anti-GLUT2 antibody. The maximum 
amount of GLUT2 precipitated was equivalent to about 2% of the total amount of 
solubilized labelled protein (results not shown).
3.2.4 Displacement of ATB-BMPA from immunoprecipitated GLUT2
As shown in Figure 14 and Table 6, ATB-BMPA binding to, and labelling of, 
GLUT2 could be reduced by using several inhibitors of glucose transport. When corrected 
for non-specific immunoprecipitation, 500 mM 4,6-0-ethylidene-D-glucose displaced 92% 
of the ATB-BMPA binding to precipitable GLUT2. 500 mM D-ffuctose, 100 /xM 
cytochalasin B and 500 mM D-glucose displaced 77%, 65% and 57% respectively of the 
ATB-BMPA binding to GLUT2. The amount of labelled protein precipitated when 
photolabelling was carried out in the presence of 100 /xM phloretin was not significantly 
different from the amount of labelled protein precipitated non-specifically by preimmune 
serum. Therefore, 100 /xM phloretin was able to displace all of the specific ATB-BMPA 
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Fig. 14 Displacement of ATB-BMPA from immunoprecipitates of liver GLUT2.
Liver plasma membranes were irradiated in the presence of ATB-BMPA and the following 
compounds which inhibit glucose transport or bind to the transport protein. 500 mM D-glucose (A), 
100 (iM cytochalasin B (A), 500 mM D-fructose (■). 500 mM 4,6-0-ethylidene-D-glucose (O) and 
100 /xM phloretin O -  Peak areas were compared with that obtained in a control sample in which 
irradiation was carried out in the presence of 500 mM D-mannitol (#). After washing and 
solubilization in buffer containing C^Eg, the labelled proteins were immunoprecipitated with 5 mg 
of Protein A-Sepharose conjugated to 50 fx\ of anti-GLUT2 C-terminal peptide antiserum and 
analysed by SDS-PAGE. Arrowheads indicate the position of molecular weight marker proteins. 
For clarity, only the glucose transporter region of the gel is shown. There were no other labelled 








(% of control) 




D-Mannitol 500 100 0
D-Glucose 500 75 ± 3.8 (3) 57
Cytochalasin B 0.1 67 ± 10.7 (3) 65
Anti-(GLUT2 D-Fructose 500 55 ± (6.2 (4) 77
C-terminus) 4,6-O-Ethylidene
-D-glucose 500 40 ± 2.2 (9) 92
Phloretin 0.1 30 ± 3.5 (3) *100
Preimmune D-Mannitol 500 32 + 9.2 (6)
Table 6. ATB-BMPA photolabelling of liver GLUT2 in the presence of inhibitors of 
glucose transport.
Photolabelling of liver plasma membranes was carried out in the presence of the indicated 
inhibitors as described in section 2.15.2. Labelled membranes were solubilized in detergent
buffer and immunoprecipitated with 5 mg of Protein A-Sepharose conjugated to 50 fil of anti-GLUT2 C- 
terminal peptide antiserum. Precipitated proteins were analysed by SDS-PAGE and a peak of labelled 
protein with an apparent molecular weight of between 45 and 66 kDa was obtained. The peak area was 
compared to that obtained in a control sample in which irradiation was carried out in the presence of D- 
mannitol. The level of non-specific immunoprecipitation was determined from the amount of 
photolabelled protein precipitated by preimmune serum. The peak areas obtained in the presence of 
inhibitors were calculated as a percentage of a control which contained D-mannitol and are means 
±S.E.M  for three to nine independent experiments as indicated. In some experiments D-mannitol was 
omitted, but this did not alter the amount of ATB-BMPA binding (results not shown).
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3.2.5 Determination of the binding constant of ATB-BMPA for liver GLUT2
The displacement of radiolabelled ATB-BMPA from liver plasma membranes by 
non-labelled ATB-BMPA was used to calculate the binding constant of ATB-BMPA for 
liver GLUT2. As shown in Figure 15a, the size of the labelled GLUT2 peak decreased as 
the concentration of unlabelled ATB-BMPA present during the irradiation was increased. 
Figure 15b shows a plot of F/B against F. The binding constant (K^) for ATB-BMPA 
binding to GLUT 2 was 250 ±78 /iM and the total number of binding sites (Bmax) was 
calculated as 2.1 ±0.29 pmol/mg of membrane protein. These values were based on mean 
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Fig. 15a-h Determination of the binding constant (kj) and the Bmax for ATB-BMPA and 
GLUT2.
presence of a range of concentrations of unlabelled ATB-BMPA, such that the final concentrations 
were 100 /xM (•) -no added unlabelled ATB-BMPA, 300 /xM (O), 500 /xM (■), 700 /xM O  and 900 
/xM (A). Labelled membranes were washed, solubilized in buffer containing the detergent 
and immunoprecipitated with 5 mg of Protein A-Sepharose coupled to 50 /x 1 of anti-GLUT2 C- 
terminal peptide antiserum. Labelled proteins were analysed by SDS-PAGE. Arrowheads indicate 
the position of molecular weight marker proteins. The figure shows a decrease in the amount of 
labelled GLUT2 immunoprecipitated as the amount of unlabelled ATB-BMPA present during 
irradiation is increased.
b: The size of the GLUT2 peak was calculated for each concentration of ATB-BMPA shown in
Figure 15b. A background value of 32% was then subtracted to take account of the binding and 
immunoprecipitation which was non-specific. Values for the binding constant (Kj) and the total 
number of binding sites (Bmax) were obtained from non linear regression (weighted for relative 
error) of the equation B = (Bmax/K(j)«F /(l+  F/K^) where B and F are the bound and free ATB- 
BMPA respectively. The data are presented as F/B against F plots. From this analysis Bmax was 
calculated as 2.1 ±0.29 pmol/mg of liver plasma membrane protein and the binding constant (Kj) 
was 250 ± 78 /xM. The results are based on the mean F/B and F values from four separate 
experiments and the error bars shown represent ±S.E.M .
a: Liver plasma membranes were photolabelled with 100 f id  of ATB-[2-^H)-BMPA in the
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PART II CHARACTERIZATION OF B-CELL LINES AND 
INVESTIGATION OF THEIR GLUCOSE TRANSPORTER ISOFORM
EXPRESSION
Cell lines often behave very differently from the original cell type from which they 
were derived. In addition, changes may be brought about by mutations which are 
accumulated during prolonged continuous culture and result in the development of a cell 
line which displays characteristics significantly different from those of the original cell 
line.
The following section of results describes the features of four B-cell lines, 
including their morphology, growth rate and insulin secretion. One of the aims of this 
section of work was to compare the features of the cell lines used in this laboratory with 
the characteristics of the same cell lines reported from other laboratories. This information 
could be used to determine whether the cells were good models of native fi-cells and 
therefore whether they were likely to be expressing similar antigenic proteins that would 
make them suitable for use in the detection of islet cell antibodies (ICA).
Since it has previously been reported that 8-cell lines show abnormal glucose 
transporter expression, this has been investigated by ATB-BMPA photolabelling and 
Western blotting. One of the main aims was to determine whether 6-cell lines expressed 
GLUT2, and therefore whether they could be used to screen for the presence of anti-6-cell- 
GLUT2 autoantibodies (Part III).
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3.3 M ORPHOLOGY AND G RO W TH  RATES O F B-CELL LINES
3.3.1 HITm2.2
As illustrated in Figures 16a-f, the appearance of HITm2.2 cells varied in a 
passage dependent manner. At early passages, the cell population was heterogeneous. The 
majority of cells were rounded with "blebs" on the surface and many were poorly adherent, 
but approximately 10% of the cells had a more elongated or fibroblastic-type appearance 
(Figure 16a). A dramatic change occurred in the cells at passage 6 (p6), when about 70% 
of the cells detached and died, of those remaining, about 50% were elongated in shape,the 
rest were still rounded (Figure 16b). By p8 the number of elongated cells had increased to 
about 90% (Figure 16c). Over a prolonged period of continuous culture, the majority of 
the cells remained elongated and their morphology did not alter significantly (Figure 16d), 
although they grew increasingly rapidly and attained a higher degree of confluence (Figure 
16e). At about p30, the cells again changed shape, becoming less elongated and more 
triangular in their appearance (Figure 16f). This shape was still predominant at p51.
This pattern of morphological changes was repeated on several occasions. The use 
of tissue culture dishes from a different manufacturer had no effect on the changes in cell 
shape. When defrosted, the cells from any given passage number behaved in the same way 
as they did prior to freezing.
The growth rate of HITm2.2 cells was dependent on the passage number. At p4- 
p5 the cells needed to be subcultured every 5 days. At pl4, the cells took 4-5 days to 
reach confluence and had a doubling time of 25 hours (Figure 20a). At passage numbers 
higher than pl8, the cells reached confluence in 3-4 days. HITm2.2 cells did not show 
contact inhibition of growth, but continued to divide and detach when fully confluent.
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Fig. 16a-f Light micrographs of HITm2.2 cultures: Demonstration of
morphological changes from p5-p37.
HITm2.2 cells were cultured in RPMI-1640 medium supplemented with 10% FCS as 
described in section 2.5.3.
a: 3 day HITm2.2 culture (p5). The majority of cells are rounded and flattened with "blebs" on 
the surface, some are growing in loosely attached clumps. Magnification x3000.
b : 5 day HITm2.2 culture (p6). The rounded cells are poorly adherent, approximately 50% of the 
cells have an elongated morphology. Magnification x3000.
C: 3 day HITm2.2 culture (p8). About 90% of cells are of the elongated shape and are firmly 
attached. Magnification x3000.
d : 3 day HrTm2.2 culture (p21). Cells are firmly attached and elongated in shape. Magnification 
xl500.
e: Confluent b iT m 2.2  culture. Magnification xl500.
f: 3 day HITm2.2 culture (p37). Most cell are round or triangular in shape. They attach well and 
grow quickly. Magnification xl500.
Fig. 17a-b Light micrographs o f RINm5F cultures.
Cells were cultured in RPMI-1640 medium with 10% FCS as described in section 2.5.3.
a: 5 day RINm5F culture (plO). Magnification xlOOO.
b : 5 day RINm5F culture (plO). Cells are irregularly shaped with extensive cytoplasmic
projections. Magnification xl500.
Fig. 18a-b Light micrograph of HIT-T15 cultures.
Cells were cultured in HAMS-F12 medium supplemented with 15% DHS and 2.5% FCS as 
described in section 2.5.1.
a : 6 day HIT-T15 culture (p51). Cells grow in clumps and fail to form a true monolayer. 
Magnification xl500.
b : 6 day HIT-T15 culture (p51). Magnification x3000.
Fig. 19a-b Light micrograph o f MIN 6 cultures.
Cells were cultured in DMEM supplemented with 10% FCS as described in section 2.5.2.
a: 2 day MIN 6 culture (pl4). Cells are rounded or triangular in shape and are firmly attached to 
the culture surface. Magnification xl500.









RINm5F were small flattened cells with irregularly shaped pseudopodia (Figures 
17a-b). Even at high passage numbers no obvious change in morphology occurred. The 
cells grew to about 90% confluence and had a doubling time of «26.5 hours (Figure 20b), 
which remained fairly constant regardless of the passage number.
3.3.3 HIT-T15
HIT-T15 cells tended to self-associate within an hour of subculturing. They did 
not form a monolayer but grew as large multi-layered "islet-like" structures, which reached 
a maximum size after 4-5 days growth (Figures 18a-b). At high confluency the cells 
rounded and detached from the colonies.
3.3.4 MIN 6
MIN 6 cells were rounded or triangular in shape. They grew in small clumps and 
were firmly attached to the culture plates. The cells reached about 70% confluence after 7- 
8 days growth (Figures 19a-b).
3.4 INSULIN SECRETION
Indirect immunofluorescence assays for insulin were performed on HITm2.2 cells 
with the aim of determining whether cells of different morphology contained different 
amounts of insulin. In HITm2.2 cultures at p l l ,  12, 14 and 16, all of which contained 
both elongated adherent and rounded poorly adherent cells, no cells could be detected 
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Fig. 20a-b Growth curve of HITm2.2 and RINm5F cells.
Cells were cultured in 2 ml dishes in RPMI-1640 containing 10% FCS as described in 
section 2.5.3.
a: The population doubling time of HITm2.2 cells at pl4 was 25 hours in the exponential phase, 
b: The population doubling time of RINm5F cells at p6 was 26.5 hours in the exponential phase.
T reatment Cell line and passage number liU insulin /60 min/2x l0  ^
cells (n)
Basal (KRB only) HITm2.2 p49 0 (1)
2 mM D-glucose HITm2.2 p49 0 (2)
11 mM D-glucose HITm2.2 p6 15 rfc 1-9 (4)
HITm2.2 p25 5±0.2 (4)
HITm2.2 p49 0.4±0.3 (1)
20 mM D-glucose HITm2.2 p49 1.2 ±0.3 (2)
15 mM arginine HITm2.2 p49 0 (2)
15 mM leucine HITm2.2 p49 0 (2)
Basal RINm5F pl 7 129 ±23 (2)
2 mM D-glucose RINm5F Pi 7 107 ±3 (2)
11 mM D-glucose RlNm5F Pl? 116 (1)
20 mM D-glucose RINm5F pl? 128 ± 1.0 (2)
15 mM arginine RlNm5F pl 7 333 ±0 (2)
15 mM leucine RINm5F pl7 131 ±8.0 (2)
Table 7 Insulin secretion from HTTm2.2 and RJNm5F cells in static culture.
Insulin secretion in the presence of secretagogues was measured by RIA as described in 
section 2.6.2. The results are expressed as means ±S.E.M . for 1-4 independent samples as 
indicated.
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However, HITm2.2 cells were demonstrated by RIA to secrete insulin and to be 
responsive to D-glucose. As shown in Table 6, at low passage numbers, HITm2.2 cells 
secreted 15 /zU of insulin/60 min/2xl0^ cells in response to 11 mM D-glucose. This 
response had decreased by p25 to 5 /zU of insulin/60 min/2xl0^ cells and by p49 to 0.4 /zU 
of insulin/60 min/2xl0^ cells. At this high passage number 1.2 /zU of insulin/60 
min/2xl0^ cells were secreted in response to 20 mM D-glucose. Under basal conditions, 
that is, in the absence of D-glucose, insulin secretion was undetectable. At p49, HITm2.2 
cells did not secrete insulin in response to arginine or leucine.
In contrast to HITm2.2 cells, the parent cell line HIT-T15, cultured in 11 mM D- 
glucose, did contain cytoplasmic insulin which could be detected in an indirect 
immunofluorescence assay (Figure 21a).
RlNm5F cells contained very high levels of insulin which stained strongly in an 
indirect immunofluorescence assay and which was associated with cytoplasmic granules 
(Figure 21b). These cells secreted a very high basal level of insulin, approximately 130 
/zU of insulin/60 min/2xl0^ cells. As illustrated in Table 6, RIN cells were unresponsive 
to D-glucose which caused no significant increase in insulin secretion. A 4.6 fold increase 
in insulin release was however observed in the presence of 15 mM arginine, but 15 mM 
leucine did not stimulate insulin secretion in this cell line.
3.5 MEASUREMENT OF 2-DEOXYGLUCOSE UPTAKE IN HITm2.2 AND 
RINm5F CELLS
Under the experimental conditions used, 2-deoxyglucose transport in HITm2.2 
cells was linear for 5 min, in RINm5F cells, transport was linear for 10 min. Both cell 
lines when cultured in 11 mM D-glucose had transport rates for 2-deoxyglucose of 0.08 
nmol/mg protein/min measured at 50 fiM 2-deoxyglucose. These results are illustrated in 
Figures 22a-b.
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Fig. 21 Detection of insulin by indirect immunofluorescence.
Cell cultures were fixed overnight in formaldehyde, then incubated with a mouse 
monoclonal antibody against insulin, binding was detected with an anti-mouse IgG conjugate. 
Insulin was located in granules in the cytoplasm.
a: HIT-T15 (p54) Magnification x3000.
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Fig. 22a-b Uptake of 2-deoxyglucose by HITm2.2 and RINm5F B-cell lines.
2-deoxyglucose uptake was measured in cells that had been grown in RPMI medium 
containing 11 mM D-glucose. The cells were brought into suspension by a brief incubation in PBS 
and 1 mM EDTA, washed and the uptake of 2-deoxyglucose (50 /*M) was measured. After the 
indicated time intervals, uptake was stopped by the addition of buffer containing phloretin and the 
cells were washed by centrifugation. Cell pellets were solubilized in 0.1 M NaOH and the 
incorporated radioactivity was counted. Counts were normalised to the protein content in each assay. 
Data are given as mean ±S.E.M . of two determinations for RJNm5F cells (a) and HIT m2.2 cells 
(b). For both cell lines 2-deoxyglucose uptake was 0.08 nmol/1 mg protein/min.
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3.6 GLUCOSE TRANSPORTER EXPRESSION IN ft-CELLS
3.6.1 Investigation of glucose transporter expression by Western blotting
When plasma membranes (prepared using the method described in section 
2.10.4.1) from HITm2.2, HIT-T15, RINm5F and MIN 6 cells were immunoblotted with 
anti-GLUTl or anti-GLUT2 C-terminal peptide antiserum, neither GLUT1 nor GLUT2 
was detected in any of these 6-cell lines. This is illustrated in Figure 23, which is a typical 
result obtained from a Western blot developed with a colourimetric detection system. As 
positive controls, anti-GLUTl and GLUT2 antisera were shown to detect proteins in 
erythrocyte and hepatocyte membranes which had molecular weights consistent with their 
being the glucose transport proteins GLUT1 (44-70 kDa) and GLUT2 (« 5 8  kDa) 
respectively. As an additional control, plasma membranes prepared from acutely insulin- 
stimulated 3T3-L1 adipocytes, (Palfreyman et al., 1992) were blotted alongside the 6-cell 
lines. GLUT4 was detected strongly as a «51 kDa band, but although these cells have 
previously been shown to express equal amounts of the GLUT1 and GLUT4 transporter 
isoforms (Calderhead et al., 1990), in this study anti-GLUTl antiserum detected only a 
very faint band with an apparent molecular mass of ~  50 kDa in the 3T3-L1 cells.
As shown in Figures 24a-d, similar results were also obtained using a more 
sensitive ^ 5 j  labelled anti-IgG detection system, which enabled quantification of the 
glucose transporter expression. GLUT2 was only detected in liver, not in HITm2.2 or 
RIN cells. GLUT4 was the predominant transporter in 3T3-L1 cells and GLUT1 was 
detected in erythrocytes and a very small amount was present in 3T3-L1 cells. GLUT1 
was not detected in HIT or RIN cells. This experiment also demonstrated that the anti­
glucose transporter antibodies were specific for the isoform against which they were raised.
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Fig. 23 Investigation of glucose transporter isoform expression in B-cell lines by Western 
blotting.
The B-cell lines were cultured as described in section 2.5 and plasma membranes were 
prepared using method I (section 2.10.4.1). 3T3-L1 adipocytes were cultured as described in section 
2.5 and membranes were prepared according to method III (section 2.10.4.3). Erythrocyte ghosts 
and liver plasma membranes were also prepared as described in the methods sections 2. 10.2 and 
2.10.3.1 respectively. Proteins were separated by electrophoresis on 10% polyacrylamide gels, and 
following electrophoretic transfer to nitrocellulose were immunoblotted for two hours with anti- 
GLUTl C-terminal peptide antiserum (A); anti-GLUT2 C-terminal peptide antiserum (B); or anti- 
GLUTl C-terminal peptide antiserum (C) at a 1:1000 dilution using blocking protocol II. Bound 
antibodies were detected with alkaline phosphatase conjugated anti-rabbit IgG antibodies.
Lane 1 - human erythrocyte membranes 
Lanes 2,8 & 13 - 3T3-L1 membranes 
Lanes 3 & 9 - HITm2.2 membranes 
Lanes 4 & 10 - HIT-T15 membranes 
Lanes 5 & 11 - RINm5F membranes 
Lanes 6 & 12 - MIN 6 membranes 
Lane 7 - liver plasma membranes
GLUT1 detected a protein with an apparent molecular weight of 44-70 kDa in eiythrocytes. 
GLUT2 detected a protein with an apparent molecular weight of =58 kDa in liver. GLUT4 detected 
a protein with an apparent molecular weight of 51 kDa in 3T3-L1 cells. Neither anti-GLUTl nor 
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Fig. 24a-d Quantification of glucose transporter isoform expression.
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50 fig of protein from liver plasma membranes (#), erythrocyte ghosts (y) and a total 
membrane fraction from HITm2.2 (O), RINm5F O  and 3T3-L1 cells (A) were subjected to SDS- 
PAGE. Proteins were transferred to nitrocellulose and incubated with a 1:500 dilution of anti- 
GLUTl C-terminal peptide antiserum (a), anti-rat GLUT2 C-terminal peptide B antiserum (b), anti- 
GLUT4 C-terminal peptide antiserum (c) or preimmune serum (d). Blots were developed with ^5j_ 
labelled anti-IgG and quantified by gamma counting. Glucose transporter isoforms were detected as 
bands of labelled proteins with apparent molecular weights of 45-66 kDa. GLUT4 was only detected 
in 3T3-L1 adipocytes (peak size 29223 cpm) and GLUT2 was detected only in liver plasma 
membranes (peak size 20439 cpm). GLUT1 was detected strongly in erythrocytes (peak size 81062 
cpm) and a small amount of this transporter was detected in the 3T3-L1 cells (peak size 7865 cpm). 
No transporter isoform was detected in either the HITm2.2 or RINm5F ft-cell lines.
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The use of whole solubilized cells, instead of plasma membranes and a very 
sensitive ECL detection system also failed to show the presence of either GLUT1 or 
GLUT2 in any of the B-cell lines tested (results not shown). Therefore, the transporter 
expressed in 6-cell lines could not be identified by Western blotting . However, as shown 
in Figure 8, B-cell GLUT2 could be detected in whole rat islet cells when they were 
immunoblotted with anti-GLUT2 C-terminal peptide antiserum.
3.6.2 Investigation of glucose transporter expression by ATB-BMPA labelling
3.6.2.1 ATB-BMPA photolabelling of HITm2.2 cells
Attempts to photolabel monolayers of HITm2.2 cells were unsuccessful owing to 
the relatively low density of cells and high dilution of the ATB-BMPA, which resulted in a 
negligible incorporation of the photolabel. However, as shown in Figure 25a, when ATB- 
BMPA was irradiated in the presence of a dense suspension of HITm2.2 cells, analysis of 
the radiolabelled proteins by SDS-PAGE revealed that ATB-BMPA was incorporated into a 
major peak with an apparent molecular weight of =45-66 kDa. 750 mM D-glucose 
displaced the labelling of this major protein by =66%, but did not significantly displace 
the binding of the photolabel to a minor peak which ran on the gel between the 29 and 45 
kDa markers.
In order to identify the protein that was photolabelled in a glucose-displaceable 
manner, immunoprecipitations using anti-C-terminal peptide antisera specific for the 
GLUT1 and GLUT2 transporter isoforms were carried out on the detergent solubilized 
photolabelled cells. As shown in Figure 25b, anti-GLUTl antiserum immunoprecipitated a 
labelled protein with an apparent molecular weight of 45-66 kDa. Neither anti-GLUT2 
antiserum nor preimmune serum precipitated any labelled proteins. The amount of labelled 
protein that was immunoprecipitated by GLUT1 was equal to approximately 9% of the 
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Fig. 25a-b Detection and immunoprecipitation of ATB-BMPA photolabelled 
proteins from HITm2.2 cells.
Suspensions of =2x10^ HITm2.2 cells (pl7) in 0.5 ml Hepes-buffered balanced salts 
solution were photolabelled with 400 /xCi of ATB-BMPA in the presence or absence of 750 mM D- 
glucose as indicated. After washing, the cells were homogenised and the pellet obtained by 
centrifugation at 100,000 gav was either analysed directly by SDS-PAGE (a), or solubilized in buffer 
containing the detergent C ^E g  and immunoprecipitated with 5 mg Protein A-Sepharose coupled to 
50 fil of the indicated antiserum (b). Arrowheads indicate the position of molecular weight marker 
proteins.
a :  750 mM D-glucose (A)
no glucose (#)
ATB-BMPA labelled a protein with an apparent molecular weight of 45-66 kDa. Labelling 
was displaced by 66% by D-glucose. Labelling of another protein with an apparent molecular 
weight of 29-45 kDa was not displaced with D-glucose.
b: Preimmune Q
Anti-GLUT2 C-terminal peptide (<•)
Anti-GLUTl C-terminal peptide (A)
Only the GLUT1 antiserum precipitated a labelled protein with an apparent molecular 
weight of 45-66 kDa from HITm2.2 cells.
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From labelling and immunoprecipitation experiments only the GLUT I transporter 
isoform could be identified in HITm2.2 cells.
3.6.2.2 ATB-BMPA photolabelling of HIT-T15 cells
When cultures of HIT-T15 cells growing in dishes were irradiated in the presence 
of ATB-BMPA, the radiolabel was incorporated into a protein which was soluble in buffer 
containing the detergent and which had an apparent molecular weight of —66 kDa.
A typical gel profile is shown in Figure 25c. The identity of the labelled protein was 
unknown since it was not immunoprecipitated by either anti-GLUTl or anti-GLUT2 C- 
terminal peptide antiserum.
3.6.2.3 ATB-BMPA photolabelling of RINm5F cells
When a dense suspension of RINm5F cells was irradiated in the presence of ATB- 
BMPA, analysis of the proteins by SDS-PAGE revealed that the photolabel was 
incorporated into two bands of protein. The heavier migrated as a broad band between the 
66 and 97 kDa molecular weight marker proteins. The second protein had an apparent 
molecular weight of approximately 45 kDa. A typical gel profile is shown in Figure 26a, 
which also shows that labelling in the presence of up to 930 mM D-glucose did not 
displace ATB-BMPA binding to either of these proteins. The identity of the 66-97 kDa 
protein was unknown, but as shown in Figure 26b, about 9% of the 45 kDa protein was 
immunoprecipitated by anti-GLUTl C-terminal peptide antiserum. ATB-BMPA labelling 
of this precipitated protein was displaced when irradiation was carried out in the presence 
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Fig. 25c ATB-BMPA photolabelling of HIT-T15 cells and attempted immunoprecipitation of 
labelled proteins.
Cultures of HIT-T15 cells in 35 mm tissue culture dishes were irradiated in the presence of 
100 f id  of ATB-BMPA in a final volume of 0.5 ml of Hepes-buffered balanced salts solution. After 
washing, the cells were solubilized in buffer containing the detergent C^Ec)- Solubilized labelled 
proteins were immunoprecipitated with 5 mg of Protein A-Sepharose coupled to 50 /d of anti- 
GLUTl (A) or anti-GLUT2 (#) C-terminal peptide antiserum. Immunoprecipitates and labelled 
proteins precipitated from the supernatant by the addition of chloroform and methanol were analysed 
by SDS-PAGE. An ATB-BMPA labelled protein with an apparent molecular weight of =66  kDa 
could be detected in the proteins solubilized from the labelled cells (O), but neither anti-GLUT2 nor 
GLUT1 antiserum precipitated any labelled protein from HIT-T15 cells.
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Fig. 26a-b Detection and immunoprecipitation of ATB-BMPA photolabelled 
proteins from RINm5F cells.
Suspensions of 9x10^ RIN cells (pl2) in 0.3 ml of Hepes-buffered salts solution were 
photolabelled with 200 fiCi of ATB-BMPA in the presence or absence of 360 mM D-glucose. After 
washing, the cells were homogenised and the pellet obtained by centrifugation at 100,000 gav was 
solubilized in buffer containing the detergent Solubilized proteins were rotated for 3 hours
with 5 mg of Protein A-Sepharose coupled to either anti-GLUT2 or anti-GLUTl C-terminal peptide 
antiserum. Immunoprecipitated proteins and soluble proteins remaining in the supernatant were 
analysed by SDS-PAGE.
a: In the absence of D-glucose (#) two bands with apparent molecular weights of 66-97 kDa
and «  45 kDa were detected in the supernatant containing the solubilized proteins which remained 
following the immunoprecipitation with anti-GLUT2 C-terminal peptide antiserum. Labelling was 
not displaced from either protein by performing the irradiation in the presence of 360 mM D-glucose
(A).
b: Anti-GLUTl C-terminal peptide antiserum immunoprecipitated a photolabelled protein with
an apparent molecular weight of *45  kDa from RINm5F cells (A). No labelled GLUT1 was 
precipitated from cells labelled in the presence of D-glucose (A). Anti-GLUT2 C-terminal peptide 
antiserum did not immunoprecipitate any labelled protein from RIN cells labelled in the absence of 
D-glucose (#).
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Anti-GLUT2 C-terminal peptide antiserum did not precipitate any labelled protein 
from ATB-BMPA labelled RINm5F cells (Figure 26b). Therefore, from
immunoprecipitation and labelling experiments, only the GLUT1 transporter isoform 
which had an apparent molecular weight of *  45 kDa could be detected in RIN cells.
3.6.2.4 ATB-BMPA photolabelling of MIN 6 cells
When monolayers of MIN 6 cells were photolabelled by irradiation in the presence 
of ATB-BMPA, the photolabel was incorporated into proteins, which when analysed by 
SDS-PAGE appeared as 2 bands. The heavier band was broader and had an apparent 
molecular weight of «45-97 kDa. The lighter protein ran as a narrow band between the 
29 and 45 kDa marker proteins. As shown in Figure 27a, binding of ATB-BMPA to the 
45-97 kDa protein could be displaced by 43% when irradiation was carried out in the 
presence of 150 mM 4,6-O-ethylidene D-glucose and by 63% by the addition of 150 mM 
D-glucose. Neither of these sugars displaced binding of the photolabel to the lower 
molecular weight protein. Similar results were obtained when either a suspension of MIN 
6 cells or cell membranes were labelled (results not shown ).
Anti-GLUTl C-terminal peptide antiserum immunoprecipitated —11% of the total 
amount of the 45-97 kDa protein labelled in a hexose displaceable manner in MIN6 cells. 
This protein was not precipitated by either preimmune or anti-GLUT2 antiserum (Figure 
27b). Anti-GLUTl, anti-GLUT2 and preimmune serum all non-specifically 
immunoprecipitated a labelled protein from MIN 6 cells, which had an apparent molecular 
weight of between 29-45 kDa. From its apparent molecular weight determined by SDS- 
PAGE analysis, this protein appeared to be identical to the protein labelled in whole MIN 6 
cells in a non-hexose displaceable manner. Its identity was unknown. Therefore from 
labelling and immunoprecipitation experiments, only the GLUT1 transporter isoform 
which had an apparent molecular weight of —50 kDa could be detected in MIN 6 cells.
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Fig. 27a-b Detection and immunoprecipitation of ATB-BMPA photolabelled 
proteins from MIN 6 cells.
MIN 6 cultures (p23) in 35 mm dishes were irradiated in the presence of 100 /iCi of ATB- 
BMPA in 0.5 ml of Hepes-buffered salts solution and the indicated hexoses. Following washing, the 
cells were either analysed directly by SDS-PAGE (a) or solubilized in buffer containing the detergent 
C12E9 and immunoprecipitated with 10 mg of Protein A-Sepharose coupled to 100 /d of the 
indicated antisera (b). Arrowheads indicate the position of molecular weight marker proteins.
a: 150 mM D-mannitol (#)
150 mM D-glucose (A)
150 mM 4,6-0-ethylidene- D-glucose (O)
ATB-BMPA labelled a protein with an apparent molecular weight of =45-66 kDa. 
Labelling was displaced by 63% by D-glucose and by 43% by 4,6-0-ethylidene-D-glucose. 
Labelling of a protein with a molecular weight of 29-45 kDa was not displaced by the addition of 
either of these hexoses.
b: Anti-GLUTl C-terminal peptide antiserum (A)
Anti-GLUT2 C-terminal peptide antiserum (#)
Preimmune serum O
All sera precipitated a non-specifically labelled protein with an apparent molecular weight of 
29-45 kDa. Only GLUT1 antiserum precipitated a protein with an apparent molecular weight of 45- 
66 kDa. Only the glucose transporter region of the gel is shown for clarity.
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3.6.2.5 ATB-BMPA photolabelling of rat islets
Preliminary experiments were carried out in order to determine whether the 
GLUT2 protein in islets could be labelled with ATB-BMPA. Since islets could only be 
isolated in small quantities, the results of many experiments in which islets were irradiated 
in the presence of ATB-BMPA and analysed by SDS-PAGE were inconclusive, since the 
incorporation of photolabel was so low. However, as shown in Figure 28a, when a 
relatively large number of freshly isolated rat islets were irradiated in the presence of a 
high concentration of ATB-BMPA, radiolabel was incorporated into proteins, which when 
analysed by SDS-PAGE were found to migrate as a very broad band between the 45 and 
116 kDa marker proteins. A similar result was obtained using a large number (*950) of 
frozen islets which were kindly supplied by Hoffmann La Roche (Nutley, New Jersey, 
U.S.A.) Labelling in the presence of 500 mM 4,6-O-ethylidene-D-glucose did not 
significantly displace the binding of the photolabel to these frozen islets (results not 
shown). Approximately 6% of the ATB-BMPA labelled protein in islets was 
immunoprecipitated with anti-GLUT2 C-terminal peptide antiserum. The precipitated 
protein had an apparent molecular weight of between 45-66 kDa. Owing to the low 
availability of islets, it could not be demonstrated whether ATB-BMPA binding to GLUT2 
was displaced by labelling in the presence of an inhibitor such as D-glucose.
As shown in Figure 28b, not all of the labelled protein precipitated from islets by 
anti-GLUT2 antiserum was necessarily GLUT2, since 48% of the labelled protein was also 
precipitated non-specifically by preimmune rabbit serum. The identity of the labelled 
proteins that were not specifically precipitated by anti-GLUT2 antibodies was unknown. 
However, since whole islets, and not fi-cells, were used, the GLUT1 transporter isoform 
may also have been present. Again, owing to the low availability of islet material the 
presence of this isoform could not be investigated.
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Fig. 28a-b Detection and imm unoprecipitation of ATB-BMPA labelled 
proteins from rat islets.
a: Islets freshly isolated from 6 rat pancreases were suspended in 200 /xl of a Hepes-buffered
balanced salts solution and irradiated in the presence of 400 /xCi of ATB-BMPA. After washing and 
solubilization of the whole islets in buffer containing the detergent solubilized proteins were
rotated for 3 hours with 5 mg of Protein A-Sepharose coupled to 50 /d of anti-GLUT2 C-terminal 
peptide antiserum. Analysis of immunoprecipitated proteins (#) and labelled proteins remaining in 
the supernatant (O) was by SDS-PAGE. Anti-GLUT2 antiserum precipitated approximately 6 % of 
the 45-66 kDa solubilized labelled protein.
b: Frozen islets were defrosted and centrifuged at 20,000 gav for 20 min to enable them to be
transferred to 200 /xl of a D-glucose-free Hepes-buffered balanced salts solution. The islets were 
irradiated in the presence of 400 /xCi of ATB-BMPA, washed, homogenised and a membrane pellet 
obtained by centrifugation at 100,000 gav. This pellet was solubilized in buffer containing the 
detergent The solubilized, labelled proteins were immunoprecipitated with 10 mg of Protein
A-Sepharose coupled to 100 /xl of anti-GLUT2 C-terminal peptide antiserum (•) or 100 /xl of 
preimmune serum (□)• Precipitated proteins were analysed by SDS-PAGE. Compared with 
preimmune serum, GLUT2 C-terminal peptide antiserum precipitated double the amount of a protein 
with an apparent molecular weight of 45-66 kDa.
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Attempts to photolabel crude membrane preparations from islet cells were 
unsuccessful. Similarly, the solubilization of labelled islets in a buffer containing the 
detergents Triton X-100 (4%) and SDS (0.05%) instead of <4 2 %  did not increase the 
amount of GLUT2 immunoprecipitated. Increasing the amount of time that the ATB- 
BMPA was left in contact with the islets both before and during irradiation in order to 
ensure complete penetration of the label into the clumps of islet cells also failed to improve 
the ATB-BMPA photolabelling of islet tissue (results not shown).
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PART HI INVESTIGATION OF THE ANTIGENS RECOGNISED BY 
AUTO ANTIBODIES PRESENT IN SERUM FROM CHILDREN WITH
IDDM
The anti-6-cell suface antibodies present in the serum of patients with new onset 
IDDM are widely believed to play a role in the pathogenesis of this disease, which is 
characterised by a specific necrosis of the islet 6-cells. Very few 6-cell autoantigens have 
been positively identified. There is a need therefore, for the identification of 6-cell 
autoantigens which may be involved in the initial pathology of IDDM. In the short term, 
this is important for the development of an assay to screen for "pre-diabetes". In the long 
term, it may result in the application of immunotherapy designed to arrest the autoimmune 
attack against a specific 6-cell antigen, and therefore to cure IDDM.
This section of results describes the development of a 6-cell line plasma membrane 
ELISA, designed to detect the presence of anti-6-cell surface antibodies in serum from 
diabetic children. Attempts were made to use Western blotting to identify 6-cell antigens 
recognised specifically by antibodies in diabetic serum.
Since, in the very early stages of autoimmune diabetes, GLUT2 expression and 
glucose transport are decreased (Tominaga et al., 1986; Orci et al. , 1990a) and 6-cells 
show a decreased glucose-induced insulin response, it is possible that anti-GLUT2 
autoantibodies play a role in the pathogenesis of IDDM and that the GLUT2 protein is 
therefore a 6-cell autoantigen. Evidence supporting this hypothesis has been obtained by 
Johnson et al. (1990). Using techniques established in and information obtained from the 
preliminary studies carried out on the GLUT2 protein (Part I), it has been attempted to 
confirm the existence of these putative anti-GLUT2 antibodies using ELISAS, Western 
blotting and immunoprecipitation of ATB-BMPA labelled proteins.
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Ideally, the GLUT2 protein used in these studies should have been obtained from 
islet tissue. However, it was not technically feasible to obtain sufficient material from this 
source. Theoretically, a 8-cell line should have been a good alternative, but as was shown 
in Part II these abnormal 8-cells do not appear to express the GLUT2 protein. Therefore, 
liver plasma membranes have been used as a source of GLUT2. They were considered to 
be a suitable substitute since Johnson et al. (1990a) confirmed that antibodies able to 
inhibit 8-cell glucose transport cross-reacted with GLUT2-containing liver plasma 
membranes.
* * * * *
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3.7 THE USE OF AN ELISA TO DETECT ANTI-B-CELL MEMBRANE 
ANTIBODIES IN SERUM FROM DIABETIC AND CONTROL CHILDREN
Serum samples were screened for the presence of antibodies against the HITm2.2 
and MIN 6 B-cell lines. The HITm2.2 line was chosen because it grew rapidly and 
appeared to retain glucose-induced insulin-secretion. MIN 6 cells were used because they 
have been reported to exhibit glucose-inducible insulin secretion comparable with that 
found in normal islets and to contain GLUT2 mRNA (Miazaki et al., 1990), although the 
GLUT2 protein was not detected in the present study.
Serum samples screened against these two cell lines were obtained from 2 sources 
designated set 1 and set 2 as detailed in section 2.3. Both sets contained samples taken 
from children with recently diagnosed IDDM and from normal children of a similar age. 
The serum samples in set 2, which were originally collected as part of an autoimmune 
diabetes study at St. Bartholomews Hospital Centre for Clinical Research, were considered 
to be a "better" set of experimental samples, since they had been collected and stored under 
controlled conditions. All IDDM samples in set 2 were known to be positive for ICCA 
tested by standard immunofluorescence assays and all control samples were ICCA 
negative. The samples in set 1 were originally drawn from patients for the purpose of 
analysis in hospital biochemistry or pathology laboratories. The conditions under which 
they were collected and stored were therefore not standardized. Many of the serum 
samples in set 1 contained high levels of lipid and some contained a white precipitate which 
had to be removed by centrifugation. The identity of the precipitate was unknown but it 
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Fig. 29 Typical standard curve used in MIN 6 ELISAS to convert absolute 
absorbance values of test sera to a percentage of the standard serum.
The reference serum has a value of 86.4 ±6.44% (mean of 10 determinations ±S.E.M).
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Since anti-B-cell autoantibodies have previously been shown to be restricted to the 
IgG class of immunoglobulins (Lernmark et al., 1978; Millward et al., 1988), only this 
class of antibody was analysed in all ELISAS. Titres of membrane-binding antibodies 
(measured by absorbance at 450 nm), were expressed as a percentage of the absorbance 
given by the standard serum, using a standard curve like the one shown in Figure 29. The 
reference samples included on each plate did not differ significantly from each other in 
their absorbance values.
Samples from set 1 and set 2 have been assayed separately, since sera from these 
two sources were not available concurrently.
3.7.1 Comparison of the levels of anti-B-cell line membrane antibodies in serum 
samples (set I) from diabetic and control children
Titres of anti-HITm2.2 membrane antibodies were measured in serum samples 
from 27 children with recently diagnosed insulin-dependent diabetes and compared with 
those of 33 samples from control children (set 1). Each sample was assayed in triplicate. 
The average variation between triplicate measurements was ±13.6% (S.E.M. expressed as 
a percentage of the mean titre). Any value that had a S.E.M. much higher than this 
average was rejected. Each sample was tested in 3-4 independent assays. The inter-assay 
variation was high, ±23% for diabetic samples and ±20% for control samples. 
Variability is expressed as the S.E.M. calculated as a percentage of the mean titre for each 
sample. The high intra- and inter-assay variation probably arose from uneven coating of 
the ELISA plates with the antigen, and from variations in the quality of the plasma 
membrane preparation used (see discussion section 4.4)
A cumulative frequency distribution was calculated from both sets of data, as 
shown in Figure 30a, and a Kolmogorov-Smimov (K-S) analysis was performed on the 
results. The greatest difference between diabetic and control samples occurred in titres
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above 25% of the standard serum. That is, 92.6% of IDDM samples and 57.6% of control 
samples had titres greater than 25% of the standard. The calculated K-S value of 0.350 
was above the critical value of D of 0.316. This indicated that there were significantly 
more IDDM samples than control samples with binding higher than 25% of the standard. 
This difference was significant at p=0.1, and was nearly significant at p=0.05, where the 
critical value of 0.352 was not quite exceeded. The distribution of the titres of the anti- 
HITm2.2 membrane antibodies in samples from IDDM and control populations is more 
clearly shown in Figure 30b. More IDDM sera have higher titres of these antibodies, but 
there is an overlap between the two populations. Therefore, it was not possible to establish 
a cut-off point which could have been used to determine whether a sample had been 
obtained from a normal or a diabetic patient.
As a comparison, the same set of serum samples was screened against MIN 6 
plasma membranes. In this assay the problems of high intra-and inter-assay variation were 
resolved by the use of plasma membranes prepared using Method I (section 2.10.4.1), 
which produced membranes of a consistent quality, and by the homogenization of the 
membranes in the coating buffer, which resulted in a more homogeneous coating of the 
ELISA plates. Using these methods the intra-assay variation was reduced to ±2.7% 
(S.E.M. expressed as a percentage of the mean titre). Due to limited availability of serum 
samples, each sample was tested in triplicate in a single assay. Statistical analysis of the 
results using the K-S test revealed that the greatest difference between diabetic and control 
samples occurred with titres of anti-MIN 6 antibodies above 25% of the standard serum, 
that is, 74.2% of the control samples and 96.6% of the diabetic samples had titres >25% 
of the standard. These results were calculated from the data shown in Figure 31a. The 
calculated K-S value of 0.224 was below the critical value of D of 0.315 necessary for 
significance at p = 0 .1, therefore in this assay the higher binding of IDDM samples was not 
significantly different from that shown by the controls. The distribution of antibody levels 
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Fig. 30a-b IgG binding to HITm2.2 B-ceil membranes. A comparison 
between antibody levels in IDDM (n=27) and control (n=33) serum samples 
from set 1.
Using an ELISA, serum samples were assayed for antibodies against HITm2.2 plasma 
membranes (prepared using method II described in section 2.10.4.2). Samples, diluted 1:100 were 
assayed in triplicate on 3-4 occasions. The titres of IgG antibodies in each test sample (measured as 
absorbance at 450 nm) has been expressed as a percentage of the standard serum.
a: Results are presented as a histogram. Analysis with the K-S statistical test revealed that
there were significantly (p=0.1) more IDDM than control samples with antibody titres above 25% of 
the standard.
b: Results are presented as a scatter diagram. The solid lines depict the mean titre of each data
set and the dashed lines + 1 standard deviation.
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Fig. 31a-b IgG binding to MIN 6 B-cell membranes. A comparison between 
antibody levels in IDDM (n=29) and control (n=31) samples from set 1.
Using an ELISA, serum samples were assayed for antibodies against MIN 6 plasma 
membranes, prepared using method I described in section 2.10.4.1. Samples diluted 1:100 were 
assayed in triplicate. The titre of IgG (measured as absorbance at 450 nm) in each sample has been 
expressed as a percentage of the standard serum.
a: Results are presented as a histogram. Although there were more higher binding IDDM
samples than control samples, by K-S analysis the difference was shown not to be significant at
p = 0 . 1.
b: Results are expressed as a scatter diagram. The solid lines depict the mean titre of each data
set, the dashed lines + 1 standard deviation.
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The small volume of the serum samples in set 1 prevented them being re-assayed 
against HITm2.2 membranes using an ELISA in which variation was reduced by the 
methods described above for the MIN ELISA. The HIT and MIN ELISAS were therefore 
repeated using a second set of serum samples (set 2).
3.7.2 Comparison of the levels of anti-B-cell line membrane antibodies in the serum of 
ICCA-positive diabetic children and ICCA-negative controls (set 2)
In this second study, antibody levels in serum samples from 21 recently diagnosed 
ICCA-positive IDDM children and 20 ICCA-negative non-diabetic siblings were assayed 
against HITm2.2 and MIN 6 membranes which had been prepared using method I (section
2.10.4.1). The membranes were homogenized in the coating buffer to produce an even 
coating of the plates and consequently to reduce the assay variation. Each sample was 
tested in triplicate against MIN 6 membranes and the mean variation was ±2.6% (S.E.M. 
expressed as a percentage of mean titre). Each sample was also tested in five independent 
experiments. The inter-assay variation was ± 11.2% (S.E.M. expressed as a percentage of 
mean titre) and a reference serum included on each plate had a value which was not 
significantly different from the mean shown in Figure 29.
A cumulative frequency distribution was calculated from the data shown in Figure 
32a and a K-S analysis was performed on the results. The greatest difference between 
diabetic and control samples occurred with titres of anti-MIN 6 antibodies above 100% of 
the standard, that is, 40% of the controls and 57.2% of the diabetics had titres > 100% of 
the standard. This difference gave a K-S value of 0.172 which was lower than the critical 
value of 0.381 (p=0.1), therefore there was no significant difference between the level of 
antibodies in the IDDM and control samples. This is also illustrated in Figure 32b, which 
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Fig. 32a-b IgG binding to MIN 6 B-cell membranes. A comparison between 
antibody levels in IDDM (n=21) and control (n=20) serum samples from set 
2 .
Using an ELISA, serum samples diluted 1:100 were assayed for antibodies against MIN 6 
plasma membranes prepared according to method I described in section 2.10.4.1. Samples were 
assayed in triplicate on five separate occasions. The titre of IgG in each test sample has been 
expressed as a percentage of the standard serum.
a: Results are presented as a histogram. By K-S analysis there was no significant (p=0.1)
difference in the levels of antibodies in the IDDM and control samples.
b: Results are presented as a scatter diagram. The solid lines depict the mean titre of each data
set and the dashed line + 1 standard deviation.
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IDDM and normal samples from set 2 were also assayed against HITm2.2 
membranes which had been prepared using Method I (2.10.4.1). The variation between 
triplicate samples was ±2.98% (S.E.M expressed as a percentage of mean sample titre). 
Each sample was tested on five separate occasions. Inter-assay variation was ±11.0% 
(S.E.M. expressed as a percentage of mean sample titre).
When a K-S analysis was performed on the data shown in Figure 33a, the greatest 
difference between control and IDDM samples was found to occur with titres of anti- 
HITm2.2 antibodies above 150% of the standard, that is, 4.77% of IDDM samples and 
15% of controls had titres > 150% of the standard. The calculated K-S value of 0.106 was 
less than 0.381, the critical value of D at p=0.1. Therefore, there was no significant 
difference between anti-HITm2.2 antibody levels in control and IDDM samples. This is 
also illustrated in Figure 33b, in which both IDDM and control sera can be seen to have a 
wide range of titres which fall into an overlapping distribution.
3.7.3 Comparison of antibody binding to MIN 6 and HITm2.2 membrane antigens
In approximately half of all the samples tested, from both set 1 and set 2, the value 
obtained for the titre of anti-6-cell membrane antibodies was very similar whether it was 
obtained by screening against HITm2.2 or against MIN 6 membranes. As illustrated in 
Figures 34a-b this was mostly, though not exclusively, observed when the antibody titres 
were low. Approximately 55% of the samples from set 1 contained levels of antibodies 
that differed by more than ±20% in their binding to MIN compared with HIT membrane 
antigens (Figure 34a). This difference in levels of antibodies recognising MIN and HIT 
antigens was also observed in the samples from set 2 (Figure 34b) in which «46% of the 
samples differed by more than ±20% in their binding in the HIT compared with the MIN 
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Fig. 33a-b IgG binding to HITm2.2 ft-cell membranes. A comparison 
between antibody levels in IDDM (n=21) and control (n=20) serum samples 
from set 2.
Using an ELISA, serum samples diluted 1:100 were assayed for antibodies against 
HITm2.2 plasma membranes, prepared according to method I described in section 2.10.4.1. 
Samples were assayed in triplicate on five separate occasions. The titre of IgG in each sample has 
been expressed as a percentage of the standard serum.
a: Results are presented as a histogram. By K-S analysis there was no significant (p=0.1)
difference in the levels of antibodies in the IDDM and control samples.
b: Results are presented as a scatter diagram. The solid lines depict the mean titre of each data
set and the dashed line -t- 1 standard deviation.
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Fig. 34a-b Comparison of the levels of antibodies in serum samples from recently diagnosed 
diabetic or control children that bind to MIN 6 and fflTm2.2 membrane antigens.
Diabetic and control serum samples from set 1 and set 2 (Fig 34a and 34b respectively) 
were assayed in MIN 6 (A) or HITm2.2 (#) membrane ELISAS as described in sections 3.7.1 and 
3.7.2. The diagram compares the value obtained for the mean antibody titre (expressed as a 
percentage of the standard serum) for each sample measured from a MIN 6 and a HITm2.2 ELISA. 
For clarity the samples have been displayed in order of increasing difference in the titre of antibodies 
measured in the two different ELISAS.
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3.7.4 Comparison of the levels of anti-rat liver plasma membrane antibodies in the 
serum of ICCA-positive diabetic children and ICCA-negative controls
Serum samples from set 2 were also assayed against liver plasma membrane, since 
higher levels of anti-liver membrane antibodies in diabetic compared with control samples 
could have been indicative of the presence of anti-GLUT2 autoantibodies. However, when 
a K-S analysis was performed on the results shown in Figure 35, it was revealed that there 
was no significant difference between the levels of anti-liver antibodies in the control 
compared with the diabetic serum samples. The greatest difference between the data sets 
occurred above 50% of the standard serum, with 80% of the normal and 57% of the IDDM 
samples having titres > 50% of the standard. This gave a K-S value of 0.229 which did 
not exceed the critical value of D of 0.381 for significance at p = 0 .1. Each IDDM (n=21) 
and control (n=20) sample was assayed in triplicate and the S.E.M., expressed as a 
percentage of the mean titre, was ±3.6%.
Therefore, serum samples from diabetic patients did not contain significantly 
higher levels of anti-liver plasma membrane antibodies than were present in normal serum. 
The ELISA was therefore not suitable for the detection of anti-GLUT2 autoantibodies. It 
was attempted to use affinity purified GLUT2 (see section 3.9) as the antigen in an ELISA, 
but in preliminary studies, binding of antibodies from IDDM serum could not be detected 
(results not shown). This was probably due to the low concentration of GLUT2 that was 
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Fig. 35 IgG binding to rat liver plasma membranes. A comparison between 
antibody levels in IDDM (n=21) and control (n=20) serum samples from set 
2.
Using an ELISA, serum samples diluted 1:100 were assayed for antibodies against liver 
plasma membranes. Samples were assayed in triplicate. The titre of IgG in each test sample has 
been expressed as a percentage of the standard serum.
By K-S analysis there was no significant (p = 0 .1) difference in the levels of antibodies in the 
IDDM and control samples.
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3.8 THE USE OF WESTERN BLOTTING TO DETECT ANTIGENS 
RECOGNISED BY ANTIBODIES PRESENT IN THE SERUM OF IDDM 
PATIENTS
Plasma membrane proteins prepared from HITm2.2, RINm5F and MIN 6 fi-cell 
lines have been immunoblotted with serum samples from children with recently diagnosed 
IDDM or from non-diabetic controls. Owing to the small volume of serum available, 
samples were not preabsorbed with rat liver powders before use.
Using the alkaline phosphatase colourimetric detection system a heterogenous 
group of 8-cell proteins were found to be recognised by antibodies present in serum 
samples from both normal and diabetic children. In MIN 6 membranes dominant bands 
with apparent molecular masses of «  69, 58, 55, 49, 45, 39, 35 and 30 kDa were 
detected. A typical result obtained by immunoblotting MIN 6 membranes with a random 
selection of IDDM and control samples is shown in Figure 36a. None of the antigens 
detected was diabetes specific. As shown in Figure 36b dominant bands at «  76, 66, 50, 
47, 40 and 33 kDa were detected in HITm2.2 membranes. Most serum samples detected 
the same major antigen(s) in HITm2.2 membranes as they detected in RINm5F cells, 
indicating that these two cell lines were antigenically similar (results not shown). No 
antigen was detected in any of the 8-cell lines tested by more than one IDDM sample 
without also being recognised by control samples. It was demonstrated that diabetic serum 
contained a wider range of antibodies that were able to recognise more antigens in 8-cell 
lines compared with serum from control children. On average, each control sample 
recognised 1.8 bands in MIN6 plasma membranes. This was compared with the 3.1 bands 
recognised on average by each IDDM sample.
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Fig. 36a-b Immunoblotting of B-cell line plasma membranes with serum from diabetic and 
control children.
Plasma membranes were prepared from MIN 6 and HITm2.2 cells according to method I as 
described in section 2.10.4.1. 50 fig of protein were loaded per lane of a thin SDS-polyacrylamide 
gel and the proteins were separated by electrophoresis. Proteins were transferred electrophoretically 
to nitrocellulose. This was overlaid with human serum samples diluted 1:100 in TBS containing 3% 
BSA (blocking protocol II). Following an overnight incubation, the blots were washed, then 
developed with alkaline phosphatase conjugated anti-human IgG antibodies, 
a: IDDM MIN 6 plasma membranes blotted with eleven IDDM serum samples from set 1
Control MIN 6 plasma membranes blotted with eleven normal serum samples from set 1 
Both control and IDDM sera recognised a heterogeneous group of proteins in MIN plasma 
membranes. More bands were detected by the diabetic samples.
b: IDDM HITm2.2 plasma membranes blotted with fifteen IDDM serum samples from set 2
Control HITm2.2 plasma membranes blotted with eleven control serum samples from set 2 
Both control and IDDM sera recognised a heterogeneous group of proteins in HIT plasma 
membranes. More bands were detected by the diabetic samples.
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In an attempt to improve the sensitivity of this blotting technique, the detergent 
Triton X-114 was used to extract amphiphilic proteins from a membrane preparation of 
HITm2.2 and RINm5F cells. The extracted proteins were separated by SDS-PAGE, 
transferred to nitrocellulose and immunoblotted. As illustrated in Figure 37,
immunoblotting of Triton X-114 extracts from HITm2.2 cells detected a protein with an 
apparent molecular mass of =58 kDa which was recognised very strongly by 2/6 IDDM 
samples and less strongly by a further 3/6 IDDM samples. This was not however a 
diabetes-specific antigen, since it was also recognised by 5/6 control samples. One IDDM 
sample also bound strongly to a protein with an apparent molecular mass of —44 kDa. 
The sera tested recognised exactly the same proteins in Triton X-l 14 extracts of RINm5F 
cells (results not shown).
The identity of the »58 kDa protein was not known, but a protein with the same 
apparent molecular mass was recognised in the Triton X-114 extract by anti-human 
GLUT2 C-terminal peptide antiserum. This serum had previously been shown to recognise 
other proteins in addition to GLUT2 including BSA and antigens present in erythrocyte and 
adipocyte membranes (see section 3.1). The 58 kDa protein was not recognised by the 
anti-rat-GLUT2 C-terminal peptide antiserum (results not shown). It was also 
demonstrated that the —58 kDa protein was not BSA, which could have been adsorbed 
onto the 8-cell lines during culture in FCS-containing medium, since the human samples 
tested did not recognise BSA in a Western blot (results not shown).
It was also attempted to demonstrate the presence of anti-GLUT2 autoantibodies in 
serum samples from diabetic children by immunoblotting against GLUT2-containing liver 
plasma membranes. Some of the diabetic sera tested did contain antibodies that reacted 
with rat liver plasma membrane proteins, but no antigens were recognised that had an 
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Fig. 37 Immunodetection of proteins extracted from HITm2.2 cells with the detergent Triton 
X-114.
Proteins were extracted from a membrane fraction of HITm2.2 cells using the detergent 
Triton X-l 14 as described in section 2.11. The extracted proteins were analysed by SDS-PAGE and 
electrophoretically transferred to nitrocellulose. Blocking protocol I (section 2.17.3.1) was used to 
immunoblot the immobilised proteins with anti-human-GLUT2 C-terminal peptide antiserum (lane 
1), serum from recently diagnosed insulin dependent diabetic children (lanes 2-7) and serum from 
non-diabetic control children (lanes 8-13). All sera were used at a 1:100 dilution. Bound IgG was 
detected by incubation with the appropriate anti-rabbit or anti-human horse-radish peroxidase 
conjugated anti-IgG. Anti-human GLUT2 antiserum detected a protein with an apparent molecular 
mass of «58  kDa. A protein with the same apparent molecular mass was strongly recognised by 2/6 
serum samples from IDDM patients and less strongly by another 3/6 samples. In addition one 
IDDM sample detected a protein with an apparent molecular mass = 44 kDa. The == 58 kDa protein 
was also detected by 5/6 control samples.
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3 .9  AFFINITY PURIFICATION OF LIVER GLUT2
Two methods were used to immunoaffinity purify a protein from rat liver plasma 
membranes which was recognised by anti-GLUT2 antiserum in a Western blot and had a 
molecular weight on SDS-PAGE consistent with its identification as GLUT2.
Method I used a protocol previously described for the purification of an integral 
membrane glycoprotein, the nicotinic acetylcholine receptor (Momoi & Lennon, 1982). 
From initial experiments, it was shown that some GLUT2 could be detected in the unbound 
fraction which washed off the column, this indicated that the binding affinity of the column 
was low and that the binding capacity of the column had been exceeded. The 0.25 M NaCl 
wash did not elute immunodetectable GLUT2 from the column. A protein with an 
apparent molecular weight of »  59 kDa could be detected in the 1 M and 2 M NaCl washes 
when they were immunoblotted with anti-rat GLUT2 C-terminal peptide antiserum. As 
shown in Figure 38a, a protein present in the fractions eluted from the column with 2 M 
NaCl was recognised strongly by anti-human GLUT2 C-terminal peptide antiserum and 
less strongly by anti-rat GLUT2 C-terminal peptide antiserum. The protein recognised by 
these sera had a molecular weight identical to the protein recognised strongly by anti- 
GLUT2 antiserum in liver plasma membranes. No bands were detected when these blots 
were probed with preimmune serum (results not shown).
Proteins present in the 1 and 2 M washes were also detected by Coomassie Blue 
staining of SDS-polyacrylamide gels. Two proteins with apparent molecular masses of 
~  59 and = 51 kDa were detected very faintly as shown in Figure 38b. The = 59 kDa 
band aligned with the protein detected by immunoblotting with anti-GLUT2 antiserum, the 
identity of the lower band was unknown, but it was possibly the lower band detected by 
immunoblotting liver plasma membranes with anti-GLUT2 antiserum. Since these were 
the only major proteins detected, albeit in very low quantities, this indicated a significant 







Fig. 38a-b Immunoaffinity purification of liver GLUT2 (method I).
Liver plasma membrane proteins adsorbed to a GLUT2 immunoaffinity column were eluted 
in buffers containing 1 M and 2 M NaCl. Following concentration, the proteins were analysed by 
SDS-PAGE and stained with Coomassie Blue (b), or transferred electrophoretically to nitrocellulose (a) 
and immunoblotted with the indicated antiserum. Bound antibody was detected using goat anti-rabbit 
IgG alkaline phosphatase conjugate.
a: Lane 1 liver plasma membrane blotted with anti-rat GLUT2 C-terminal peptide antiserum
Lane 2 2 M NaCl wash blotted with anti-human GLUT2 C-terminal peptide antiserum 
Lane 3 2 M NaCl wash blotted with anti-rat GLUT2 C-terminal peptide antiserum 
GLUT2 in liver plasma membrane had an apparent molecular weight of = 59-60 kDa with a 
lower band at —51 kDa also detected. Anti-human GLUT2 serum detected a broad band with an 
apparent molecular weight of = 60 kDa in the 2 M NaCl affinity column wash. A weaker band of 
the same apparent molecular weight was detected by anti-rat GLUT2 antiserum.
b: Lane 1 Coomassie Blue stain of the 2 M NaCl wash
Lane 2 Coomassie Blue stain of the 1 M NaCl wash
Two bands with apparent molecular masses of — 59 and 51 kDa were detected in both the 1 





Fig. 39 Immunoaffinity purification of liver GLUT2 (method II).
Liver plasma membrane proteins adsorbed to a GLUT2 immunoaffinity column were eluted 
in a glycine buffer (pH 2.4) according to method II described in section 2.14.2. Fractions were 
pooled, concentrated and electrophoresed (lane 2) alongside liver plasma membrane (lane 1). 
Proteins were transferred electrophoretically to nitrocellulose and immunoblotted with anti-GLUT2 
C-terminal peptide antiserum. Bound antibody was detected using the ECL detection system. A 
protein with an apparent molecular mass of =60 kDa was recognised in the eluant from the affinity 
column which aligned with the =60 kDa GLUT2 protein detected in the liver plasma membranes.
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The second immunoaffinity purification method had previously been used for the 
purification of GLUT 1 from human erythrocytes (Davies, 1990).
The amount of GLUT2 that bound to the column was again low, since large 
amounts of GLUT2 could be detected in the unbound fraction which was washed off the 
column. Some protein was however adsorbed, and could be eluted by washing in a glycine 
buffer at pH 2.4. When proteins present in the glycine eluant were analysed by Western 
blotting using a sensitive ECL detection system, a protein with an apparent molecular 
weight of *  59 kDa was recognised by anti-rat GLUT2 antiserum. This protein aligned 
with the upper GLUT2 band detected by anti-GLUT2 antiserum in liver plasma membranes 
(Figure 39).
When the pH 2.4 wash was subjected to electrophoresis on a 10% SDS- 
polyacrylamide gel and stained with Coomassie Blue, no proteins could be detected (results 
not shown). This indicated that only a very low amount of the protein detected by anti- 
GLUT2 antiserum was present, but it also showed that the preparation was free of high 
amounts of other contaminating proteins.
Neither of these methods enabled GLUT2 to be purified in sufficiently large 
quantities for it to be used in the detection of putative anti-GLUT2 autoantibodies in 
human diabetic serum.
3.10 USE OF THE PHOTOLABEL ATB-BMPA TO INVESTIGATE THE 
PRESENCE OF ANTI-GLUT2 AUTOANTIBODIES IN THE SERUM OF 
DIABETIC CHILDREN
Serum samples (100 /zl) from 4 mammalian species were incubated with 5 mg of 
Protein A-Sepharose. The antibody-Protein A-Sepharose complex was then rotated with 
ATB-BMPA photolabelled proteins from liver plasma membrane, which had been
163
solubilized in buffer containing the detergent C 1 2 E9 . Immunoprecipitated proteins were 
analysed by SDS-PAGE. Normal rabbit, horse and sheep serum did not precipitate a 
significant amount of photolabelled protein (results not shown). Human serum from a 
child with IDDM however, contained Protein A-binding antibodies that did 
immunoprecipitate ATB-BMPA labelled proteins. When analysed by SDS-PAGE the 
labelled proteins appeared as a double peak, the heavier protein ran as a broad band with 
an apparent molecular weight of ~ 45-66 kDa. The second peak was narrower but higher, 
and ran between the 29 and 45 kDa marker proteins. The ratio of the areas of the two 
peaks was 1:1 ±0.23% (mean and S.E.M. of four serum samples).
The ATB-BMPA labelled liver plasma membrane proteins precipitated by human 
diabetic serum were compared with the labelled proteins precipitated by anti-GLUT2 C- 
terminal peptide antiserum. When equivalent amounts of serum were used for the 
immunoprecipitations, human serum was found to precipitate 1.5 fold as much total 
labelled protein as the anti-GLUT2 antiserum. This is illustrated in Figure 40, in which 
the GLUT2 peak aligned with the broad 45-66 kDa peak precipitated by the human serum. 
In other experiments, as for example the one illustrated in Figure 41, in which 
immunoprecipitated GLUT2 was resolved into two separate labelled peaks (see section
3.2.1), these two bands aligned with the two peaks precipitated by the human serum. This 
immunoprecipitation was not specific to IDDM samples, all human sera tested, including 
samples from normal children, children with IDDM and samples from Pima Indians with 
NIDDM (results not shown), precipitated a similar amount of the same labelled protein. A 
typical example is shown in Figure 40.
As shown in section 3.2.4, the binding of ATB-BMPA to the photolabelled 
GLUT2 immunoprecipitated by C-terminal peptide antiserum, could be displaced by 
60±2.2% (mean and S.E.M. of nine independent experiments) by photolabelling in the 
presence of 500 mM 4,6-0-ethylidene-D-glucose.
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Fig. 40 Immunoprecipitation of ATB-BMPA photolabelled liver plasma membrane proteins 
with normal and diabetic human serum and anti-GLUT2 peptide antiserum.
Liver plasma membranes (100 fig) were photolabelled with 100 f i d  of ATB-BMPA. 
Following washing, the membranes were solubilized in buffer containing the detergent C^Ec)-
Solubilized labelled proteins were immunoprecipitated with 5 mg of Protein A-Sepharose coupled to
50 fi\ of the following sera. Anti-GLUT2 C-terminal peptide (#), a serum sample from a diabetic 
child (A) and a serum sample from a normal child (A). Immunoprecipitated proteins were analysed 
by SDS-PAGE. Anti-GLUT2 C-terminal peptide antiserum precipitated labelled protein with an 
apparent molecular weight of 45-66 kDa. Human serum immunoprecipitated labelled proteins with 
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Fig. 41a-c 4,6-0-ethylidene-D-glucose displacement of ATB-BMPA binding to the rat liver plasma membrane proteins immunoprecipitated with human serum and 
rabbit anti-GLUT2 antiserum.
Liver plasma membranes (100 fxg) were photolabelled with ATB-BMPA in the presence (open symbols) or absence (solid symbols) of 500 mM 4,6-0-ethylidene-D- 
glucose. After washing and solubilization in buffer containing the detergent solubilized proteins were immunoprecipitated with 5 mg of Protein A-Sepharose
coupled to 50 /xl of normal human serum (D,H) [Fig a], serum from an insulin-dependent diabetic patient (A,A) [Fig b], or anti-rat GLUT2 C-terminal peptide antiserum 
(0 ,0)  [Fig c]. Immunoprecipitates were analysed by SDS-PAGE. In the illustrated example, 4,6-0-ethylidene-D-glucose inhibited the photolabelling of proteins 
immunoprecipitated with human sera by 46%. Photolabelling of GLUT2 was inhibited by 58%. In this example the protein immunoprecipitated by anti-GLUT2 antiserum 
was resolved as a double peak.
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By comparison, it was shown that the immunoprecipitation of photolabelled proteins by 
immunoglobulin from control and diabetic children was reduced by 49±3.4% and 
51 ±2.4% (means and S.E.M. from four normal and four diabetic samples respectively), 
when ATB-BMPA was irradiated in the presence of 500 mM 4,6-0-ethylidene-D-glucose.
Analysis of the peak areas also revealed that 4,6-0-ethylidene-D-glucose caused a 
similar displacement of labelling to both of the proteins precipitated by the human serum. 
On average, 4,6-0-ethylidene-D-glucose inhibited the binding of ATB-BMPA to the 45-66 
kDa protein by 47±7.2% (mean and S.E.M. for four independently tested serum samples) 
and binding to the 29-45 kDa protein by 41 ±7.5% (mean and S.E.M. for four 
independently tested serum samples). There was no significant (p=0.05) difference in the 
amount of 4,6-0-ethylidene-D-glucose-inhibition of ATB-BMPA labelling of proteins 
precipitated by the control compared with the diabetic serum samples tested (Student's T- 
Test, eight samples tested in two independent experiments). The result of a typical 
displacement experiment is shown in Figures 41a-c.
The immunoprecipitating antibodies in human serum were present in high titres, or 
had a high affinity or avidity for the ATB-BMPA labelled protein. As illustrated in Figure 
42, a significant amount of labelled protein was precipitated using only 1 mg of Protein A- 
Sepharose coupled to 10 /xl of serum. Increasing the amount of Protein A-Sepharose and 
immunoprecipitating antibody from 1 mg to 2 mg, resulted in a 2.6±0.61 fold increase in 
the amount of labelled protein precipitated (mean and S.E.M. of four independently 
analysed serum samples). Increasing the amount of Protein A-Sepharose-antibody 
conjugate from 2 mg to 5 mg, resulted in only 0.95±0.33 (mean and S.E.M. of four 
independently analysed samples) fold more ATB-BMPA labelled protein being 
immunoprecipitated. This indicated that 5 mg of Protein A-Sepharose-antibody conjugate 
precipitated an approximately maximal amount of ATB-BMPA labelled protein from 100 
fig liver plasma membranes. Similar results were obtained using both diabetic and normal 
serum.
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Fig. 42 Immunoprecipitation of ATB-BMPA photolabelled liver plasma membrane proteias 
using a range of concentrations of normal human serum.
Liver plasma membranes (100 fig ) were photolabelled with ATB-BMPA, washed and 
solubilized in buffer containing the detergent Solubilized labelled proteins were
immunoprecipitated with 1, 2 or 5 mg of Protein A-Sepharose conjugated to 10, 20 or 50 /xl of 
normal human serum ®>A,A respectively).
The illustrated example is representative of a number of normal and diabetic samples tested. 
The amount of labelled protein precipitated increased as the quantity of immunoprecipitating serum 
was increased. Maximum precipitation was obtained with =»5 mg of Protein A-Sepharose 
conjugated to 50 /xl of human serum.
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The preliminary experiments described above demonstrated that all human serum 
contains antibodies able to immunoprecipitate a rat liver plasma membrane protein labelled 
by the photoprobe ATB-BMPA in a 4,6-0-ethylidene-D-glucose displaceable manner. 
When analysed by SDS-PAGE, the labelled protein had an apparent molecular weight 
identical to that of immunoprecipitated liver GLUT2. The following experiments were 
carried out in an attempt to demonstrate whether any of these precipitating antibodies were 
present only in serum from diabetic patients and whether the protein prepipitated by the 
human serum was liver GLUT2.
As illustrated previously in Figure 13b, it was possible to remove «80% of the 
total photolabelled immunoprecipitatable GLUT2 from 100 /xg of liver plasma membrane 
by a single treatment with 5 mg of Protein A-Sepharose coupled to 50 /xl of anti-GLUT2 C- 
terminal peptide antiserum. By carrying out an initial immunoprecipitation of the 
solubilized ATB-BMPA labelled liver proteins by treatment with 5 mg of Protein A- 
Sepharose-anti-GLUT2 conjugate, it was possible to reduce the amount of labelled protein 
subsequently precipitated by 5 mg of Protein A-Sepharose coupled to 50 /xl of human 
serum. This is shown in Figures 43a-d. The amount of labelled protein precipitated by 
human serum was reduced to 58.5 ±0.2% (mean and S.E.M. for two samples) of the total 
amount precipitated from membranes not depleted of GLUT2. When the 
immunoprecipitation treatment was carried out in reverse order, that is, photolabelled 
proteins were precipitated by incubation with human serum followed by treatment with 
anti-GLUT2 antiserum, the amount of precipitated GLUT2 was reduced to 41.8±4.1% 
(mean and S.E.M. of two samples) of the quantity normally precipitated. Regardless of the 
order of immunoprecipitation, approximately the same amount of labelled protein was 
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Fig. 43a-d Competition between anti-GLUT2 peptide antibodies and antibodies in human 
serum for the immunoprecipitation of photolabelled liver proteins.
Liver plasma membranes were photolabelled with ATB-BMPA, washed and solubilized in 
the detergent C^Et)- Solubilized labelled proteins were subjected to a double immunoprecipitation 
with 5 mg of Protein A-Sepharose coupled to 50 /xl of anti-GLUT2 C-terminal peptide antiserum, 
and either a normal human serum sample or a serum sample from an IDDM patient. 
Immunoprecipitated proteins were analysed by SDS-PAGE.
Figure 1st Precipitation 2nc* Precipitation
43a GLUT2 antiserum (•) Diabetic serum (▲)
43b Diabetic serum (A) GLUT2 antiserum (•)
43c GLUT2 antiserum (#) Control serum (A)
43d Control serum (A) GLUT2 antiserum (t)
13b GLUT2 antiserum (#) GLUT2 antiserum (#)
When GLUT2 was removed from the liver plasma membranes, the human serum (Figs a 
and c) precipitated =42% less labelled protein. Attempts to precipitate GLUT2 following a 
precipitation with human serum resulted in =58% less GLUT2 being immunoprecipitated (Figs b 
and d).
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Fig. 44 Preabsorption of human and anti-GLUT2 sera with liver plasma membranes prior to 
their use in the immunoprecipitation of ATB-BMPA photolabelled proteins from liver plasma 
membranes.
Serum samples (50 fil) from a recently diagnosed insulin-dependent diabetic (A) and rabbit 
anti-rat GLUT2 C-terminal peptide antiserum (O) were incubated for 3 hours at 4°C with 2 mg of 
liver plasma membrane protein. The membranes were removed by centrifugation at 800 gav (2x5 
mm) and at 50,000 gav for 20 mm (Johnson et cil., 1990a). The remaining supernatant was then 
coupled to 5 mg of Protein A-Sepharose and was used to immunoprecipitate solubilized photolabelled 
proteins from rat liver plasma membranes. The results obtained were compared with 
immunoprecipitations carried out using diabetic (▲) and anti-GLUT2 sera (#) which had not been 
preabsorbed. The immunoprecipitated proteins were analysed by SDS-PAGE. Preabsorption with 
liver plasma membranes reduced immunoprecipitation by GLUT2 antiserum but not by human 
serum. Arrowheads indicate the position of molecular weight marker proteins.
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Although these experiments were only carried out on a small number of samples, 
the results suggested that between 42-58% of the antibodies in human and anti-GLUT2 C- 
terminal peptide antiserum were competing for the same antigen, namely GLUT2. Again, 
there was no significant difference between amounts of protein precipitated by the diabetic 
compared with the control samples. Attempts were made to immunoblot the human serum 
precipitated proteins using anti-GLUT2 antiserum but the results obtained were 
inconclusive. Although no GLUT2 was detected, it may have been present but at a level 
below the sensitivity of detection of the assay. The large amounts of human IgG also 
present may have contributed to the poor results obtained with this technique. Similar 
problems were encountered with the detection of the GLUT2 protein precipitated with anti- 
GLUT2 antiserum (see section 3.2.3).
As shown in Figure 44, the immunoprecipitating antibodies in human serum could 
not be removed by preabsorption with liver plasma membranes. This contrasted with the 
anti-GLUT2 peptide antiserum which immunoprecipitated 56% less labelled GLUT2 
following preabsorption with liver plasma membranes. This suggested that the antibodies 
in human serum, which precipitated ATB-BMPA labelled proteins, only recognised these 




4.1 INTERACTION OF THE GLUT2 PROTEIN WITH ANTI-GLUT2 
PEPTIDE ANTIBODIES
It is well documented that antibodies raised against synthetic peptides conjugated to 
carrier proteins can recognise the proteins from which the peptides were derived (Feamey 
et al., 1971; Maron et al., 1971). The antigenic regions of native proteins often consist of 
only a few amino acids, usually polar residues located in hydrophilic regions on the surface 
of the protein. The C-terminus of a protein is an ideal region against which to raise anti­
peptide antibodies since, in the native protein it is probably conformationally less restricted 
than other parts of the molecule. However, a short peptide can assume a number of 
different conformations that do not exist in the native protein, therefore only a proportion 
of the anti-peptide antibodies are likely to be able to recognise the peptide sequence as it 
exists in the native protein. Therefore, the more mobile the region of the protein chosen 
for the production of anti-peptide antibodies, the higher the number that are likely to bind 
to the native protein.
Immunisation with the purified erythrocyte glucose transporter protein generates 
antibodies that react with the C-terminal hydrophilic tail, therefore, this is naturally an 
immunogenic region of this protein (Davies, 1990). Investigation of the glucose 
transporter family has been aided by the fact that the C-terminal regions of the different 
isoforms, with the exception of GLUT2 and GLUT7 (Waddell et al., 1992), are 
sufficiently different to enable antibodies raised against C-terminal peptides to be isoform 
specific. In the case of GLUT2, peptide sequences from the hydrophilic loop between Ml 
and M2 have also been used to produce anti-GLUT2 peptide antibodies (Thorens et al., 
1988; Orci etal., 1989; Oka etal., 1990b).
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The present study has described the production of anti-GLUT2 C-terminal and 
exofacial-loop peptide antibodies which have been demonstrated to bind to the GLUT2 
protein when it is immobilised on nitrocellulose paper or ELISA plates and when 
detergent-solubilized.
The quality of the anti-GLUT2 antibodies produced was dependent on the sequence 
of the immunising peptide. It was found that peptides that included the arginine and lysine 
residues at positions 507 and 508 (rat) and 510 and 511 (human) seemed to generate 
especially high titres of antibodies that cross-reacted with the GLUT2 protein. These 
residues may therefore form part of an important immunogenic epitope in the peptide, 
which is also present in the same conformation in the whole GLUT2 protein. Of the anti- 
rat GLUT2 C-terminal peptide antisera tested, those raised in response to rat C-terminal 
peptides B and C (residues 507-522 and 499-508 respectively), contained the highest titres 
of antibodies that recognised liver plasma membrane proteins in ELISAS and Western 
blots. It is therefore suggested that these sequences may produce "better" anti-GLUT2 
antisera than the C-terminal decapeptide containing residues 513-522, which has previously 
been widely use to produce anti-GLUT2 antibodies (Thorens et al., 1988; 1990a; 1990e; 
Orci et al., 1989; 1990a).
Thorens and co-workers (1988; 1990a) have previously shown that an antibody 
raised against the rat GLUT2 C-terminal decapeptide detected a single 53 kDa protein in 
Western blots of crude liver membranes. In the present study these results could not be 
repeated using the same crude membrane preparation and antibodies raised against the C- 
terminal 13 or 16 amino acids of rat GLUT2, although the same anti-peptide antibodies 
successfully detected GLUT2 when purified liver plasma membranes were used. It is 
proposed that this discrepancy arose from two sources, first from the use by Thorens et al. 
(1988) of a more sensitive 1  ^ - l a b e l l e d  j g Q  detection system, and secondly from the 
different concentration of GLUT2 in the membrane preparation.
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The method used routinely in the present study to prepare liver plasma membranes, 
has previously been shown to produce a membrane fraction with a high 5' nucleotidase 
activity of 24 /zmol/mg/30 min (Prpic et al., 1984). This method uses a Percoll gradient to 
purify plasma membranes from material pelleted at low speed (1500 g) from homogenised 
cells. This contrasts with the method used by Thorens et al. (1988) in which homogenised 
material pelleted at 6000 g is discarded. This is likely to result in the loss of a substantial 
amount of the total plasma membrane. The subsequent very high speed spin included in 
the Thorens protocol may also be expected to contaminate the membrane preparation with 
light microsomes. Therefore, the detection of GLUT2 with anti-C-terminal peptide 
antibodies in immunoblots either requires that a high concentration of GLUT2 is present 
(as in the membranes used in the present study), or that a sensitive detection system, as 
used by Thorens et fl/.(1988) is used. Similarly, in the present study it was found that the 
anti-exofacial loop peptide antibodies only detected GLUT2 in immunoblots of liver plasma 
membranes when a very sensitive ECL detection system was used.
These results suggest that the titre of anti-GLUT2 peptide antibodies that are 
actually able to recognise the whole GLUT2 protein is quite low. This situation could 
arise if the antigenic epitopes in the whole protein do not adopt the same conformation as 
in the peptide, or if they are not accessible to the antibodies. For example, the C-terminal 
region of GLUT2 may not project sufficiently from the protein to enable the antibodies to 
bind. It was not established why both the anti-loop and anti-C-terminal peptide antibodies 
had an equally low affinity for GLUT2. Fortunately, the detection problems caused by the 
low affinity for GLUT2 of the anti-peptide antibodies could largely be circumvented by the 
use of a plasma membrane preparation which contained a high concentration of this 
protein.
From Western blotting the apparent molecular mass of the major GLUT2 species 
present in liver plasma membranes was estimated to be about 57 kDa. A strong band of 
the same apparent molecular mass was also detected in islets. The size difference between
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rat liver (53 kDa) and fi-cell (55 kDa) GLUT2 previously noted by Thorens et a l \  1988) 
was not observed in the present study. However, the reported apparent molecular mass 
assigned to the GLUT2 protein has been variable. Johnson et al. (1990b) detected fi-cell 
GLUT2 as a 60 kDa protein and Oka et al. (1990b) detected liver GLUT2 as a 55 kDa 
protein. In the present study, in addition to the main 57 kDa band, other bands with 
apparent molecular weights of —51 and «36  kDa were also recognised specifically by 
anti-GLUT2 C-terminal peptide antibodies. Other studies have previously detected 
multiple bands in Western blots of GLUT2. A weak band of unknown identity has been 
detected below the main GLUT2 band in islets (Orci et al., 1989; Johnson et al., 1990b) 
and in liver (S. A. Baldwin-personal communication). Using anti-rat (509-522) and anti­
human (511-522) GLUT2 C-terminal peptide antibodies, Brant et al. (1992) detected 
proteins with apparent molecular masses of 56, 50 and 33 kDa in oocytes expressing 
GLUT2, and proteins of 56, 42 and 31 kDa in a rat liver plasma membrane preparation 
very similar to the one used in the present study (Pilkis et al., 1974; Marchmont et al., 
1981). These results suggest that the «57, 51 and 33 kDa proteins recognised by the anti- 
GLUT2 antisera used in the present study were derived from the GLUT2 protein itself. It 
was not known how the minor bands differed from the main (57 kDa) GLUT2 species, but 
they were unlikely to be proteolysed fragments, since proteinase inhibitors were included 
at all stages of the membrane preparation and the C-terminus was still present.
The erythrocyte-type glucose transporter has previously been successfully affinity 
purified using anti-GLUTl peptide antibodies (Davies, 1990). However, in the present 
study problems were encountered with the immunoaffinity purification of GLUT2, which 
were attributed to the low affinity of the anti-GLUT2 C-terminal peptide antibody for the 
solubilized GLUT2 protein. The binding capacity of the immunosorbent appeared to be 
very low, since most of the loaded GLUT2 did not bind to the column. However, despite 
the low amount of binding, a protein with an apparent molecular mass of ~ 59 kDa, which 
was recognised by anti-GLUT2 C-terminal peptide antibodies in a Western blot, was eluted 
from the affinity matrix using either high salt (Momoi & Lennon, 1982) or low pH
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conditions (Schroer et al., 1986; Davies, 1990). Similar results were produced using both 
methods. Analysis of proteins was however facilitated by the use of n-octyl 6-D- 
glucopyranoside as the solubilizing detergent since it was easily removed by dialysis. The 
drawback of this detergent was its cost. Solubilization in the detergent Triton X-100 had 
the disadvantage that it could not be readily removed.
Although the four different molecular mass protein species detected by 
immunoblotting with anti-GLUT2 antibodies were present in the original solubilized liver 
plasma membranes, it was mainly the major —59 kDa protein that was eluted from the 
column, presumably since this was the predominant species present.
Although these results have indicated that GLUT2 can be immunoaffinity-purified 
from liver plasma membranes, the yield was so low that it was insufficient to be used in 
assays to detect anti-GLUT2 autoantibodies. It will therefore be necessary to improve both 
the degree of purification and to increase the yield before purified GLUT2 can be used for 
antigenic studies.
4.2 PHOTOLABELLING OF GLUT2 WITH ATB-BMPA
It has previously been shown that the bis-D-mannose compound ATB-BMPA can 
photolabel the glucose transporter isoforms GLUT1 (Clark & Holman, 1990) and GLUT4 
(Holman et al., 1990) in erythrocytes and adipocytes respectively. The photoactive group 
is selective enough for highly specific labelling of these glucose transport proteins to be 
obtained. The specificity is not simply a result of the impermeant nature of ATB-BMPA, 
since it has also been successfully used to label isolated membranes (Clark & Holman, 
1990).
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The results shown in part I of this thesis have demonstrated for the first time that 
ATB-BMPA can be used to photolabel the glucose transporter isoform GLUT2. 
Previously, the only available method of labelling the liver glucose transport protein was 
with the endofacial ligand cyt B, when used in conjunction with a photochemical cross- 
linking agent (Ciaraldi et al., 1986). In the study by Ciaraldi and co-workers, 
approximately 50% of the cyt B binding was displaced by 500 mM D-glucose. A more 
recent study by Hellwig & Joost (1991) failed to detect any glucose-inhibitable binding of 
cyt B to liver plasma membranes. It was suggested that cyt B has a much lower affinity for 
GLUT2 than it does for the transporter isoforms GLUT1 and GLUT4, and that this 
indicated important structural differences between the isoforms in the specific domains 
responsible for cyt B binding. Since cyt B is an endofacial ligand (Basketter & Widdas, 
1978; Devds & Krupka, 1978; Holman & Rees, 1987) this indicates that variations at the 
endofacial hexose binding site, reflected by differences in the affinity for cyt B, may be 
responsible for functional differences between the transporter isoforms. GLUT2 is 
different from the other members of the facilitative glucose transporter family, in that it has 
a particularly low affinity for D-glucose as well as having an approximately 10 fold lower 
affinity for cyt B (Axelrod & Pilch, 1983).
It is proposed that fewer differences are present at the exofacial than at the 
endofacial binding sites of the transporter isoforms. In the present study an ATB-BMPA 
binding constant of 250 nM was measured for GLUT2 which is similar to the value of 150 
fiM previously reported for the GLUT1 and GLUT4 isoforms (Palffeyman et al., 1992). 
This suggests that the ATB-BMPA binding site, in contrast to the cyt B binding site, is 
conserved in all glucose-transporter isoforms. Recent studies have indicated that on 
irradiation ATB-BMPA labels the exofacial region of helix 8 and that helices 7, 8 and 9 are 
important in exofacial ligand binding (A.F. Davies, A. Davies, R.A.J. Preston, A.E. 
Clark, G.D. Holman and S. A. Baldwin - personal communication). Therefore, the ATB- 
BMPA photolabel and translocated substrates probably bind at the same exofacial site.
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Since ATB-BMPA apparently has a similar affinity for all of the transporter isoforms, it 
has advantages over the cyt B label which has a much lower affinity for GLUT2.
Irradiation of ATB-BMPA in the presence of hepatocytes or liver plasma 
membranes resulted in the photolabelling of a broad band of protein with an apparent 
molecular mass of between 45 and 66 kDa. The broadness of the peak suggested that the 
specificity of ATB-BMPA labelling in liver tissue was not as high as in erythrocytes or 
adipocytes, that is, that ATB-BMPA was labelling some polypeptides unrelated to glucose 
transporters. In erythrocytes, ATB-BMPA labels a single band of protein which has an 
apparent molecular mass of -45-66 kDa. It has been demonstrated that the label is 
specifically binding to a glucose transporter protein, namely GLUT1, by displacing ATB- 
BMPA labelling totally with 100 mM D-glucose (Clark & Holman, 1990). In adipocytes, 
the ATB-BMPA labelling of a 55 kDa protein, namely GLUT4, is also completely 
displaceable with D-glucose. In these fat cells a second protein with an apparent molecular 
mass of about 75 kDa is also labelled, but it can be demonstrated that this protein is not a 
glucose transporter protein since labelling is not displaced with D-glucose (Holman et al.,
1990). The increased amount of non-specific labelling observed in liver tissue in the 
current study may be partially due to the use of membranes instead of whole cells. It may 
also reflect the low abundance of GLUT2 in liver cells compared with the number of other 
proteins present. Photolabelling of liver plasma membrane proteins could be displaced by 
43% by 4,6-0-ethylidene-D-glucose, a sugar which has an affinity for the exofacial glucose 
binding site (Barnett et al., 1973b). The poor glucose displacement of ATB-BMPA 
photolabelling of membrane proteins was probably the result of a combination of the low 
affinity of GLUT2 for D-glucose (Elliott & Craik, 1982; Granner & Pilkis, 1990), in 
addition to the presence of some non-specific photolabelling.
It was demonstrated that some of the ATB-BMPA labelled protein in liver plasma 
membranes was GLUT2, since labelled protein with an apparent molecular mass of *  45- 
66 kDa was precipitated by anti-GLUT2 antiserum. 500 mM D-glucose was able to inhibit
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the specific ATB-BMPA binding to GLUT2 by 57%. Since the Km for D-glucose 
transport in hepatocytes is 60 mM (Granner & Pilkis, 1990), 500 mM D-glucose would be 
expected to inhibit ATB-BMPA labelling by more than 80%. Therefore the Kj for D- 
glucose displacement of ATB-BMPA from GLUT2 may be even higher than the Km for 
glucose transport by hepatocytes.
Since the exofacial binding site of the transporter isoforms appears to be 
conserved, the observed differences in affinities of the different transporters for D-glucose 
are likely to arise from differences in the interaction of the substrate with the internal site 
of the transporter. The ability to bind a non-transported ligand such as ATB-BMPA or
4,6-0-ethylidene-D-glucose at the outside site is kinetically a simpler reaction than that 
involved in binding and transporting a substrate molecule. The apparent Km for 
equilibrium sugar binding or exchange is dependent both on the rate constant for the 
membrane translocation step and on the affinity constant at the inside site. It is these 
parameters that may vary between the different transporter isoforms resulting in the 
observed different affinities for transported substrates.
Inhibition of ATB-BMPA labelling of immunoprecipitable GLUT2 was greatest 
when photolabelling was performed in the presence of non-transported ligands known to 
have an affinity for the exofacial binding site of the transporter. The hexose 4,6-0- 
ethylidene-D-glucose, which like the ATB-BMPA molecule has bulky groups at the C4 and 
C6 positions (Holman, 1989), has an affinity for the outside binding site but cannot be 
translocated, therefore the 92% inhibition produced by this sugar was a reflection of the 
affinity of binding at the exofacial hexose binding site only. Maximum inhibition 
(~  100%) of ATB-BMPA labelling of GLUT2 was produced by phloretin, which is also 
considered to bind at the extracellular binding site (Krupka, 1971; Krupka & Devds, 1980; 
Krupka & Dev6s, 1981), although other evidence does suggest that it may also bind to 
some inside-specific sites (Basketter & Widdas, 1978).
180
The previously reported low affinity binding of the endofacial ligand cyt B to liver 
membranes and GLUT2 (Axelrod & Pilch, 1983; Hellwig & Joost, 1991) has been 
confirmed in the present study. Cyt B inhibited the binding of ATB-BMPA to GLUT2 by 
65%, this contrasts with its ability to totally displace photolabel from the GLUT1 and 
GLUT4 transporter isoforms (Clark & Holman, 1990; Holman et al., 1990). According 
to the carrier model of glucose transport, the internal and external substrate binding sites 
are not available simultaneously (Dev6s & Krupka, 1978; Carruthers, 1990). By binding 
at an endofacial site, cyt B can therefore block the binding of the exofacial ligand ATB- 
BMPA by causing a conformational change which occludes the external substrate binding 
site (Devds & Krupka, 1978; Holman, 1989). The most likely explanation for the poor 
displacement by cyt B of ATB-BMPA binding to GLUT2, does not propose a fundamental 
difference in the mechanism of transport in this isoform, but simply that cyt B binds poorly 
to GLUT2 (Hellwig & Joost, 1991). It is not clear whether cyt B and glucose bind at 
exactly the same endofacial site, but this would seem unlikely owing to the very different 
structures of the two molecules (Dev6s & Krupka, 1978). However, it has also been 
suggested that the cyt B does actually bind to the same region of the glucose transporter 
that interacts with the transported hexose (Hellwig & Joost, 1991).
In summary, all of the evidence from inhibition studies suggests that the different 
kinetic properties of GLUT2 arise from differences on the endofacial surface of the 
protein.
D-fructose caused a 77% inhibition in ATB-BMPA binding to GLUT2. This is in 
accordance with the observations made by Okuno and Gliemann (1986) who demonstrated 
that D-fructose is transported with low affinity by the glucose transporter in hepatocytes 
and by Gould et al. (1991) who found that oocytes expressing GLUT2 can transport D- 
fructose.
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The present study of GLUT2 was affected by difficulties with the specificity of 
ATB-BMPA labelling and poor immunoprecipitation efficiency which were not a problem 
in previous studies of GLUT1 and GLUT4 (Clark & Holman, 1990; Holman et al., 1990). 
Both of these factors caused significant problems when it was attempted to photolabel 
GLUT2 in rat islet tissue. The problems were compounded by the fact that islets could 
only be isolated in very low numbers. ATB-BMPA did label a very broad band of protein 
in islets, but labelling was not displaced by 4,6-0-ethylidene-D-glucose. This strongly 
suggested that most of the photolabelling of whole islets was non-specific. However, some 
GLUT2 was shown to be photolabelled, since anti-GLUT2 antiserum specifically 
precipitated approximately 3% of the labelled protein from the islets. Further experiments 
on islet cells must await the resolution of the technical difficulties responsible for the poor 
recovery of photolabelled GLUT2. These difficulties can probably be more easily resolved 
using rat liver plasma membrane which is a plentiful and easily available source of 
GLUT2.
The amount of photolabelled GLUT2 that was immunoprecipitated from 
hepatocytes or liver plasma membranes was low compared with the total amount of 
labelling. Approximately 2% of the total amount of protein labelled in whole hepatocytes 
was precipitated by anti-GLUT2 antiserum. This value was increased slightly by the use of 
liver plasma membranes from which approximately 7% of the total proteins labelled in a
4,6-0-ethylidene-D-glucose displaceable manner were specifically immunoprecipitated by 
anti-GLUT2 antiserum. Although preimmune serum did not recognise any bands in 
Western blots of liver plasma membranes, when coupled to Protein A-Sepharose it did 
immunoprecipitate a peak of labelled protein of similar molecular mass to that precipitated 
by the anti-GLUT2 antiserum. On average, this non-specific precipitation accounted for 
about 32% of the total amount of precipitation by anti-GLUT2 antiserum. By Western 
blotting it was demonstrated that the labelled protein non-specifically precipitated by 
normal rabbit serum was not GLUT2, since anti-GLUT2 antiserum did not detect GLUT2 
in preimmune serum immunoprecipitates. The identity of the protein was not known.
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It was shown by Western blotting that the low recovery of labelled GLUT2 was 
partially caused by poor immunoprecipitation of the detergent solubilized protein. The 
conditions used prevented quantification of the immunoprecipitation efficiency, but did 
demonstrate that although some GLUT2 was precipitated, some also remained in the 
supernatant and was not precipitated. Therefore, the immunoprecipitation of GLUT2 
appeared to be incomplete. However, the amount of precipitated GLUT2 could not be 
significantly enhanced either by increasing the amount of precipitating antiserum or by 
carrying out repeated rounds of immunoprecipitation.
It was considered possible that the anti-peptide antibodies had a particularly low 
affinity for the detergent-solubilized GLUT2 protein. This could possibly explain the poor 
immunoprecipitation efficiency for GLUT2 observed in this, and other studies (Dr. G. W. 
Gould - personal communication). However, this would not have been expected to affect 
both the anti-loop peptide and anti-C-terminal peptide antibodies to the same extent, 
although the results demonstrated that both antibodies precipitated equally low amounts of 
labelled GLUT2. The solubilization of membrane proteins in two alternative detergents 
was also shown not to significantly improve the recovery of labelled GLUT2. The proteins 
were solubilized in the anionic detergent SDS, which denatures proteins, in order to 
determine whether the anti-GLUT2 C-terminal peptide antibody was able to recognise the 
GLUT2 protein more efficiently when it was denatured, but no improvement in GLUT2 
precipitation was observed. The low recovery of GLUT2 was also shown not to result 
from incomplete solubilization of the labelled transporter, since by Western blotting it was 
shown that GLUT2 was fully solubilized in the C 1 2 E9  detergent used routinely.
Proteolytic activity, which could have cleaved the C-terminus of the transporter 
resulting in a loss of immunoreactivity, was prevented by the inclusion of proteinase 
inhibitors. Proteolysis was not thought to have been responsible for the poor recovery of 
GLUT2, since it would have been expected to have had a greater effect on precipitation by
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the anti-C-terminal peptide than the anti-loop peptide antibody, whereas both precipitated a 
similar amount of GLUT2 protein.
Although the discrepancy between the amount of protein labelled in liver plasma 
membranes and the amount of GLUT2 immunoprecipitated was in part due to the 
incomplete precipitation of the GLUT2 protein, it was also necessary to consider whether 
the apparent low recovery of GLUT2 was in fact largely a result of non-specific labelling 
by ATB-BMPA of non-GLUT2 proteins. However, since 4,6-0-ethylidene-D-glucose 
displaced 43% of the ATB-BMPA binding to whole liver plasma membranes, this suggests 
that at least this amount of labelling was specific to a glucose-transport protein. The 
possibility that the non-GLUT2 precipitable but 4,6-0-ethylidene-D-glucose inhibitable 
binding of ATB-BMPA to liver plasma membranes was due to binding to another glucose 
transporter proteins has been considered.
Waddell and co-workers (1992) have recently described the cloning of another 
glucose transporter protein from liver. GLUT7, as it has been named, is present in liver 
microsomes and is virtually identical to GLUT2, the major region of variation being the C- 
terminus. The liver membranes photolabelled in the present study were believed to be a 
relatively pure preparation of plasma membranes uncontaminated with microsomes. 
However, since the 5' nucleotidase activity was lower than that measured by Prpic et al. 
(1984) for membranes prepared using the same method, it was possible that non-plasma 
membrane components of the liver cell were present. If GLUT7 had accounted for a 
substantial amount of the photolabelling in the liver membranes used, it would have been 
expected that the anti-loop peptide antibody would have precipitated more labelled protein 
than the anti-C-terminal peptide antibody, since the loop sequence is shared by GLUT2 and 
GLUT7 whereas the C-terminus is exclusive to GLUT2. Since both antibodies precipitated 
the same amount of labelled protein, unless the loop antibody was less efficient than the C- 
terminal peptide antibody, photolabelling of GLUT7 does not appear to account for the
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non-GLUT2 precipitable, 4,6-0-ethylidene-D-glucose displaceable ATB-BMPA labelling of 
liver plasma membrane proteins.
The number of GLUT2 ATB-BMPA binding sites measured in liver plasma 
membranes was 2.1 pmol/mg of membrane protein. This is lower than the number of cyt 
B binding sites measured in earlier reports. The number of cyt B binding sites in liver 
plasma membranes has been measured as 130 pmol/mg of membrane protein and 42 
pmol/mg by Axelrod and Pilch (1983) and Ciaraldi et al. (1986) respectively. In 
comparing the number of binding sites estimated either from ATB-BMPA or cyt B binding, 
several factors need to be considered. First, some variation may be due to the different 
methods used to prepare liver plasma membranes in each case. Secondly, in the present 
study ATB-BMPA labelling has been followed by specific immunoprecipitation of labelled 
GLUT2, whereas the binding of cyt B to liver plasma membranes has not been shown to be 
specific for GLUT2. In fact, Hellwig and Joost (1991) failed to detect a specific binding 
site for cyt B on GLUT2. However, the value of 2.1 pmol/mg is likely to be an 
underestimation of the number of GLUT2 binding sites, since, as discussed above, it is 
probable that the immunoprecipitation of GLUT2 was incomplete. Only «7%  of the 
proteins labelled in liver plasma membranes in a 4,6-0-ethylidene-D-glucose displaceable 
manner could be precipitated by anti-GLUT2 antiserum. If an assumption is made that the 
remaining 93% of 4,6-0-ethylidene-D-glucose inhibitable binding is also to the GLUT2 
protein (which, it is proposed was not precipitated due to low antibody affinity), then a 
value of 30 pmol/mg of membrane protein can be obtained for the number of binding sites. 
This is closer to the value obtained by Ciaraldi et al. (1986) for the number of cyt B 
binding sites in whole liver plasma membranes, but is based on a correction which assumes 
that all the 4,6-0-ethylidene-D-glucose displaceable ATB-BMPA labelling of liver plasma 
membrane is specific for GLUT2.
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4.3 CONSIDERATION OF THE SUITABILITY OF B-CELL LINES AS 
MODELS OF NATIVE ISLET B-CELLS
It has recently become possible to prepare populations of islet cells enriched in 6- 
cells using autofluorescence-activated cell sorting (Christie et al., 1990), but it is a 
technically demanding, expensive and time-consuming procedure. For these reasons, fi- 
cell lines that can be maintained in continuous culture have been widely used in studies of 
6-cell physiology and autoantigenicity. Although the cell lines are convenient to work 
with, they are derived from cells that have been immortalised by viral transformation (HIT 
and MIN cells - Santerre et al., 1981; Miyazaki et al., 1990) or irradiation (RIN cells - 
Gazdar et al., 1980). This treatment, and the adaptation of cells to culture conditions, may 
cause the cell lines to have biochemical and physiological features very different from those 
displayed by the original cell type in vivo. An additional problem with cell lines is that 
their characteristic features are not necessarily permanent. Cell lines often exhibit 
morphological and physiological changes dependent on passage number and culture 
conditions.
The HIT-T15 cells used in the current study contained insulin and grew in poorly 
adherent clumps that resembled islets, these morphological characteristics were consistent 
with those previously described for this cell line (Santerre et al., 1981; Hill & Boyd
1985). MIN 6 cells also grew in clusters that differed from those of the HIT-T15 cells by 
being smaller and more adherent. Since both cell lines were obtained directly from the 
laboratory in which they were developed, were cultured as recommended, and were used at 
early passage numbers it was assumed that their physiology was essentially as described by 
the original authors (Santerre et al., 1981; Miyazaki et al., 1990).
The use of HITm2.2 cells as models of 6-cells has not been widely reported. This 
cell line was developed as a subclone of HIT-T15 cells showing increased stability of 
transfection competence (Edlund et al., 1985). In the present study this stability was
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shown not to extend to the morphological or insulin-secretory characteristics of the cells, 
since they exhibited passage-dependent changes. The original population of HITm2.2 cells 
was a mixture of adherent and non-adherent cells. The culture conditions used selected for 
the growth of the adherent cells which divided more rapidly. Gillard et al. (1989), have 
previously described a mixed population of RINm5F ceils which, by selective harvesting, 
could be used to develop adherent and non-adherent RIN sub-clones. The RINm5F cells 
used in the present study were all of the rapidly dividing adherent type (Thomas et al.,
1987). Their doubling time in the exponential growth phase was 26.5 hours this was faster 
than the 30-40 hours doubling time previously observed (Lambert & Atkins, 1987). The 
adherent nature of the RINm5F and HITm2.2 cells made them easier to work with than the 
HIT-T15 and MIN 6 cells which detached more easily from culture plates and clumped 
together making enumeration difficult.
Cytoplasmic insulin could not be detected in HITm2.2 cells using an indirect 
immunofluorescence assay. Dr. D. Boam has also detected only very low levels of insulin 
in this cell line (personal communication). However, by RIA it was shown that HITm2.2 
cells retained the ability to secrete insulin in response to glucose, a characteristic feature of 
the parent HIT-T15 cell line which makes it a good model of the native islet 6-cell (Hill & 
Boyd, 1985; Lambert et al., 1986). The glucose response was shown to decrease at high 
passage numbers, as has also been observed in HIT-T15 cells (Zhang et al., 1989). 
HITm2.2 cells did not secrete insulin in response to arginine or leucine which contrasted 
with the observed stimulation by these amino acids in HIT-T15 cells (Lambert et al.,
1986). This discrepancy may have reflected a difference in the m2.2 and T15 lines, or may 
have been a result of a general decrease in insulin secretion at high passage number.
The RINm5F cells used in the present study secreted very high levels of insulin. 
The basal level of secretion was about five fold higher than that produced by the RINm5F 
cells used in a study by Lambert and Atkins (1987). Gazdar et al. (1980) have however 
reported wide fluctuations in the insulin-secretory capacity of the original RINm cell line.
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Therefore, these differences may have been due to the use in the present study of a 
different RIN subclone to that used by Lambert and Atkins (1987). RINm5F cells have 
previously been shown to increase their insulin secretion 1.3 fold when stimulated with 15 
mM arginine (Lambert & Atkins, 1987). In the present study 15 mM arginine caused a 2.5 
fold increase in insulin release. However, despite their arginine response and high levels 
of basal insulin secretion, RINm5F cells are poor models of islet 6-cells, as they are unable 
to secrete insulin in response to glucose.
Due to the presence of the high Km glucose transporter GLUT2 , the rate of 
glucose uptake by native islet 6-cells is not limiting to its subsequent metabolism. This 
ability to equilibrate D-glucose rapidly across the cell membrane is believed to be 
important in enabling 6-cells to secrete insulin in response to glucose (Thorens et al.,
1988). The defect in RINm5F cells that is responsible for their inability to respond to D- 
glucose is unknown. It has previously been reported that 6-cell lines exhibit slow sugar 
uptake (Meglasson et al., 1986), but since identical rates of 2-deoxyglucose uptake were 
measured in the present study in both the non-glucose responsive RINm5F line and the 
glucose responsive HITm2.2 cells, a low rate of sugar transport cannot be the only factor 
that prevents RIN cells from responding to D-glucose. The rate measured in the present 
study using cells cultured in 11 mM D-glucose was lower than the 2.3 nmol/0.1 mg/min 
measured previously for 1 mM 2-deoxyglucose uptake in HIT-T15 cells cultured in 16.7 
mM D-glucose (Purrello et al., 1991), whereas a reduction in glucose transport would have 
been expected at this higher glucose concentration (Purrello et al., 1991; Seino et al.,
1991). The difference was attributed to the use in the present study of HITm2.2 rather 
than H1T-T15 cells. This illustrates one of the disadvantages of working with cell lines, 
that is, the variability that can arise from the use of different subclones. These may even 
have been produced inadvertently in different laboratories by the selective pressures 
imposed by slightly different culture conditions. Discrepancies in results are not 
uncommon, even between laboratories ostensibly using the same cell line. One example is 
in the measurement of 3-O-methyl-D-glucose uptake in RINm5F cells. Trautmann and
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Wollheim (1987) demonstrated that these cells had a high Km for this sugar which was 
equilibrated within 2 min, whereas Malaisse (1988) measured a low Km of 2 mM for the 
same sugar.
The photolabel ATB-BMPA has been used in conjunction with anti-GLUTl and 
anti-GLUT2 specific antibodies to identify the glucose transporter isoforms present in the 
8-cell lines. Since the aim was solely to establish whether the GLUT2 protein was present 
in these cells, it was not attempted to accurately quantify glucose transporter expression. 
However, it is proposed that ATB-BMPA could be of future use in investigations of the 
regulation of GLUT1 and GLUT2 expression in 8-cells or islets cultured under different 
conditions.
In HITm2.2, RINm5F and MIN 6 cells, ATB-BMPA photolabelled protein with an 
apparent molecular mass of 45-66 kDa. Photolabelling in the presence of D-glucose 
inhibited the labelling of this protein by 66% and 63% in HITm2.2 and MIN 6 cells 
respectively. This strongly suggested that most of the photolabel was binding to a glucose 
transporter. The GLUT1 isoform was identified in RIN, MIN and HITm2.2 (but not HIT- 
T15) cells by the immunoprecipitation of an ATB-BMPA labelled protein using anti- 
GLUTl antiserum. This confirmed previous reports that the normal tissue-specific pattern 
of glucose transporter isoform expression does not occur in immortal cell lines, which 
generally show a predominant, if not exclusive, expression of the GLUT1 glucose 
transporter isoform (Kahn & Flier, 1990; Mueckler, 1990). GLUT1 has been detected 
previously in MIN, RIN, HIT and B-TC cells both at the level of mRNA (Thorens et al., 
1988; Buchs et al., 1990; Miyazaki et al., 1990) and protein (Buchs et al., 1990; Brant 
etal., 1992).
The inability to detect GLUT2 in any 8-cell line by immunoprecipitation of ATB- 
BMPA photolabelled proteins with anti-GLUT2 antiserum is at variance with the
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previously reported detection of GLUT2 mRNA in RINm5F (Thorens et al., 1988), HIT 
(Seino et al., 1991) and MIN 6 cells (Miyazaki et al., 1990). However, the detection of 
mRNA does not necessarily mean that large quantities of the protein are also present in the 
plasma membranes (Seino et al., 1991). When the actual amount of GLUT2 protein has 
been measured in 6-cell lines by immunoblotting, it has been shown that the GLUT2 
protein is present in much lower amounts than the GLUT1 transporter isoform. Therefore, 
it is proposed that the amount of GLUT2 in RIN, HIT and MIN cells was low enough to be 
below the level of detection of the ATB-BMPA labelling and precipitation assay.
Only about 10% of the 6-cell line proteins labelled in a hexose-displaceable manner 
were immunoprecipitated with anti-GLUTl antiserum. The ability to displace the labelling 
with glucose implied that a glucose transporter protein was being photolabelled, therefore 
the low recovery of labelled transporter may have resulted from an incomplete 
immunoprecipitation. However, there was no evidence that GLUT1 immunoprecipitation 
was inefficient. The anti-GLUTl antiserum used in the present study has previously been 
shown to efficiently precipitate photolabelled GLUT1 (Clark & Holman, 1990). If an 
assumption is made that these 6-cell lines do not contain appreciably more GLUT1 than 
3T3-L1 cells, the conditions used in the present study, which were comparable with those 
used in a study by Palfreyman et al. (1992), should have enabled at least 80% of the 
photolabelled GLUT1 to be precipitated.
From the studies with liver tissue it was known that the efficiency of GLUT2 
precipitation was low. Therefore, the possibility must be considered that some of the 
hexose-displaceable binding of ATB-BMPA to 6-cell proteins was to GLUT2, which for 
some unknown reason was not precipitated. However, since GLUT2 could be detected in 
hepatocytes and even in very small numbers of islets, the amount of the GLUT2 protein 
present in the 6-cell lines would have to be very low for it not to be detected by ATB- 
BMPA photolabelling and immunoprecipitation. Therefore, the identity of the majority of 
the protein labelled in a hexose-displaceable manner, but not immunoprecipitated was
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unknown. It is however possible that it could have been a different glucose transporter 
iso form, that is, neither GLUT1 nor GLUT2, since Brant et al. (1992) have demonstrated 
the presence of GLUT4 in the 6-TC 6-cell line. The presence of this isoform was not 
investigated in the present study.
It was also evident that ATB-BMPA was labelling non-glucose transporter proteins 
in all of the 6-cell lines. In MIN 6 and HITm2.2 cells, a peak with an apparent molecular 
mass of 29-45 kDa was labelled in a non-hexose-displaceable manner, and in RINm5F cells 
a non-precipitated peak with an apparent molecular mass of 66-97 kDa was labelled. In 
HIT-T15 cells photolabelling of a 66 kDa protein appeared to be non-specific, since the 
labelling was not hexose displaceable. The high degree of non-specific photolabelling in 
these 6-cell lines appears to be similar to the situation observed in liver tissue and may 
reflect the low abundance of glucose transporter protein compared with other membrane 
proteins. The photolabelling of HIT-T15 cells, which grew in large clumps, may have 
been poorly efficient due to the decreased penetration or activation of the photolabel.
In the present study the absence of a large amount of GLUT2 in the 6-cell lines 
was confirmed by immunoblotting. The antibody used was known to recognise GLUT2 
under Western blotting conditions, yet GLUT2 was not detected in 6-cells using either 
whole cells or plasma membrane fractions and sensitive immunodetection systems (ECL 
and ^^I-labelled anti-IgG). These results were at variance with the reported detection of 
GLUT2 in HIT and RIN cell lines by Brant et al. (1992). This discrepancy may be 
attributed to differences in the cell lines that were used in the two studies. However, some 
GLUT2 may have been present in the HITin2.2 and RINm5F cell lines used in the current 
study, since when membrane proteins were extracted with the detergent Triton X-l 14, a 58 
kDa protein was detected with anti-human GLUT2 C-terminal peptide antiserum. This 
antiserum was known to show some non-specific binding, therefore it can only be 
concluded tentatively that the cells were expressing some GLUT2.
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The inability to detect GLUT1 in B-cell lines by Western blotting, despite 
demonstrating its presence by ATB-BMPA labelling and immunoprecipitation, could be 
explained if the antibody used had a low affinity for the denatured GLUT1 protein. This 
may be expected to cause a problem when attempting to immunodetect relatively low 
amounts of GLUT1, as in the cell lines, but would not be a problem in the Western 
blotting of erythrocytes in which very high expression of GLUT1 occurs. Similar results 
have been obtained in 3T3-L1 cells from which labelled GLUT1 could be 
immunoprecipitated (Palffeyman et al., 1992), although using the same antibody it could 
not be detected in the present study by Western blotting.
In summary, the presence of GLUT1 in MIN 6, HITm2.2 and RINm5F cells has 
been demonstrated by photolabelling and immunoprecipitation, although it could not be 
confirmed by Western blotting. The GLUT2 protein was either absent or expressed at 
such a low level that it could not be detected by ATB-BMPA photolabelling and 
immunoprecipitation or by normal Western blotting techniques. It must therefore be 
concluded that B-cell lines are not ideal models of native islet fi-cells. The absence or low 
expression of GLUT2 precludes their use in assays designed to screen for the presence of 
anti-B-cell GLUT2 autoantibodies. However, other evidence including the retention of 
insulin secretion, suggests that the cell lines do possess some B-cell-like properties and 
therefore that they may be used successfully to detect other anti-B-cell autoantibodies.
4.4 ASSAYING FOR ANTI-B-CELL SURFACE ANTIBODIES IN HUMAN 
SERUM.
ICSA, which may be of pathogenic significance and diagnostic importance in 
IDDM, have traditionally been detected in an assay which uses freshly isolated rat islets 
and detects bound human IgG using an FITC-conjugated second antibody (Lemmark et al., 
1978). This is not an assay that can be readily standardised nor quantified and it is too 
time-consuming and expensive to be of practical use in the screening of large numbers of
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samples. Attempts to improve the detection of ICS A have largely focused on the 
replacement of rat islet cells with cultured 8-cell lines. The potential disadvantage of using 
cell lines is that the antigens present on the cultured cells might not be present on the native 
cells in vivo, and vice versa. However, there have been a number of reports demonstrating 
that 8-cell lines do express some of the same cell surface antigens as are present in 
pancreatic islets in vivo (Eisenbarth et al., 1981; Karounos & Thomas, 1990) and that 
these antigens can be specifically recognised by antibodies present in serum from diabetic 
patients (Maclaren etal., 1975; Mamer et al. , 1984; Thom as# al., 1990). Although the 
use of cell lines can reduce the cost and improve the convenience and reproducibility of 
ICSA assays, most of those that have been described still use whole viable cells, making 
them cumbersome to use.
It was the aim of the present study to determine whether an assay could be 
developed to detea ICSA using 8-cell line plasma membranes in an ELISA. A similar 
approach to ICSA detection has been described by Peakman et al. (1989), who developed 
an ELISA using rat islet plasma membranes that deteaed significantly higher binding of 
IgG from diabetic compared with normal serum. A plasma membrane ELISA offers 
advantages over traditional whole cell assays in terms of greater convenience and 
reproducibility, lower cost and increased number of samples that can be handled.
In the early stages of autoimmune diabetes, most patients have antibodies against 
both cytoplasmic (ICCA) and islet cell surface (ICSA) antigens (Leramark et al., 1978; 
1981). It is the ICSA that are potentially of greater significance in the aetiology of the 
disease, since they are directed against antigens that are accessible in living cells. A 
possible drawback of a plasma membrane ELISA is therefore that, in addition to deteaing 
antibodies direaed against cell surface antigens, the assay may also be able to detect 
binding by ICC A to "cytoplasmic" epitopes. That is, to regions of proteins present in a 
plasma membrane preparation that would not be exposed to the immune system at the 
surface of a viable cell. However, the 8-cell membrane ELISAS developed in the present
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study did not appear to detect antibodies directed against cytoplasmic antigens, since the 
IDDM samples in set 2, which were known to be positive for ICCA, did not show 
significantly higher binding than the ICCA-negative control samples.
Initially, variation in the plasma membrane assay was found to be high. Intra- 
assay variation was successfully reduced from ±13.6% to ±2.7% by homogenisation of 
the membrane sample in the coating buffer which ensured an even coating of the plate. 
Two different methods were used to prepare plasma membranes from the fi-cell lines. In 
the first method, cells were disrupted by vigorous homogenisation and plasma membranes 
were separated using a Ficoll gradient. The vigorous homogenisation necessary to disrupt 
these small cultured cells in a hypertonic buffer also tended to disrupt the nuclear 
membrane releasing DNA which caused clumping of cytoplasmic components and 
prevented the reproducible preparation of a pure plasma membrane fraction (Howell et al. ,
1989). It appeared that the variability in the quality of the plasma membranes prepared by 
this method contributed to the high inter-assay variation (±21.5%). Inter-assay variation 
was reduced to about ±11% when membranes were prepared from cells that had been 
disrupted by lysis in a hypotonic buffer aided by gentle homogenisation. This method was 
chosen since it has previously been used by Karounos et al. (1990) to detect anti-RINm5F 
membrane antibodies in diabetic serum.
Although, at a significance level of p=0.05, there was no statistically significant 
difference in the levels of anti-MIN or anti-HIT antibodies in diabetic compared with 
control serum that were measured in any of the ELISAS developed in the present study, the 
trend was definitely for the diabetic samples to show higher levels of binding. This was 
particularly evident when the samples in set 1 were assayed against HITm2.2 membranes 
that had been prepared on a Ficoll gradient. In this assay IDDM samples showed an 
increased binding above that shown by control samples which was significant at p = 0 .1. 
The difference was almost significant at p=0.05, the standard acceptable level for 
significance testing.
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It was apparent that a different distribution of antibody titres was present in the 
samples in set 1 compared to set 2. In set 1, the majority of control samples had very low 
levels of anti-MIN and anti-HIT membrane antibodies, that is, titres less than 25% of the 
standard serum, whereas the majority of IDDM samples had titres that were slightly 
higher, that is between 25-50% of the standard. In contrast, in set 2 there was no excess of 
control samples with very low antibody titres. In view of the difference in titres in the 
samples from set 1 compared to set 2, the possibility must be considered that the 
significantly (p= 0 .1) higher binding of IDDM samples to HITm2.2 membranes was 
obtained using a non-representative set of serum samples. It is possible that the low 
binding of many of the control samples in set 1 was caused in some way by treatment to 
which they had been subjected before they were received in the laboratory. For example, 
the samples could have been left at room temperature for prolonged periods, although since 
IgG is a robust antibody (Johnstone & Thorpe, 1987) it should have been able to withstand 
this putative treatment. Additionally, there was no reason to believe that the control 
samples had been treated any differently from the IDDM samples. One known difference 
between the control samples in set 1 and 2 which could have influenced the results, was 
that the samples in set 2 were all from healthy children, whereas those in set 1 had all been 
hospitalised for some reason (not IDDM). Therefore in conclusion, there was no a priori 
reason to believe that set 1 serum samples were any less representative than the samples 
from set 2.
The ideal assay for IDDM marker antibodies should be able to detect all cases of 
IDDM and yet should be specific enough not to give a positive result for a normal sample. 
This is especially important if immunotherapeutic or immunosuppressive treatments are to 
initiated based on the results of tests for the presence of marker antibodies. Even in the 
assay in which IDDM samples showed significantly (p=0.1) higher binding, an overlap 
still existed in the levels of anti-B-cell antibodies in the control and IDDM populations,
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which would prevent the assay being used for screening purposes without some 
modification.
The nature of the antigens in the 6-cell lines to which the human antibodies were 
binding was unknown. Approximately half of the sera tested showed a very similar 
amount of binding to both HIT (hamster origin) and MIN (mouse origin) membranes. This 
suggests that there are common 6-cell antigens, recognised by human antibodies, that are 
shared by both of these cell lines and that they are not species-specific (Leramark et al., 
1978). The remaining samples showed quite different levels of binding to the two cell 
lines, indicating that each cell line may also express unique antigens or different amounts 
of the same antigen. Such differences in antigen expression between different cell lines are 
to be expected since they have previously been observed in different subclones of the same 
6-cell line (Eisenbarth et al., 1981; Gillard et al., 1989).
Obviously these 6-cell line membrane ELISAS require further refinement and 
evaluation by the testing of much larger numbers of samples (all of which should be 
collected under standardised conditions). However, the results were promising in view of 
the trend for higher binding, albeit not statistically significant, of the IDDM serum 
samples. Since the best results were obtained using HITm2.2 plasma membranes prepared 
on a Ficoll gradient, future work would need to investigate the possibility of improving the 
reproducibility of this method of membrane preparation. Due to limited availability of the 
sera that were used in the present study, they were not preabsorbed with rat or mouse 
tissue powders before being assayed. It was therefore possible that the high binding shown 
by some normal sera was due to non-specific binding to rodent antigens and that the assay 
may be improved if the sera could be preabsorbed. However, although some authors have 
previously claimed to get better results in ICA assays by preabsorbing sera with rodent 
tissue (Matsuba et al., 1987) others have found that the preabsorption did not affect the 
results (Lemmark et al., 1978; Lander et al., 1989).
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4.5 THE ATTEMPTED IDENTIFICATION OF ANTIGENS IN B-CELLS 
THAT ARE RECOGNISED BY AUTO ANTIBODIES IN IDDM SERUM
The first report of islet cell surface antibodies in IDDM patients was published in 
1978 (Lemmark et al., 1978). Since then numerous studies, including the present one, 
have confirmed the higher incidence of anti-B-cell antibodies in IDDM compared to control 
serum, but to date the only positively identified B-cell autoantigen is a 64 kDa protein 
called glutamic acid decarboxylase (Baekkeskov et al., 1990). It is not currently known 
whether autoantibodies against this antigen are actually involved in the aetiology or 
pathogenesis of IDDM. Therefore, it is important to identify as many other B-cell antigens 
as possible, the aim being to maximise the chances of identifying a novel diabetes-specific 
autoantigen that is involved in causing the disease. This antigen could potentially be used 
to develop a highly specific assay designed to detect the pre-overt stage of diabetes.
Many of the assays that have previously been applied to the detection of diabetes- 
specific autoantigens have employed complex methodology, such as detergent extractions 
and immunoprecipitations (Baekkeskov et al., 1982). In the current study it has been 
attempted to identify diabetes-specific islet cell surface antigens using a simple Western 
blotting method.
When plasma membranes from MIN 6 and HrTm2.2 B-cells were immunoblotted 
with a selection of serum samples from control and diabetic children a heterogeneous group 
of antigens were detected. The main conclusion drawn from these results was that 
typically, the diabetic samples recognised a larger number of distinct B-cell antigens than 
the control sera. This suggested that the higher binding shown by the IDDM samples in 
the 6-cell line ELISAS was a result of antibody binding to a large number of antigens, 
rather than being due to a high titre of antibodies against a single antigen. The majority of 
these antibodies were probably generated as a result of the exposure of the immune system 
to antigens liberated from B-cells which were damaged at the onset of diabetes. Therefore,
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although possibly enhancing the rate of B-cell necrosis, these antibodies may not have 
played a role in the actual initiation of the disease.
The current Western blotting technique was not, however, sensitive enough to 
enable the positive identification of any diabetes-specific autoantigens in 6 -cell plasma 
membranes. This contrasts with earlier reports of the use of Western blotting to detect 
multiple diabetes-specific islet cell antigens (Karounos et al., 1988; Buchs et al., 1990). 
However, comparing results obtained from different laboratories is difficult, largely due to 
the use of different sources of B-cells and different methods of antigen extraction. In 
particular, earlier work has often used antigens solubilized in detergents such as NP-40 
(Kuo et al., 1991) or SDS. This treatment extracts both cytoplasmic and cell surface 
antigens (Karounos et al., 1988; 1990), whereas in the present study purified plasma
membranes were used, which is a method more suitable for the detection of cell surface 
antigens. The method of antigen preparation can make a large difference to the results 
obtained, as has been illustrated by Karounos and co-workers. Antigens with apparent 
molecular masses of 150, 84, 60, 49 and 35 kDa were detected by diabetic sera in 
detergent extracts from whole RIN cells (Karounos et al., 1988), whereas completely 
different proteins with masses of 166, 136, 52 and 49 kDa were recognised in extracts 
from plasma membranes (Karounos & Thomas, 1990).
It is possible that whole plasma membranes may be used more successfully to 
detect diabetes-specific cell surface autoantigens if the non-specific background binding 
could be reduced. This may be achieved by the preabsorption of sera with rat tissue 
powders, which was not carried out in the present study due to the small volumes of serum 
available.
It was attempted to increase the sensitivity of the Western blotting procedure by the 
extraction of membrane proteins into the detergent Triton X-114. This technique has 
previously been used with rat islet cells and has reportedly been demonstrated to detect
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antibodies in diabetic serum against the 64 kDa islet cell GAD protein (Herold et al.,
1988). The results obtained using this extraction procedure were very different from those 
obtained using whole plasma membranes from the same cells. Instead of multiple antigens, 
a single protein with an apparent molecular mass of about 58 kDa was detected by most 
samples. However the technique still failed to detect any diabetes-specific autoantigens in 
the HITm2.2 and RINm5F cells. The inability to detect the 64 kDa autoantigen confirms 
previous reports that this protein is not expressed in cultured B-cell lines (Baekkeskov et 
al. , 1988; 1990).
The identity of the 58 kDa protein was not known, although it showed some 
similarities to the protein that was photolabelled by ATB-BMPA in liver plasma 
membranes and immunoprecipitated with human serum. Both proteins had apparent 
molecular masses of between 45 and 6 6  kDa and were recognised in detergent-solubilized 
membrane proteins by antibodies present in most human serum samples. Since both 
proteins have an apparent molecular mass similar to that of the GLUT2 protein, it is 
suggested that this may have been the identity of the antigen that was recognised by the 
antibodies present in the human serum. This possibility is discussed in further detail 
below.
4.6 IDENTIFICATION OF PUTATIVE ANTI-GLUT2 ANTIBODIES IN 
HUMAN SERUM
At present, the evidence for the involvement of anti-6 -cell GLUT2 autoantibodies 
in the pathogenesis of autoimmune diabetes is largely circumstantial. The major evidence 
comes from animal models of IDDM in which 6 -cell glucose transport and expression of 
GLUT2 are reduced at the onset of diabetes (Tominaga et al., 1986; Orci et al., 1990a). 
Serum samples from recently diagnosed diabetic patients have also been shown to contain 
IgG antibodies that can both inhibit glucose-induced insulin secretion (Kanatsuna et al., 
1983) and glucose transport in islet B-cells (Johnson et al., 1990a).
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In this present study it has been attempted to confirm the existence of these putative 
anti-GLUT2 autoantibodies. Although the autoimmune response that occurs in diabetes is 
generally directed specifically against the 6 -cell (Leramark et al.y 1978), it has been shown 
that human antibodies that inhibit 6 -cell glucose transport can be removed from diabetic 
serum by preabsorption with liver membranes (Johnson et al., 1990a). Therefore, it is 
theoretically possible to detect anti-6 -cell GLUT2 autoantibodies using GLUT2-containing 
liver plasma membranes. Although it has been shown that liver plasma membranes can be 
used in ELISAS and Western blots to detect anti-GLUT2 peptide antibodies in rabbit 
immune serum, in the present study neither of these techniques enabled anti-GLUT2 
autoantibodies to be detected in human serum.
The results obtained by assaying IDDM sera in a liver plasma membrane ELISA, 
confirmed that diabetic serum does not contain especially high levels of antibodies that 
react with any antigens in liver membranes, as there was no significant difference between 
antibody binding in control and IDDM samples. Similarly, the GLUT2 protein was not 
detected by any human serum sample when immunoblotted against liver plasma 
membranes. Therefore, if anti-GLUT2 autoantibodies were present, they were either at 
titres to low to be detected by these assays, or they did not recognise the antigen in the 
conformation it assumed when immobilised on an ELISA plate or nitrocellulose paper. 
Baekkeskov et al. (1990) have also previously been unable to demonstrate the presence of 
low levels of anti-64 kDa autoantibodies using Western blotting.
The possibility was considered that increasing the proportion of GLUT2 present in 
the antigen preparation used for either Western blotting or ELISAS could improve the 
sensitivity of these assays, thereby enabling low levels of anti-GLUT2 autoantibodies to be 
detected. However, it has not been possible to affinity purify sufficient GLUT2 to enable 
this theory to be tested.
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Radiolabelling of islet cell proteins followed by an immunoprecipitation with 
human serum has previously been shown to be a technique that is sensitive enough to detect 
very low amounts of the 64 kDa B-cell autoantigen (Baekkeskov et al., 1990). A similar 
strategy was applied in the current investigation. Instead of using methionine to label 
all of the proteins in the islet tissue, ATB-BMPA was used to specifically photolabel the 
glucose transporter protein, GLUT2. It was then attempted to demonstrate the presence of 
anti-GLUT2 autoantibodies by immunoprecipitation of labelled protein with human 
diabetic and control serum samples. The antibodies previously detected in human serum, 
that inhibited B-cell glucose transport were of the IgG class (Johnson et al., 1990a), so they 
should have a high affinity for Protein A-Sepharose (Richman et al., 1982). Therefore, if 
present in sufficiently high titres they may be expected to be able to immunoprecipitate 
detectable quantities of labelled GLUT2.
However, this technique did not detect any antigens that were recognised 
exclusively by antibodies present in diabetic serum. In fact, all human serum samples 
tested were demonstrated to precipitate ATB-BMPA labelled proteins from liver plasma 
membranes, which had apparent molecular masses of about 6 6  kDa and 45-66 kDa. The 
similarity of the apparent molecular masses of the proteins precipitated by human serum 
and anti-GLUT2 C-terminal peptide antiserum, together with the observation that labelling 
of proteins precipitated by both sera could be displaced to a similar extent (50-60%) by 
4,6-0-ethylidene-D-glucose, suggested that it was the same protein that was being 
precipitated by rabbit anti-GLUT2 peptide antibodies and by antibodies present in human 
serum.
Other evidence supporting the hypothesis that human IgG and rabbit anti-GLUT2 
antibodies were precipitating the same labelled protein was obtained from competition 
studies. By performing a pre-immunoprecipitation with human serum, it was possible to 
reduce the amount of GLUT2 that could be subsequently precipitated by about 58%. A 
pre-immunoprecipitation with rabbit anti-GLUT2 antiserum resulted in a decrease of
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approximately 41% in the amount of labelled protein subsequently precipitated by human 
serum. It is possible to account for the slight discrepancy that was observed in the 
percentage reduction depending on the order of precipitation, since the 
immunoprecipitation with anti-GLUT2 antiserum was of low efficiency (see section 4.1) 
and did not totally remove all of the GLUT2 protein, whereas more of the labelled GLUT2 
appeared to be removed by precipitation with the human serum.
No accurate measurement was made of the maximum amount of labelled protein 
that could be precipitated by the human antibodies, although it was estimated that human 
serum precipitated approximately 1.5 fold more labelled protein than anti-GLUT2 
antiserum. The possibility has been considered that the high amount of precipitation by the 
human serum could be due to the precipitating antibody being IgM and not IgG, since the 
polyvalent nature of IgM makes it a high avidity antibody (Roitt, 1984). However, it has 
previously been shown that although human IgM can bind to Protein A, it does not bind as 
well as IgG. Therefore the precipitating antibodies were likely to have been of the IgG 
class.
Although these results imply that all human serum contains antibodies that can 
immunoprecipitate GLUT2 from liver membranes, it does not seem likely that these 
antibodies bind to GLUT2 in whole cells, since this would contradict the results obtained 
by Johnson et al. (1990a), who found no evidence of antibodies inhibiting B-cell glucose 
transport in normal human serum samples. It is therefore proposed that antibodies 
(probably IgG but maybe IgM) are present universally in normal human serum which 
cross-react, not with GLUT2 epitopes accessible on the surface of living cells, but with 
epitopes on the GLUT2 protein only exposed under certain experimental conditions. For 
example, if the antibodies only bound to epitopes exposed in the detergent solubilized 
protein, they would not be expected to have any pathogenic effect in vivo. This could also 
explain why the precipitating antibodies could not be pre-absorbed with non-solubilized
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liver plasma membranes, and why human serum did not detect any strong 45-66 kDa band 
in Western blots of liver plasma membrane proteins.
When human serum immunoprecipitates were immunoblotted with rabbit anti- 
GLUT2 peptide antiserum, GLUT2 could not be detected, this suggests either that human 
serum was not precipitating GLUT2 or, more probably, that ATB-BMPA labelling and 
immunoprecipitation provided a more sensitive method of GLUT2 detection compared to 
immunoblotting. Confirmation that the human serum does precipitate GLUT2 must await 
improvements in the sensitivity of GLUT2 detection by Western blotting.
In summary, it was shown that all of the small number of human serum samples 
tested contained antibodies able to precipitate an ATB-BMPA labelled protein from liver 
plasma membranes. It has been tentatively proposed that the protein is GLUT2 and that 
antibodies directed against it recognise cytoplasmic epitopes not normally accessible in 
vivo. The origin of these antibodies is not known, but they could have been formed 
against antigens that were released from damaged liver tissue during, for example, mild 
liver disease. Unless it can be demonstrated that the high level of background 
immunoprecipitation with control sera represents binding to a protein other than GLUT2, 
and a way can be found of removing it, it does not seem likely that ATB-BMPA 
photolabelling will be able to be used to detect the putative anti-GLUT2 diabetes-specific 
antibodies that inhibit B-cell glucose transport (Johnson et a l.y 1990a).
None of the techniques described in this thesis was able to demonstrate the 
presence of anti-GLUT2 autoantibodies present exclusively in serum from diabetic 
patients. However, it cannot be assumed from these results that the anti-GLUT2 
autoantibodies do not exist. Indeed, in view of the problems associated with the detection 
of the relatively abundant GLUT2 protein in liver tissue using a specific high titre antibody 




This thesis has described the first use of the exofacial probe, ATB-BMPA, to label 
the glucose transporter isoform GLUT2. The protein which was labelled in liver plasma 
membranes had an apparent molecular mass of «45-66 kDa, and could be specifically 
immunoprecipitated with an anti-GLUT2 C-terminal peptide antibody. Since only 43% of 
the ATB-BMPA binding to liver membrane proteins was inhibited by 4,6-O-ethylidene-D- 
glucose, this suggested that the ATB-BMPA labelling of liver tissue was less specific than 
that observed in erythrocytes (Clark & Holman, 1990) and adipocytes (Holman et al., 
1990). Nevertheless, it is suggested that ATB-BMPA provides a good alternative to the 
endofacial label cyt B. Since ATB-BMPA was shown to have a similar binding affinity 
(K^) for GLUT2 as for GLUT1 and GLUT4 (Palffeyman et al., 1992), it has been 
proposed that these isoforms are all similar at the exofacial binding site and that the 
reported differences shown by GLUT2, such as a lower affinity for cyt B and D-glucose, 
may arise from differences at the endofacial binding site.
The inability to immunoprecipitate any more than 7% of the total liver plasma 
membrane protein labelled in a 4,6-O-ethylidene-D-glucose displaceable manner has been 
attributed to a low immunoprecipitation efficiency, probably resulting from a poor affinity 
of the anti-GLUT2 C-terminal peptide antibody for the detergent-solubilized GLUT2 
protein. This putative weak interaction may also explain the inability to purify large 
amounts of GLUT2 from liver membranes by immunoaffinity chromatography. More 
work needs to be carried out in order to improve the efficiency of GLUT2 
immunoprecipitation. This may also enable GLUT2 to be investigated in other tissue, such 
as islet 0-cells, where the source material is limited. Immunoprecipitation may possibly be 
improved by the use of anti-peptide antibodies raised against different regions of the 
GLUT2 protein.
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Using both Western blotting and ATB-BMPA photolabelling followed by 
immunoprecipitation, GLUT1 was the only glucose transporter isoform detected in the 
cultured /3-cell lines HITm2.2, MIN6  and RINm5F. The normal /3-cell isoform GLUT2 
could not be detected. This confirmed the earlier reports of GLUT1 expression in cultured 
/5-cells, but contrasted with the reported detection of GLUT2 mRNA (Thorens et al., 1988; 
Miyazaki et al., 1990). This may be attributed either to differences in the cell lines used, 
or it may indicate that the GLUT2 protein was being expressed at a level below the 
detection limits of the assays used in the present study. In view of the abnormal glucose 
transporter expression it is concluded that these 6 -cell lines are not ideal models of native 
islet 6 -cells.
Plasma membranes prepared from the HITm2.2 and MIN6  /3-cell lines have been 
used as the antigen in ELISAS in which serum from diabetic and control children was 
tested for the presence of anti-/5-cell surface antibodies. The largest difference between 
antibody titres in control and diabetic samples was obtained when serum samples were 
assayed against plasma membranes prepared from HITm2.2 cells using a Ficoll gradient, 
but the increased binding shown by the diabetic samples in this assay was not statistically 
significant. The aim of this work was to investigate the feasibility of using a simple 
membrane ELISA as a screening assay to aid early diagnosis of pre-diabetes. It is 
concluded that a /3-cell line membrane ELISA is potentially suitable for the detection of 
diabetes-specific anti-/3-cell surface antibodies, although the assays presented in this thesis 
require further refinement. Larger numbers of serum samples need to be screened and 
assay variation needs to be reduced, possibly by the use of a different plasma membrane 
preparation.
Human serum has been shown to contain antibodies that can immunoprecipitate 
protein from liver plasma membranes labelled with ATB-BMPA in a 4,6-O-ethylidene-D- 
glucose displaceable manner. This protein has been tentatively identified as GLUT2. It 
has been proposed that the immunoprecipitating antibodies were directed against epitopes
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of GLUT2 which were only recognised in the detergent solubilized protein, but were not 
accessible in living cells. The origin of these antibodies is unknown, but they are present 
in all human serum samples and are not therefore the same as the diabetes-specific anti- 
GLUT2 antibodies previously detected by Johnson et al. (1990a). The current work has 
not been able to confirm the presence of putative diabetes-specific anti-GLUT2 
autoantibodies using either Western blotting, which proved unsuitable for the detection of 
any diabetes-specific anti-/3-cell autoantibodies, or ATB-BMPA photolabelling. It is 
proposed that a better technique for the investigation of these antibodies may be an ELISA 
which uses purified GLUT2 protein as the antigen. In view of the difficulties experienced 
in purifying GLUT2 from liver tissue, the most convenient source of GLUT2 may be the 
protein obtained from the cloned gene.
In conclusion, this thesis contributes to the basic information available about 
GLUT2, and should therefore be of relevance to future investigations of the putative role 
of this protein in the pathogenesis of both NIDDM and IDDM.
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